{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/contentassets/00c2c40952bb4c3da07216b656b72a7b/rapport-legemiddelstatistikk-2020.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "2020 Lege middelforbruket i Norge 2015-2019 Data fra Grossistbasert legemiddelstatistikk og Reseptregisteret Drug Consumption in Norway 2015-2019 Data from Norwegian Drug Wh olesales Statistics and the Norwegian Prescription DatabaseLEGEMIDDELSTATISTIKK Legemiddelforbruket i 2015-2019 Data fra Grossistbasert legemiddelstatistikk og Reseptregisteret Drug Concumption in Norway 2015-2019 Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database Hilchen Thode Sommerschild Christian Lie Berg - Data fra Grossistbasert legemiddelstatistikk og Reseptregisteret Drug Consumption in Norway 2015 -2019 - Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database Forfattere/Authors: Hilchen Thode nettsider: www.fhi.no The report is only design omslag: - Data fra Grossistbasert legemiddelstatistikk og Reseptregisteret / Drug Consumption in Norway 2015 -2019 - Data from Norwegian Drug Wholesales Statistics and the Norwegian , Legemiddelstatistikk 20 1981: Legemiddelforbruket Legemiddelforbruket 1985: Legemiddelforbruket 1987: Legemiddelforbruket 1988: Legemiddelforbruket Legemiddelforbruket i 1990: Legemiddelforbruket Legemid Legemiddelforbruket 2008: Reseptregisteret 2004 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004 2011: Legemiddelstatistikk 2011:2: Prescription Database 2007 - 2011. Topic: Drug use in the elderly 2013: Legemiddelstatistikk 2013:2: Reseptregisteret 2008 -2012 2014: Legemiddelstatistikk 2014:2: Reseptregisteret 2009 Reseptregisteret 2010 -2014. Tema: Antibiotika 2010 2014. Topic: Antibiotics 2016: Legemiddelstatistikk 2016:2: Reseptregisteret 2011 2017: Legemiddelstatistikk 2017:2: Reseptregisteret 2012 The Norwegian Prescription Database 2010 - 2014. Topic: Drug use in the elderl 2019: Legemiddelstatistikk 2019:2: Reseptregisteret 2014 -2018 2014 -2018. 2 Innhold INNHOLD 2 SAMMENDRAG 3 SUMMARY 4 1 INNLEDNING 5 2 MATERIALE OG METODE 7 2.1 Datakilder 7 2.2 Vareregisteret 7 2.3 ATC og DDD 8 2.4 M\u00e5leenheter og indikatorer 9 2.5 Vurderinger og forbehold 10 3 11 3.1 Totalt legemiddelsalg 11 3.2 Sammenstilling av datakildene 14 3.3 Utleveringsgrupper (A, B, C og F) og reseptkategorier (norma l-/refusjonsresepter) 15 3.4 Reseptpliktige legemidler 16 3.5 Reseptfrie legemidler 20 3.6 Veterin\u00e6re legemidler (ATC gruppe Q) 22 4 STATISTIKK FOR ATC H OVEDGRUPPER 23 4.1 Forklaringer til hovedtabellene 23 4.2 A Ford\u00f8yelsesorganer og stoffskifte 24 4.3 B Blod og bloddannende organer 36 4.4 C Hjerte og kretsl\u00f8p 41 4.5 D Dermatologiske midler 51 4.6 G Urogenitalsystem og kj\u00f8nnshormoner 57 Hormoner til 71 4.9 L Antineoplastiske og M Muskler og skjelett 4.11 Nervesystemet 97 4.12 P Antiparasit\u00e6re midler, insekticider og insektmidler 108 4.13 R Respirasjonsorganer 111 4.14 S Sanseorganer 118 4.15 V Varia 122 5 HISTORIKK OG BAKGRUN NSINFORMASJON 124 FOLKEMENGDE I NORGE 2015 i salget m\u00e5lt i definerte d\u00f8gndoser 2019, angitt i kroner (AIP) og DDD. Kostnadsveksten har over i kroner , og utgjorde 25 % av ble utlevert til enkeltpersoner i 2019 . De resterende 3 % ble i hovedsak utlevert til institusjon er. Av den utlevert minst ett legemiddel p\u00e5 resept i 2019, 78 mennene J), legemidler med N) og legemidler fremg\u00e5 med antal l og andel brukere . 4 Summary This year's report Drug consumption in Norway includes data and information from two sources, Norwegian Drug Wholesale s Statistics and the Norwegian Prescription Database (NorPD) , for the period 2015 -2019. Together, these sources provide a complementary picture of drug sales and consumption in Norway. Norwegian Drug W holesale s Statistics In 2019, drugs for human use were sold for a total of NOK 19.7 thousand million (pharmacy purchase price (AIP )), an increase of 3.3% from the previous year (Table 3.1). In addition, the sales of veterinary medicines were NOK 1.3 thousand million. Over time, there has been a steady increase in sales measured in defined daily doses (DDD). In 2019, the number of DDDs was 2.6% higher than the previous year. Over time, the increase in cost has been higher than the increase in volume, measured in DDD. The sale includes medicines with and without Marketing Authorization in Norway. Non -prescription drugs accounted for aroun d 10% of total sales measured in DDD. Figure 3.1 shows the development in total sales of drugs for human use in the period 2000 to 2019 in NOK (AIP) and DDD. Increased prices as well as the use of more expensive drugs have affected cost increases. Costs w ill also be affected by exchange rates. Population growth and an increased proportion of older people contribute to increased drug consumption. Antineoplastic and immunomodulatory agents (ATC group L), had the highest turnover in NOK and accounted for 25% of costs for human medicines in 2019 (Table 3.1). The group includes expensive drugs for the treatment of cancer as well as biological drugs for the treatment of, for example, arthritis and multiple sclerosis. Norwegian Prescription Data base (NorPD) Since the Norwegian Prescription Register was established in 2004, almost 6 million have been included. The number of drugs dispensed according to prescription during this period is just below 679 million. About 97% of the medicines in the No rPD (measured in DDD) were dispensed to individuals in 2019. Of the Norwegian population, 71% were dispensed at least one drug in 2019, 78% of the women and 65% of the men (Table 3.4.1). The proportion (prevalence) was lowest in the age group 5 -9 years for both genders and increases with age. In people over the age of 70, more than 90% of the individuals w ere given a prescription drug (f igure 3.4.1). The three drug groups most commonly used by both genders are antiinfectives for systemic use (ATC group J), agents acting on the nervous system (ATC group N), and agents acting on the respiratory system (ATC group R). Table 3.4.2 shows prevalence for each of the 14 ATC main groups; total and among women and men. The main tables in Part 4 contain data from both data sources. Data from NorPD include medicines on prescription to individuals indicated as number and proportion of users. The Norwegian Drug Wholesale s Statistics also include s sales to hospitals , other health institutions and non -pharmacy outlets , mainly listed as DDD/1000 inhabitants/day. Not all medicines have an assigned DDD, here only data from NorPD is included with number and proportion of users. 5 1 Innled ning \u00c5rets rapport , Legemiddelforbruket i og i Del 2 Materiale og metoder. WHO Collaborating Centre for Drug Statistics Methodology er lokalisert ved Avdeling for legemiddelstatistikk, Folkehelseinstituttet, de store legemiddelgrossistene (Alliance Healthcare Norge AS, Apotek 1 ordnet etter mmenteres aktuelle ATC grupper i Del 4. Se nettsiden til WHO Collaborating Centre for Drug Statistics Methodology for mer informasjon om ATC/DDD systemet de tilfeller der legemiddelet kun er aktuelt for en del sovemiddel i l\u00f8pet av et \u00e5r, enten , angitt i (AIP) og DDD. Kostnadsveksten har h\u00f8yere i kroner , og utgjorde 25 % av kostnadene til humane multippel sklerose. Figure 3.1 Total sales of medicines for human use in 2000 to 2019, NOK in 1000 million (AIP, left axis) and number of DDD in 1000 million (right axis). Source: Norwegian Drug Wholesales Statistics. 01234567 0510152025 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018 1000 million DDD1000 million NOK (AIP)Sales in 1000 million NOK (AIP) Sales in 1000 million DDDs Year 12 Table 3.1: Sales of drugs per ATC main group in 2019 and changes (%) from 2018. Both drugs with and without marketing authorisation are included. Sales in NOK in pharmacy purchase price (AIP). Source: Norwegian Drug Wholesales Statistics. ATC main group Sales in mill DDD % change in DDDs Sales in mill NOK (AIP) % change in NOK (AIP) % share of total cost human medicines A - Alimentary tract and metabolism 512 -3.8 2 192 7.46 11.1 B - Blood and blood forming organs 294 2.5 1 996 7.74 10.1 C - Cardiovascular system 867 3.6 1 16 6 2.02 5.9 D - Dermatologicals 6 3.1 467 9.61 2.4 G - Genito urinary system and sex hormones 238 3.3 839 1.11 4.3 H - Systemic hormonal preparations, excl. sex hormones and insulins 97 1.2 465 9.25 2.4 J - Antiinfectives for systemic use 37 0.1 1 606 -2.44 8.2 L - Antineoplastic and immunomodulating agents 46 6.2 4 977 -2.43 25.3 M - Musculo -skeletal system 123 1.9 727 2.48 3.7 N - Nervous system 489 4.3 2 713 5.08 13.8 P - Antipar asitic products, insecticides and repellents 2 3.1 38 37.00 0.2 R - Respiratory system 449 6.6 1 631 7.06 8.3 S - Sensory organs 37 0.1 519 13.45 2.6 V - Various 1 19.7 346 16.51 1.8 Total human medicines 3 198 2.6 19 683 3.3 100 13 Reseptregisteret Reseptregisteret ble opprettet 1. januar og har % legemidlene (m\u00e5lt I 2019 utgjorde det rundt 85 %. Table 3.2 Comparison of drug sale based on data from the Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database in 2019 . Source: Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database ATC group Norwegian Drug Whol esales Statistics NorPD Total sale (millon DDD) OTC sale in percent (%) of total sales in DDD Sale to individuals in percent (%) of total sales in DDD A - Alimentary tract and metabolism 512 22 75 B - Blood and blood forming organs 294 4 91 C - Cardiovascular system 867 0 97 D - Dermatologicals1) 6 NA 98 G - Genito urinary system and sex hormones 238 3 95 H - Systemic hormonal preparations, excl. sex hormones and insulins 97 0 86 J - Antiinfectives for systemic use 37 0 84 L - Antineoplastic and immunomodulating agents1) 46 NA 82 M - Musculo -skeletal system 123 17 80 N - Nervous system 489 10 81 P - Antiparasitic products, insecticides and repellents 2 18 76 R - Respiratory system 449 25 72 S - Sensory organs1) 37 NA 95 V - Various 1 5 73 Total 3198 10 85 1) In the ATC -groups D, L and S a major proportion of the substances have not been assigned a DDD 15 3.3 Utleveringsgrupper (A, B, C og F) og reseptkategorier (normalresept, i kroner (AIP). Reseptfrie legemidler hadde i el av totalt salg i frie legemidler reduksjonen Sales according to prescription groups 2015 -2019, (narcotics (A), addictive medicines (B), other prescription medicines (C), Over the Counter (OTC) (F) in million DDD and million NOK (AIP). Both drugs with and without marketing authorisation are i ncluded. Source: Norwegian Drug Wholesales Statistics Year Narcotics (A) Addictive medicines (B) Other prescription medicines (C) OTC medicines (F) Total sales (AIP) Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK 2015 35 452 128 231 2 379 13 564 386 1 281 2 928 15 527 2016 38 527 126 249 2 473 14 878 386 1 380 3 022 17 034 2017 40 575 120 247 2 549 16 094 383 1 475 3 091 18 392 2018 41 574 120 284 2 614 16 682 343 1 523 3 119 19 063 2019 44 585 123 313 2 717 17 152 314 1 632 3 199 19 683 Table 3.3.2 Sales according to prescription groups 2015 -2019, (narcotics (A), addictive medicines (B), other prescription medicines (C), Over the Counter (OTC) (F) in million DDD. Both drugs with and without marketing authorisation in Norway are included. Source: Norwegian Prescription Database Year Narcotics (A) Addictive medicines (B) Other prescription medicines (C) OTC medicines (F) Mill DDD Number of prescriptions Mill DDD Number of prescriptions Mill DDD Number of prescriptions Mill DDD Number of prescriptions 2015 31 1 051 904 119 4 988 221 2228 40 052 910 19 1 313 244 2016 33 1 131 263 116 5 021 879 2317 41 817 942 19 1 430 709 2017 35 1 225 098 111 4 927 120 2404 43 410 010 20 1 613 943 2018 37 1 273 168 112 4 951 915 2474 44 557 320 18 1 596 890 2019 39 1 341 519 114 5 033 589 2562 45 853 182 16 1 663 318 16 Table 3.3.3 Number of individuals and proportion of the population by prescription category 2015 -2019. Source: Norwegian Prescription Database Year Non -reimbursable prescriptions Reimbursement prescriptions Health trust financed prescriptions Number of individuals Proportion (%) of the population Sales in mill NOK Number of individuals Proportion (%) of the population Sales in mill NOK Number of individuals Proportion (%) of the population Sales in mill NOK 2015 3 069 625 59.4 3014 2 330 047 45.1 11554 23 240 0.4 2233 2016 3 107 622 59.6 3253 2 391 792 45.9 11720 35 807 0.7 3297 2017 3 144 537 59.8 3294 2 477 356 47.1 12056 46 020 0.9 4169 2018 3 152 088 59.5 3265 2 534 644 47.9 11922 57 871 Reseptpliktige legemiddel p\u00e5 l\u00e5 den p\u00e5 i underkant av 1,4 %. Fra 2010 er andelen uten g yldig f\u00f8dselsnummer under 1 % (0 ,14 % i 2019 ). Table 3 .4.1 Number of individuals and one -year prevalence (%) of the population who had at least one drug dispensed in Norway 2015 -2019. Source: Norwegian Prescription Database Year 2015 2016 2017 2018 2019 Women n (%) 1 956 085 (76.2) 1 981 012 (76.5) 2 007 231 (76.9) 2 022 967 (77.0) 2 054 099 (77.7) Men n (%) 1 622 617 (62.4) 1 649 902 (62.9) 1 680 866 (63.4) 1 701 415 (63.8) 1 741 580 (64.9) Both genders (%) 3 578 702 (69.3) 3 630 914 (69.6) 3 688 097 (70.1) 3 724 382 (70.3) 3 795 679 (71.2) 17 Figure 3.4.1 One -year prevalence (%) of the population who had at least one drug dispensed in 2019 in Norway according to age and gender. The orange line shows the one -year prevalence (%) for women excluding contraceptives for topical use (ATC code G02B) a nd hormonal contraceptives for systemic use (ATC code G03A). Source: med virkning p\u00e5 nervesystemet (ATC N) og legemidler som brukes sykdommer i luftveiene (ATC gruppe R). Table 3.4.2 One-year prevalence (%) of the population who had at least one drug dispensed in Norway in 2019 according to the main ATC groups. Source: Norwegian Prescription Database ATC Number of individuals per age group Total number of individuals Women % Men % Both genders % <15 15-44 45-69 70 A Alimentary tract and metabolism 48 725 278 074 477 458 343 946 1 148 203 24.5 18.7 21.5 B Blood and blood forming organs 5 995 85 378 281 041 356 027 728 441 13.8 13.6 13.7 C Cardiovascular system 10 753 102 238 555 862 485 706 1 154 559 21.6 21.7 21.7 D Dermatologicals 124 379 294 807 250 505 137 267 806 958 16.8 13.6 15.1 G Genito urinary system and sex hormones 4 707 442 186 296 863 165 918 909 674 25.8 8.4 17.1 H Systemic hormonal preparations . excl. sex hormones and insulins 18 850 116 798 203 383 145 260 484 291 12.1 6.1 9.1 J Antiinfectives for systemic use 119 495 470 361 397 657 228 188 1 215 701 27.5 18.3 22.8 L Antineoplastic and immunomodulating agents 1 691 27 488 55 938 36 969 122 086 2.6 2.0 2.3 M Musculo -skeletal system 15 645 320 153 444 570 183 746 964 114 20.9 15.4 18.1 N Nervous system 34 749 478 671 638 594 360 814 1 512 828 33.6 23.2 28.4 P Antiparasitic products , insecticides and repellents 5 105 43 473 36 307 12 862 97 747 2.2 1.5 1.8 R Respiratory system 161 327 537 103 524 390 232 519 1 455 339 30.8 23.9 27.3 S Sensory organs 108 237 211 995 231 273 169 869 721 374 15.5 11.6 13.5 V Various 5 929 14 475 11 911 8 145 40 46 0 0.8 0.8 0.8 19 Tabell 3.4.3 viser en oversikt the highest number of users in Norway 2019. Source: Norwegian Prescription Database ATC code Active ingredient Use Number of individuals Proportion (%) of the population 1 N02BE01 paracetamol1) Analgesic 602 090 11.3 2 J01CE02 854 7.3 3 050 6.6 4 C10AA05 atorvastatin modifying 349 027 6.6 5 N02AJ06 codeine paracetamol Analgesic 345 968 6.5 6 R06AX27 311 5.8 7 A02BC02 pantoprazole1) 295 5.4 11 288 054 5.4 12 N05CF01 459 5.3 13 897 4.1 16 H03AA01 levothyroxine 216 028 4.1 17 corticosteroid 200 577 3.8 18 S01AA01 drops 200 108 3.8 19 J01CA08 Antibacterial 199 160 3.7 20 A02BC05 esomeprazole Reflux oseofagitis (pro ton pump inhibitor) 191 338 3.6 21 R01AD09 mometasone1) Corticosteroid nasal spray 190 474 3.6 22 174 850 3.3 esomeprazole NSAID/analgesic 3.2 24 amlodipine Antihypertensive/cardiac disease 163 575 3.1 25 A11CC05 colecalciferol Vitamin supplement 156 657 2.9 26 G03AA07 levonorgestrel and ethinylestradiol Hormonal contraception 150 374 2.8 27 G03CA03 estradiol Hormonal replacement and postmenopausal osteoporosis 149 693 2.8 28 C09CA06 candesartan Antihypertensive/cardiac disease 141 509 2.7 139 113 2.6 30 N05BA04 oxazepam Anxiolytic 131 846 2.5 1) The ATC -level comprises OTC -medicinal products. The number of individuals is registered for prescription sale only 20 Listen inneholder i hovedsak de Norge m\u00e5lt i kroner de utgj\u00f8r % totale legemiddelsalget i kroner utenom apotek. Table 3.5.1 Top selling OTC medicines available in non -pharmacy outlets and in pharmacies 2015- 2019, total OTC sale given in DDD/1000 inhabitants /day . Source: Norwegian Drug Wholesales Statistics. Active ingredient Total OTC sale given in DDD/1000 inhabitants/day (ATC code) Indication 2015 2016 2017 2018 2019 ibuprofen1) Pain 9.3 9.2 9.3 8.7 8.8 (M01AE01 ) paracetam ol1) Pain 15 15 14.8 14.9 15.2 (N02BE01 ) nicotine Smoking cessation 7.1 7.4 5 5.5 5.8 5.8 6.4 (R06AE07 ) 1) Includes sales of OTC packages only . 2) Includes oxymetazolin og xylometazolin (inclusive combinations with ipratropium), for sales per active substance . 21 Table 3.5.2 Top selling OTC medicines available in non -pharmacy outlets and in pharmacies 2015 -2019, proportion (%) of OTC sale in DDDs sold in non -pharmacy outlets . Source: Norwegian Drug Wholesales Statistics. Active ingredient Proportion (%) of OTC sale in DDDs sold in non -pharmacy outlets (ATC code) 2015 2016 2017 2018 2019 ibuprofen1) 40 39 39 38 38 (M01AE01 ) paracetamol1) 54 54 55 55 56 (N02BE01 47 47 50 50 50 (N07BA01 69 70 71 (R01AA07 ) e 35 32 33 32 ) cetirizine1) 26 23 23 24 25 (R06AE07 ) 1) Includ es sales of OTC packages midler Salget av reseptfrie svakt opp i 2019. Figur e 3.5.1 Total sales of paracetamol (OTC and pricription only packages) in DDD/1000 inhabitants/day in pharmacy and non -pharmacy outlets 2004 -2019. Source: Norwegian Drug Wholesales Statistics. 05101520253035404550 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019DDD/1000 inhabitants/dayPrescription only OTC - non-pharmacy outlets OTC - in pharmacies Year 22 Figur 3. 5.1 viser utviklingen i salg 2019 \u00f8kte salget m\u00e5lt i dos er med 6 %. %. For var andelen 5 % . 3.6 Veterin\u00e6re legemidler (ATC gruppe Q) Salg i ATC gruppe Q - Veterin\u00e6re legemidler var av 1. 4.2 A ing (GERD). Protonpumpehemmer til bruk ikke klassifiseres i noen av de andre viser at % av de totale legemiddelkostnadene (m\u00e5lt i AIP) 16 % \u00f8kt med 22 % fra Reseptregisteret viser utvikling i andel brukere perioden 2010 til 2019. \u00d8kt bruk av diabetes midler kan skyldes at det tilfeller , og at de som diabetes lever lengre og h ar et bedre behandlingstilbud. Diabetes til grad ler i gruppe A10B har \u00f8kt med 21 % fra 2015 til 2019, noe som tilsvarer en \u00f8kning p\u00e5 ca. 30 000 karsykdommer og nyresykdom . Figure 4. 2 Proportion of the population (prevalence %) who had dispensed at least one drug for treatment of diabetes (A10) 2010 - 2019. Source: The Norwegian Prescription Database 0,00,51,01,52,02,53,03,5 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019Proportion (%) of the population A10A - Insulins and analogues A10B - Blood glucose lowering drugs, excl. insulins Year 27 Norwegian Drug Wholesales Statistics Norwegian Pr escription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 A ALIMENTARY TRACT AND METABOLISM A02 DRUGS FOR ACID RELATED DISORDERS 63.40 64.12 66.63 68.52 71.42 467 624 90.6 106.5 A02A ANTACIDS 1.26 1.29 1.26 1.18 1.17 6 151 6 361 6 351 6 488 6 869 1.2 1.3 A02AA Magnesium compounds 0.00 0.00 0.00 0.00 0.01 magnesium hydroxide (3 g) 0.00 0.00 0.00 0.00 0.01 30 69 84 99 A02AC Calcium compounds 0.79 0.82 0.80 (3.5 600 600 497 503 0.1 0.1 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 0.47 0.46 0.45 0.44 0.43 1 823 1 771 1 489 1 488 1 614 0.4 0.3 A02AD01 ordinary salt combinations 0.47 0.46 0.45 0.44 0.43 1 823 1 771 1 489 1 488 1 614 0.4 0.3 A02AH Antacids with sodium bicarbonate 0.22 0.23 0.25 0.26 - 3 707 3 996 4 249 4 444 4 659 0.7 0.9 A02B DRUGS FOR PEPTIC ULCER 3.67 3.56 2.56 49 972 45 877 45 543 47 143 42 314 9.7 7.9 A02BA01 cimetidine (0.8 g) 0.00 0.00 0.00 18 18 64 0.0 0.0 A02BA02 ranitidine (0.3 g) 3.61 3.28 3.19 3.13 2.13 49 572 45 523 45 163 46 860 41 396 9.6 7.8 A02BA03 famotidine (40 mg) 0.34 0.47 0.47 0.43 0.43 630 434 441 303 1 649 0.1 0.3 A02BB Prostaglandins 0.03 0.03 0.03 0.03 0.03 264 371 476 512 471 0.1 0.1 A02BB01 misoprostol (0.8 mg) 0.03 0.03 0.03 0.03 0.03 264 371 476 512 471 0.1 39 132 8.5 A02BC02 pantoprazole (40 21.35 23.93 25.74 27.87 30.38 217 250 239 547 281 762 309 511 42.1 58.1 A02BC03 lansoprazole (30 mg) 5.40 5.11 4.92 4.61 4.48 38 478 36 516 34 983 33 068 31 735 7.5 6.0 A02BC05 esomeprazole (30 mg) 21.55 23.28 24.43 24.94 26.37 159 849 168 378 176 064 181 114 191 338 30.9 35.9 A02BX Other drugs for peptic ulcer and disease (GORD) 0.59 0.61 0.64 0.66 0.66 3 788 4 273 5 367 5 382 6 110 0.7 1.2 A02BX02 sucralfate (4 g) bismuth subnitrate - - - - - 34 37 58 11 12 0.0 0.0 A02BX13 alginic acid 0.55 0.55 0.59 0.59 0.60 3 300 3 788 4 824 4 894 5 612 0.6 1.1 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 2.89 2.82 2.82 2.75 2.79 66 795 68 127 70 684 72 780 75 450 12.9 14.2 A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 1.55 1.53 1.53 1.47 1.49 4 775 5 059 5 738 5 628 6 099 0.9 1.1 28 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 A03AA Synthetic anticholinergics, amino group 0.00 0.00 0.00 0.00 41 36 56 (0.3 g) 0.00 0.00 0.00 0.00 0.00 76 64 0.0 0.0 A03AB Synthetic anticholinergics, quaternary ammonium compounds 0.04 0.04 0.05 0.05 0.05 938 1 155 1 382 1 411 1 731 0.2 0.3 A03AB02 glycopyrronium bromide (0.3 mg P) 0.04 0.04 0.05 0.05 0.05 932 1 148 1 373 1 401 1 722 0.2 (0.1 g) 0.00 0.00 0.00 0.00 0.00 37 42 45 28 40 0.0 0.0 A03AX Other drugs for functional gastrointestinal disorders 1.51 1.49 1.47 1.42 1.43 3 776 3 848 4 284 4 134 4 294 0.7 0.8 A03AX13 silicones (0.5 g) 1.51 1.49 1.47 1.42 1.43 3 776 3 848 4 284 4 134 4 294 0.7 0.8 A03B BELLADONNA AND DERIVATIVES, PLAIN 0.14 0.15 0.15 0.15 0.15 2 603 2 680 3 108 3 398 3 788 0.5 0.7 A03BA Belladonna alkaloids, tertiary amines 0.11 0.12 0.12 0.12 0.12 1 879 1 850 1 919 2 096 2 206 0.4 0.4 A03BA01 atropine (1.5 mg) 0.05 0.05 0.05 0.04 0.04 21 21 8 13 13 0.0 0.0 A03BA03 hyoscyamine (1.2 mg) 0.07 0.07 0.07 0.07 0.08 1 858 1 830 1 911 2 083 2 193 0.4 0.4 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 0.03 0.03 0.03 0.03 0.04 738 842 1 202 1 318 1 602 0.1 0.3 A03BB01 butylscopolamine (60 mg) 0.03 0.03 0.03 0.03 0.04 725 842 1 202 1 318 1 602 0.1 0.3 A03BB03 methylscopolamine (12 mg) 0.00 19 22 19 19 0.0 0.0 A03CA Synthetic anticholinergic agents in combination with psycholeptics 0.00 0.00 0.00 0.00 14 psycholeptics 0.00 0.00 0.00 19 19 0.0 0.0 A03F PROPULSIVES 1.20 1.14 1.14 1.12 1.15 60 678 61 727 63 378 65 341 67 370 11.8 12.6 A03FA Propulsives 1.21 1.15 1.15 1.13 1.15 60 678 61 727 63 378 65 341 67 370 11.8 12.6 A03FA01 metoclopramide (30 mg) 1.20 1.14 1.14 1.12 1.15 60 583 61 627 63 262 65 211 67 268 11.7 12.6 A03FA03 domperidone (30 mg O,P/0.12 g R) 0.01 0.01 0.01 0.01 0.01 97 110 133 141 110 0.0 0.0 A03FA05 alizapride (0.15 g) ANTINAUSEANTS 0.60 0.38 0.36 0.35 0.38 18 971 19 680 20 854 22 099 23 852 3.7 4.5 A04A ANTIEMETICS AND ANTINAUSEANTS 0.60 0.38 0.36 0.35 0.38 18 971 19 680 20 854 22 099 23 852 3.7 4.5 A04AA Serotonin (5HT3) antagonists 0.35 0.34 0.33 0.33 0.35 15 454 16 470 18 169 19 412 21 022 3.0 A04AA01 ondansetron (16 mg) 0.34 0.33 0.32 0.31 0.34 15 366 15 859 15 811 16 482 17 610 3.0 3.3 29 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 A04AA02 granisetron (2 mg O/3 0.00 0.00 0.00 0.00 62 80 113 134 0.0 0.0 A04AA05 palonosetron (0.5 mg O/0.25 P mg) 0.01 0.01 0.00 0.00 0.00 107 83 52 16 12 0.0 0.0 A04AA55 palonosetron, combinations 0.00 0.01 0.01 0.01 983 3 760 4 678 5 146 1.0 A04AD Other antiemetics 0.25 0.04 0.03 0.03 0.03 6 483 5 953 3 785 3 257 3 269 1.3 0.6 A04AD01 scopolamine (1 plaster) 0.23 0.02 0.03 0.02 0.02 2 487 2 355 2 572 2 710 2 904 0.5 0.6 A04AD12 aprepitant (150 mg P/ 165 mg O) 0.02 0.02 0.01 0.00 0.00 4 008 3 605 1 223 551 369 0.8 0.1 A05 BILE AND LIVER THERAPY 0.42 0.45 0.47 0.50 0.54 3 013 3 210 3 373 3 599 3 766 0.6 0.7 A05A BILE THERAPY 0.42 0.45 0.47 0.50 0.54 3 013 3 210 3 373 3 599 3 766 0.6 0.7 A05AA Bile acids and derivatives 0.42 0.45 0.47 0.50 0.54 3 013 3 210 3 373 3 599 3 766 0.6 0.7 A05AA02 ursodeoxycholic acid (0.75 g) 0.42 0.45 0.47 0.50 0.53 3 013 3 209 3 373 3 595 3 758 0.6 0.7 A05AA04 obeticholic acid (10 mg) 0.00 0.00 0.00 22.15 22.63 22.85 22.76 22.46 73 418 83 960 94 189 102 443 109 059 14.2 20.5 A06A DRUGS FOR CONSTIPATION 22.15 22.63 22.85 22.76 22.46 73 418 83 960 94 189 102 443 109 059 14.2 20.5 A06AA Softeners, emollients 0.06 0.09 0.10 0.12 0.00 1 112 1 295 1 344 1 521 1 421 0.2 0.3 A06AA01 liquid paraffin 0.06 0.09 0.10 0.12 1 112 1 295 1 344 1 521 1 421 0.2 0.3 A06AB Contact laxatives 9.07 9.03 8.76 8.48 8.25 28 650 30 656 30 836 30 018 29 853 5.6 5.6 A06AB02 bisacodyl (10 mg) 3.21 3.12 2.97 2.84 2.66 5 586 5 667 5 533 5 642 5 430 1.1 1.0 A06AB06 senna glycosides 1.61 1.49 1.41 1.30 1.19 1 475 1 462 1 329 1 270 1 162 0.3 0.2 A06AB08 sodium picosulfate (5 mg) 4.21 4.37 4.33 4.29 4.35 15 122 16 038 16 766 17 244 17 864 2.9 3.4 A06AB20 contact laxatives in combination - - - - - 22 21 16 0.0 A06AB56 senna glycosides, combinations - - - - - 59 <5 0.0 A06AB58 sodium picosulfate, combinations 0.05 0.05 0.05 0.05 0.05 7 990 9 198 8 889 7 628 7 046 1.6 1.3 A06AC Bulk -forming laxatives 1.26 1.35 1.56 1.61 1.60 3 049 3 643 4 717 6 120 7 542 0.6 1.4 A06AC01 ispaghula (psylla seeds) (7 g) 1.26 1.35 1.56 1.61 1.60 3 049 3 643 4 717 6 120 7 542 0.6 A06AD Osmotically acting laxatives 10.40 10.75 10.98 11.09 11.17 46 213 54 417 64 136 72 531 78 188 9.0 14.7 A06AD11 lactulose (6.7 g) 9.01 9.00 8.87 8.59 8.52 16 713 17 324 18 482 18 532 19 491 3.2 3.7 A06AD12 lactitol (10 g) 0.00 0.00 0.00 0.00 23 19 macrogol (10 g) 0.01 0.00 0.00 0.00 0.00 212 33 28 17 17 0.0 sodium phosphate (50 g) 0.00 0.00 0.00 0.00 0.00 055 671 801 A06AD65 macrogol, combinations 1.37 1.74 2.10 2.49 2.64 30 255 38 581 47 418 56 190 61 537 5.9 11.6 A06AG Enemas 1.24 1.21 1.18 1.16 1.15 6 105 6 254 6 790 6 748 6 920 1.2 1.3 A06AG02 bisacodyl 0.15 0.14 0.13 0.12 0.12 1 674 1 556 1 452 1 263 1 159 0.3 0.2 A06AG04 glycerol - - - - - 905 819 1 024 1 069 1 027 0.2 0.2 A06AG06 oil - - - - - 64 129 114 106 183 0.0 0.0 30 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 A06AG10 docusate sodium, incl. combinations 0.11 0.11 0.10 0.10 0.10 1 578 1 709 1 900 2 023 2 131 0.3 0.4 2 470 2 779 2 773 2 892 0.4 0.5 A06AH Peripheral opioid receptor antagonists 0.01 0.05 0.07 0.08 0.10 194 637 801 903 1 078 0.0 0.2 A06AH01 methylnaltrexone bromide (6 mg) 0.01 0.01 0.01 0.01 0.01 138 153 132 82 103 0.0 0.0 A06AH03 naloxegol (25 mg) 0.00 0.04 0.06 0.08 693 836 1 005 0.0 0.2 A06AX Other drugs for constipation 0.10 0.17 0.20 0.22 0.20 1 811 2 478 2 676 2 984 3 226 0.4 0.6 A06AX01 glycerol - - - - - 40 137 134 128 204 0.0 0.0 A06AX04 linaclotide (0.29 mg) 0.07 0.14 0.16 0.18 0.15 1 362 1 927 2 160 2 478 2 592 0.3 0.5 A06AX05 prucalopride (2 mg) 0.03 0.03 0.04 0.04 0.04 475 504 480 464 549 0.1 0.1 A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/A NTIINFECTIVE AGENTS 7.10 7.83 7.85 8.22 8.57 83 057 85 501 88 869 92 403 94 456 16.1 17.7 A07A INTESTINAL 35 536 36 202 36 965 37 503 37 756 6.9 7.1 A07AA Antibiotics 0.30 0.30 0.30 0.31 0.32 35 536 36 202 36 965 37 503 37 756 6.9 A07AA01 neomycin (5 A07AA02 0.27 0.25 0.24 0.23 0.23 35 051 35 641 36 290 36 737 36 929 6.8 A07AA06 paromomycin (3 g) 0.00 0.00 0.00 0.00 0.00 174 77 42 76 vancomycin (2 g) 0.00 0.00 0.00 0.00 391 370 rifaximin (0.6 g) 0.03 0.04 0.06 0.08 0.09 197 276 303 403 A07B INTESTINAL ADSORBENTS 0.06 0.06 0.04 0.04 0.04 176 173 196 261 290 0.0 0.1 A07BA Charcoal preparations 0.06 0.06 0.04 0.04 0.04 94 94 65 95 74 0.0 0.0 A07BA01 medicinal charcoal (5 g) 0.06 0.06 0.04 0.04 0.04 94 94 65 95 74 0.0 0.0 A07BB Bismuth preparations - - - - - 82 79 131 166 216 0.0 0.0 A07C ELECTROLYTES WITH CARBOHYDRATES 0.04 0.04 0.04 0.04 0.04 451 444 445 444 447 0.1 0.1 A07CA Oral rehydration salt formulations 0.04 0.04 0.04 0.04 0.04 441 427 426 420 424 0.1 0.1 A07D ANTIPROPULSIVES 1.51 1.51 1.60 1.68 1.74 20 595 21 467 23 288 25 560 26 595 4.0 5.0 A07DA Antipropulsives 1.51 1.51 1.60 1.68 1.74 20 595 21 467 23 288 25 560 26 595 4.0 5.0 A07DA02 opium (0.1 g) 0.02 0.02 0.02 0.03 0.04 223 268 306 400 486 0.0 0.1 A07DA03 loperamide (10 mg) 1.43 1.44 1.50 1.55 1.62 20 232 21 098 22 778 24 846 26 083 3.9 4.9 A07DA06 eluxadoline (0.2 g) 0.00 0.02 0.00 119 432 A07DA53 loperamide, combinations 0.06 0.05 0.07 0.09 0.08 362 400 437 423 438 AGENTS 5.18 5.91 5.86 29 31 533 32 418 5.5 6.1 A07EA Corticosteroids acting locally 0.36 0.41 0.44 0.44 0.45 6 043 6 834 7 507 7 712 7 977 1.2 1.5 A07EA01 prednisolone (1 enema) 0.00 0.00 0.00 69 10 17 17 0.0 0.0 31 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 A07EA02 hydrocortisone 0.02 0.03 0.02 0.01 0.00 339 390 322 198 67 0.1 0.0 A07EA06 budesonide (1 enema R/9 mg O) 0.34 0.38 0.42 0.43 0.45 5 720 6 500 7 230 7 543 7 902 1.1 1.5 47 0.0 A07EB01 cromoglicic acid (0.8 g) 0.00 0.00 0.00 0.01 0.00 46 42 47 53 47 0.0 0.0 A07EC Aminosalicylic acid and similar agents 4.81 5.50 5.41 5.69 5.97 24 112 25 111 25 797 26 488 27 071 4.7 5.1 A07EC01 0.59 5 771 5 683 5 457 5 410 5 240 1.1 1.0 A07EC02 mesalazine (1.5 g) 3.99 4.34 4.66 4.96 5.32 18 010 19 121 20 045 20 861 21 617 3.5 4.1 A07EC03 olsalazine (1 g) 0.05 0.42 0.04 0.04 0.04 343 281 273 254 230 0.1 0.0 A07EC04 balsalazide (6.75 g) 0.04 0.04 0.03 0.03 0.03 528 479 471 388 374 0.1 0.1 A07F ANTIDIARRHEAL MICROORGANISMS 0. 01.. 0. 01... 0. 01... 0. 00... 0. 00... 1 185 725 559 422 418 0.2 0.1 A07FA Antidiarrheal microorganisms 0.01 0.01 0.01 0.00 0.00 1 185 725 559 422 418 0.2 0.1 A07FA01 lactic acid producing organisms - - - - - 742 370 294 215 153 0.1 0.0 A07FA02 saccharomyces boulardii (1 g) 0.01 0.01 0.01 0.00 0.00 528 377 287 217 268 0.1 0.1 A07FA51 lactic acid producing organisms, combinations - - - - - 20 53 <5 <5 <5 0.0 - A07X OTHER ANTIDIARRHEALS - - - - - 67 7 <5 0.0 A07XA Other antidiarrheals - - - - - 67 7 <5 0.0 A07XA04 racecadotril - - - - - 57 <5 0.0 A08 ANTIOBESITY PREPARATIONS, EXCL. DIET 6 361 6 293 6 256 10 415 1.2 2.0 A08A ANTIOBESITY PREPARATIONS, EXCL. DIET 0.35 0.32 0.31 6 361 6 293 6 256 8 051 10 415 1.2 2.0 A08AA Centrally acting antiobesity products 0.01 0.13 0.28 265 3 072 6 090 1.1 A08AA62 bupropion and naltrexone 0.01 0.13 0.28 265 3 072 6 090 1.1 A08AB Peripherally acting antiobesity products 0.35 0.32 0.31 0.27 0.24 6 361 6 293 6 019 5 186 4 625 1.2 0.9 A08AB01 orlistat (0.36 g) 0.35 0.32 0.31 0.27 0.24 6 361 6 293 6 019 5 186 4 625 1.2 0.9 A09 DIGESTIVES, INCL. ENZYMES 0.72 0.75 0.79 0.81 0.91 5 925 6 091 6 597 6 919 7 356 1.2 1.4 A09A DIGESTIVES, INCL. ENZYMES 0.72 0.75 0.79 0.81 0.91 5 925 6 091 6 597 6 919 7 356 1.2 1.4 A09AA Enzyme preparations 0.71 0.75 0.79 0.81 0.91 5 849 6 022 6 364 6 657 7 013 1.1 (lipase, protease etc.) 0.71 0.75 0.79 839 6 012 6 359 6 648 6 999 1.1 1.3 A09AB Acid preparations 0.09 0.08 0.08 0.09 0.09 50 64 65 63 73 0.0 0.0 A09AB01 glutamic acid hydro - chloride (1.5 g) 0.09 0.08 0.07 0.08 0.09 36 53 51 53 52 hydrochloride (1 g) 0.00 0.00 0.00 0.00 9 9 10 18 0.0 0.0 A09AB03 hydrochloric acid - - - - - <5 <5 5 <5 - - 32 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 A09AC Enzyme and acid preparations, combinations - - - - - 31 31 195 217 289 0.0 0.1 A09AC01 pepsin and acid preparations - - - - - 5 28 194 217 289 0.0 0.1 A09AC02 multienzymes and acid preparations - - - - - 26 <5 <5 0.0 A10 DRUGS USED IN DIABETES 51.55 53.03 55.42 56.23 58.50 176 615 183 452 192 542 199 563 208 034 34.2 39.0 A10A INSULINS AND 20.71 61 559 63 529 65 733 68 136 70 320 11.9 13.2 A10AB Insulins and analogues for injection, fast -acting 7.89 8.03 8.36 8.71 8.87 40 730 42 145 43 534 45 172 46 167 7.9 8.7 A10AB01 insulin (human) (40 U) 0.14 0.12 0.11 0.09 0.07 911 825 742 640 541 0.2 0.1 A10AB04 insulin lispro (40 U) 2.19 2.29 2.35 2.06 1.95 10 214 10 717 11 202 10 699 10 017 2.0 1.9 A10AB05 insulin aspart (40 U) 5.48 5.53 5.82 6.50 6.79 30 073 31 059 32 700 35 590 36 819 5.8 6.9 A10AB06 insulin glulisine (40 U) Insulins and analogues for injection, intermediate -acting 6.70 6.64 6.35 5.86 5.45 33 618 34 174 33 804 32 246 30 443 6.5 5.7 A10AC01 insulin (human) (40 U) 6.70 6.64 6.35 5.86 5.45 33 618 34 174 33 804 32 246 30 443 6.5 5.7 A10AD Insulins and analogues for injection, inter - mediate - or long -acting combined with fast - acting 1.44 1.27 1.13 0.94 0.79 5 938 5 323 4 678 4 081 3 474 1.2 0.7 A10AD04 insulin lispro (40 U) 0.11 0.10 0.09 0.07 0.06 481 405 342 296 0.1 0.1 insulin aspart (40 U) 1.33 1.18 1.05 0.87 0.73 5 404 4 853 4 278 3 741 3 182 1.1 0.6 A10AE Insulins and analogues for injection, long -acting 3.55 3.85 4.41 4.99 5.60 19 708 21 381 25 315 29 213 33 165 3.8 6.2 A10AE04 insulin glargine (40 U) 2.31 2.60 2.77 2.80 2.86 13 617 15 044 16 352 16 677 16 950 2.6 3.2 A10AE05 insulin detemir (40 U) 1.22 1.11 0.99 0.82 0.72 6 284 6 126 5 721 4 957 4 536 1.2 0.9 A10AE06 insulin degludec (40 U) 0.02 0.14 0.51 0.97 1.34 127 1 087 3 386 5 938 8 349 0.0 1.6 A10AE54 insulin glargine and lixisenatide (40 U) 0.00 0.02 32 129 0.0 A10AE56 insulin degludec and liraglutide (40 U) 0.00 0.16 0.40 0.66 46 1 642 3 459 5 152 1.0 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 31.96 33.24 35.17 35.74 37.79 139 072 145 588 21.4 23.8 A10BB Sulfonylureas 7.78 7.33 6.77 5.82 5.20 34 201 32 265 29 721 26 538 23 787 6.6 4.5 A10BB01 glibenclamide (7 mg) 0.12 0.09 0.09 0.07 615 530 471 A10BB07 glipizide (10 mg) 0.43 0.37 0.31 0.27 0.23 2 790 2 466 2 109 1 785 1 552 0.5 0.3 A10BB12 glimepiride (2 mg) 7.23 6.87 6.37 5.48 4.91 30 775 29 212 27 064 24 274 21 820 6.0 4.1 A10BD Combinations of oral blood glucose lowering drugs 3.40 3.67 4.21 4.54 4.94 20 716 23 050 26 294 781 31 085 4.0 36 27 23 27 30 0.0 0.0 33 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 A10BD07 metformin and sitagliptin (2 UD) 1.48 1.72 2.05 2.36 2.63 9 169 10 815 13 391 15 199 16 627 1.8 3.1 A10BD08 metformin and (2 1.76 1.62 1.54 10 629 10 786 10 655 10 162 9 710 2.1 1.8 A10BD10 metformin and saxagliptin (2 UD) 0.02 0.02 0.02 0.02 0.01 109 117 110 112 101 0.0 0.0 A10BD11 metformin (2 UD) 0.06 0.09 0.13 0.16 0.22 436 588 852 1 166 1 519 0.1 0.3 A10BD19 linagliptin and empagliflozin (2 UD) 0.01 0.03 A10BD20 metformin empagliflozin (2 UD) 0.00 0.04 0.12 0.22 0.33 <5 331 881 1 527 2 278 - 0.4 A10BD21 saxagliptin and dapagliflozin (1 UD) 0.01 0.03 0.04 91 metformin 0.01 17 67 0.0 A10BF Alpha glucosidase inhibitors 0.04 0.04 0.04 0.03 0.02 495 463 442 416 369 0.1 0.1 A10BF01 acarbose (0.3 g) 0.04 0.04 0.04 0.03 0.02 495 463 442 416 369 0.1 0.1 A10BG Thiazolidinediones 0.25 0.23 0.20 0.23 0.20 1 500 1 492 1 415 1 373 1 327 0.3 0.3 A10BG03 pioglitazone (30 mg) 0.25 0.23 0.20 0.23 0.20 1 500 1 492 1 415 1 373 1 327 0.3 0.3 A10BH Dipeptidyl peptidase 4 inhibitors 3.04 3.39 3.86 4.28 19 048 21 861 25 212 27 093 28 211 3.7 5.3 A10BH01 sitagliptin (0.1 g) 1.60 1.78 2.14 2.40 2.60 10 158 12 060 14 903 16 770 18 144 2.0 3.4 A10BH02 vildagliptin (0.1 g) 0.35 0.34 0.33 0.30 0.28 2 540 2 500 2 374 2 163 2 035 0.5 0.4 A10BH03 saxagliptin (5 mg) 0.25 0.23 0.21 0.19 0.17 1 438 1 351 1 233 1 087 968 0.3 0.2 A10BH05 linagliptin (5 mg) 0.85 1.03 1.18 1.22 1.23 5 225 6 268 7 066 7 333 7 379 1.0 1.4 A10BJ Glucagon -like 2.93 9 715 11 074 12 861 14 626 20 448 1.9 3.8 A10BJ01 exenatide (15 mcg/ 0.286 mg) 0.18 0.20 0.18 0.16 0.14 1 317 1 324 1 251 1 112 1 004 0.3 0.2 A10BJ02 liraglutide (1.5 mg) 1.23 1.28 1.39 1.52 1.63 7 488 7 980 9 083 10 119 11 206 1.5 2.1 A10BJ03 lixisenatide (20 mcg) 0.11 0.10 0.07 0.06 0.05 940 725 525 398 347 0.2 0.1 A10BJ05 dulaglutide (0.16 mg) 0.02 0.22 0.40 0.56 0.70 335 1 432 2 314 3 277 4 135 0.1 0.8 A10BJ06 semaglutide (0.11 mg) 0.00 0.41 18 5 267 1.0 Sodium -glucose co - transporter 2 (SGLT2) inhibitors 1.39 2.05 2.90 3.62 4.52 9 442 14 041 20 330 25 613 31 293 1.8 5.9 A10BK01 dapagliflozin (10 mg) 1.32 1.51 1.68 1.79 1.96 8 475 9 437 10 588 11 297 12 225 1.6 2.3 A10BK02 canagliflozin (0.2 g) 0.03 0 0 0 0 440 0.0 0.1 A10BK03 empagliflozin (17.5 mg) 0.07 0.55 1.21 1.83 2.52 1 102 4 910 10 105 14 625 18 907 0.2 3.6 A10BK04 ertugliflozin (10 mg) 0.00 0.02 0 0 0 49 189 0.0 0.0 A10BX Other blood glucose lowering drugs, excl. insulins 0.03 0.03 0.03 0.02 0.02 184 172 163 156 149 0.0 0.0 A10BX02 repaglinide (4 mg) 0.03 0.03 0.03 0.02 0.02 184 172 163 156 149 0.0 0.0 34 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 A12 MINERAL SUPPLEMENTS 20.00 20.76 21.97 22.58 23.88 149 619 29.0 19.26 147 490 161 849 24.9 30.4 A12AA Calcium 0.32 0.30 0.31 0.14 0.13 1 183 1 193 1 233 1 017 887 0.2 0.2 0.00 8 5 6 9 - 0.0 A12AA04 calcium carbonate (3 g) 0.00 154 0.0 A12AA06 calcium lactate gluconate (3 g) 0.31 0.30 0.31 0.14 0.12 1 175 1 184 1 228 1 012 843 0.2 0.2 A12AX Calcium, combinations with vitamin D and/or other drugs 16.80 17.75 18.95 19.89 21.02 127 683 137 414 146 576 152 946 161 232 24.7 30.3 A12B POTASSIUM 1.55 1.51 1.48 1.39 1.42 20 554 20 684 20 365 20 526 20 556 4.0 3.9 A12BA Potassium 1.55 1.51 1.48 1.39 1.42 20 554 20 684 20 365 20 526 20 556 4.0 3.9 A12BA01 potassium chloride (3 g) 1.32 1.29 1.25 1.16 1.18 18 469 18 437 18 209 18 118 17 922 3.6 3.4 A12BA02 potassium citrate (4 g) 0.22 0.22 0.23 0.23 0.24 3 048 2 705 2 647 2 898 3 104 0.6 0.6 A12BA30 potassium (different salts in combination) - - - - - 6 <5 5 6 5 0.0 0.0 A12C OTHER MINERAL SUPPLEMENTS 1.34 1.20 1.22 1.16 1.31 7 483 8 088 8 996 9 500 9 419 1.5 1.8 A12CA Sodium 0.57 0.46 0.48 0.60 0.67 1 851 2 277 2 554 3 114 3 292 0.4 0.6 A12CA01 sodium chloride (1 g) 0.57 0.46 0.48 0.60 0.67 1 851 2 277 2 554 3 114 3 292 0.4 0.6 A12CB Zinc 0.04 0.04 0.03 0.03 0.03 621 607 566 456 405 0.1 0.1 A12CB01 zinc sulfate (0.6 g) 0.04 0.04 0.03 0.03 0.03 621 607 566 456 405 0.1 0.1 A12CC Magnesium 0.73 0.70 0.70 0.54 0.61 5 148 5 385 6 063 6 184 5 926 1.0 1.1 g) 0.00 0.00 0.00 53 80 146 0.0 0.0 A12CC10 magnesium oxide - - - - - 189 222 289 399 412 0.0 0.1 A12CC30 magnesium (different salts in combination) 0.73 0.70 0.70 0.53 0.61 4 942 5 139 5 750 5 803 5 465 1.0 1.0 A12CX Other mineral products - - - - - 10 16 17 15 21 0.0 0.0 A13 TONICS - - - - - <5 <5 <5 - A14 ANABOLIC AGENTS FOR SYSTEMIC USE 0.01 0.01 0.00 0.00 0.00 1 279 1 067 1 017 998 987 0.3 0.2 A14A ANABOLIC STEROIDS 0.01 0.01 0.00 0.00 0.00 1 279 1 067 1 017 998 987 0.3 0.2 A14AA Androstan derivatives - - - - - 1 230 1 030 974 951 928 0.2 0.2 A14AA07 prasterone - - - - - 1 228 1 028 973 951 928 0.2 0.2 A14AA08 oxandrolone - - - - - <5 Estren derivatives 21 20 11 <5 0.0 nandrolone (2 mg) 0.01 0.01 0.00 0.00 0.00 28 21 20 11 <5 0.0 - 35 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/day 2015 2016 2017 2018 2019 A16 OTHER METABOLISM PRODUCTS 163.55 184.51 219.76 410 462 466 497 TRACT AND METABOLISM PRODUCTS 163.55 184.51 219.76 405 409 462 466 acids and derivatives 24.90 30.60 37.10 39.50 36.56 200 208 229 (2 g) 57.88 63.63 73.06 84.12 186 169 174 0.0 0.0 A16AA03 glutamine - - - - - 16 7 5 <5 <5 0.0 - A16AA04 mercaptamine (2 g) 6.00 5.90 6.50 6.90 6.36 9 10 10 10 10 0.0 0.0 A16AA05 carglumic acid (0.2 g) 3.40 9.60 11.30 7.90 <5 18.90 21.30 21.00 21.30 22.30 25 23 24 24 0.0 A16AB Enzymes 67.67 63.94 66.23 64.43 66.38 80 82 (300 U) 5.97 6.24 6.43 6.13 8 9 agalsidase alfa (1 mg) 20.20 16.70 15.50 14.30 14.30 20 17 16 16 16 beta (5 mg) 35.00 35.50 38.70 38.40 40 41 43 43 0.0 0.0 A16AB05 laronidase (1 TU) 1.70 1.30 1.30 1.20 1.33 A16AB07 alglucosidase alfa (0.1 - <5 <5 mg) 2.90 4.40 5.20 5.3 <5 6 10 12 12 - 0.0 A16AX Various alimentary tract and metabolism products 62.70 69.01 81.18 122 155 thioctic acid (0.6 g) 9.30 6.91 7.48 6.08 5.93 64 41 42 35 32 0.0 0.0 A16AX03 sodium phenylbutyrate (20 47.00 16 15 16 17 18 0.0 0.0 A16AX05 zinc acetate (0.15 g) 10.20 9.20 8.00 9.40 9.25 13 14 14 15 17 0.0 0.0 A16AX06 miglustat (0.3 g) 6.10 5.70 7.40 8.40 9.21 6 6 8 10 8 0.0 0.0 A16AX07 sapropterin - - - - - 21 22 33 36 39 0.0 0.0 A16AX08 teduglutide (5 mg) 1.40 4.20 15.80 (15 g) 1.14 <5 - <5 - - A16AX12 trientine - - - - - 8 12 14 14 16 0.0 0.0 A16AX14 migalastat (61.5 mg) 0.80 3.60 6.75 <5 5 9 0.0 A16AX15 telotristat (0.75 g) 1.73 6.99 <5 21 i DDD Innen utgj\u00f8r antitrombotiske 78 % av etterfulgt av mot 83 % av all DDD i gruppe B01AC, etterfulgt av klopidogrel (8 %). Reseptregisteret et preparat innen gruppe n peroral e antikoagulanti 2015 ble andel brukere av apik saban \u00f8kt fra 18 % i 2015 til 53 % i 2019. 37 Figure 4.3.1. Sales of oral anticoagulants at andel brukere 12 har \u00f8kt siste 5 \u00e5r. I som bruker tabletter \u00f8kt fra 0, 5 % i 2016 til 39 % i 2019. Dette er i tr\u00e5d med 2018 . 0510152025 2010 2011 2012 apixaban rivaroxaban dabigatran etexilate warfarinDDD/1000 inhabitants/day Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 B BLOOD AND BLOOD FORMING B01AA Vitamin K antagonists 8.19 7.16 6.02 5.01 4.20 69 357 60 605 51 304 42 737 35 585 13.4 6.7 B01AA01 dicoumarol (0.1 g) 0.01 0.00 0.00 0.00 0.00 51 47 39 33 29 0.0 B01AA03 warfarin (7.5 mg) 8.19 7.16 6.02 5.01 4.20 69 306 60 561 51 268 42 704 35 558 13.4 6.7 B01AB Heparin group 6.29 6.20 6.25 6.08 6.09 54 116 56 268 56 928 56 295 54 853 10.5 10.3 B01AB01 heparin (10 TU) 0.17 0.15 0.17 0.16 0.17 1 180 1 184 1 327 1 230 1 227 0.2 0.2 B01AB04 dalteparin (2.5 TU) 3.31 3.42 3.58 3.59 3.32 31 785 34 748 36 168 36 792 33 337 6.2 6.3 B01AB05 enoxaparin (2 TU) 2.81 2.62 2.50 2.34 2.60 21 964 21 078 20 307 19 037 21 309 390 695 385 978 76.7 72.4 B01AC04 clopidogrel (75 mg) 3.96 4.07 4.55 5.18 6.05 26 629 27 618 30 764 34 742 40 351 5.2 7.6 B01AC05 ticlopidine (0.5 g) 0.02 0.02 0.02 0.01 0.01 132 108 104 81 72 0.0 0.0 B01AC06 acetylsalicylic acid (1 2.49 2.11 19 030 18 752 17 789 16 485 14 447 3.7 (4.3 mg) 0.00 0.00 0.00 24 18 20 0.0 0.0 B01AC22 prasugrel (10 mg) 0.23 0.20 0.20 0.20 0.20 1 745 1 627 1 625 1 645 1 599 0.3 0.3 B01AC23 cilostazol (0.2 g) 0.00 <5 - B01AC24 ticagrelor (0.18 g) 1.07 1.13 1.12 1.11 1.14 9 022 9 476 9 588 9 654 9 857 1.8 B01AC25 cangrelor 21 0.0 B01AC30 acetylsalicylic acid and dipyridamole (2 caps) 2.66 2.75 2.70 2.61 2.72 16 239 16 805 16 809 16 207 17 199 3.1 3.2 number of DDDs/year 2015 2016 Direct thrombin inhibitors 1.95 1.89 1.88 1.87 1.84 13 846 13 331 13 118 12 918 12 373 2.7 2.3 B01AE07 dabigatran etexilate (0.3 g) 1.95 1.89 1.88 1.87 1.84 13 846 13 331 13 118 12 918 12 373 2.7 2.3 B01AF Direct factor Xa 988 170 8.9 3.79 4.43 4.80 5.02 5.08 25 492 28 935 30 795 31 822 32 160 4.9 6.0 B01AF02 apixaban (10 mg) 2.45 4.62 7.03 9.27 11.53 21 514 37 297 54 002 69 381 84 053 4.2 15.8 B01AF03 edoxaban (60 mg) 0.00 0.05 0.18 0.35 15 448 1 479 2 antithrombotic agents 0.00 0.00 0.00 0.00 (2.5 mg) 0.00 0.00 0.00 0.00 0.00 12 18 21 34 26 0.0 0.0 39 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 B02 ANTIHEMORRHAGICS 0.22 0.22 0.22 0.21 0.22 13 700 13 711 14 447 14 723 13 968 2.7 2.6 B02A ANTIFIBRINOLYTICS 0.20 0.20 0.20 0.20 0.20 13 162 13 112 13 819 14 074 13 247 2.6 2.5 B02AA Amino acids 0.20 0.20 0.20 0.20 0.20 13 160 13 110 13 817 14 073 13 246 2.6 2.5 B02AA02 tranexamic acid (2 g) 0.20 0.20 0.20 0.20 0.20 13 160 13 110 13 817 14 073 13 246 2.6 2.5 B02B VITAMIN K AND OTHER HEMOSTATICS 0.02 0.02 0.02 0.01 0.01 627 697 740 771 827 0.1 0.2 B02BA Vitamin K 0.02 0.02 0.02 0.01 0.01 260 280 269 283 272 0.1 0.1 B02BA01 phytomenadione (20 mg) 0.02 0.02 0.02 0.01 0.01 260 280 269 283 272 0.1 0.1 B02BD Blood coagulation factors - - - - - 274 280 287 295 313 0.1 0.1 B02BD02 coagulation factor VIII - - - - - 189 191 198 200 212 0.0 0.0 B02BD03 factor VIII inhibitor bypassing activity - - - - - 9 11 8 6 5 0.0 0.0 B02BD04 coagulation factor IX - - - - - 47 49 51 58 53 0.0 0.0 B02BD06 von Willebrand factor and coagulation factor VIII in combination - - - - - 16 12 14 12 23 0.0 0.0 B02BD08 coagulation factor VIIa - - - - - 10 17 15 19 21 0.0 0.0 B02BX Other systemic hemostatics 0.01 0.02 0.03 0.03 0.04 91 137 182 192 248 0.0 0.1 B02BX04 romiplostim (30 mcg) 0.01 0.01 0.01 0.01 0.01 23 30 41 45 45 0.0 0.0 B02BX05 eltrombopag (50 mg) 0.01 0.01 0.02 0.02 0.02 72 113 150 154 206 0.0 0.0 B02BX06 emicizumab (15 mg) 31.9 42.0 B03A IRON PREPARATIONS 6.80 6.80 6.65 6.40 6.51 33 866 38 027 41 525 44 374 48 560 6.6 9.1 B03AA Iron bivalent, oral preparations 6.73 6.72 6.55 6.29 6.39 306 36 331 39 42 478 46 688 6.3 8.8 B03AA01 ferrous glycine sulfate (0.2 g) 1.44 1.53 1.22 1.33 1.51 9 522 11 113 10 275 12 755 15 799 1.8 3.0 B03AA02 ferrous fumarate (0.2 g) 0.17 0.17 0.16 0.08 1 623 1 822 1 959 1 380 7 0.3 0.0 B03AA07 ferrous sulfate (0.2 g) 5.29 5.19 5.34 4.96 4.88 21 566 23 850 28 907 29 018 31 408 4.2 5.9 B03AB Iron trivalent, oral preparations - - - - - 10 45 0.0 0.0 B03AB10 ferric maltol - - - - - 10 45 0.0 0.0 B03AC Iron, parenteral preparations 0.07 0.08 0.09 0.10 0.12 1 702 1 853 1 968 2 065 2 028 0.3 0.4 B03B VITAMIN B 12 AND FOLIC ACID 33.77 35.69 37.81 39.55 42.28 134 171 521 182 574 26.0 19.89 18.75 19.04 20.15 97 519 102 261 104 146 111 351 118 472 18.9 22.2 B03BA01 cyanocobalamin (1 mg O/20 mcg P) 3.04 2.67 3.09 5.79 7.97 15 171 14 032 20 180 39 217 53 135 2.9 10.0 B03BA03 hydroxocobalamin (20 mcg) 16.97 17.19 15.64 13.25 12.17 85 109 91 031 87 855 76 289 69 701 16.5 13.1 B03BA05 mecobalamin (1.5 mg O/0.2 mg P) 0.05 0.03 0.02 0.01 0.01 257 173 179 64 45 0.1 0.0 B03BB Folic acid and derivatives 13.71 15.80 19.06 20.51 22.13 40 763 49 263 62 657 67 279 72 327 7.9 13.6 B03BB01 folic acid (0.4 mg) 13.71 15.80 19.06 20.51 22.13 40 717 49 204 62 614 67 205 72 212 7.9 13.6 40 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 B03X OTHER ANTIANEMIC PREPARATIONS 0.60 0.63 0.64 0.66 0.73 3 491 3 591 3 653 3 758 4 010 0.7 0.8 B03XA Other antianemic preparations 0.60 0.63 0.64 0.66 0.73 3 491 3 591 3 653 3 758 4 010 0.7 0.8 B03XA01 erythropoietin (1 TU) 0.07 0.06 0.06 0.07 0.08 284 259 237 254 332 (4.5 mcg) 0.49 0.54 0.57 0.55 0.57 2 985 3 190 3 336 3 277 3 046 0.6 0.6 B03XA03 methoxy polyethylene glycol -epoetin beta (4 mcg) 0.03 0.03 0.01 0.04 0.08 244 205 109 372 731 0.1 0.1 number of DDDs/year ATC 2015 2016 3346 4221 5024 5943 HEMATOLOGICAL AGENTS 3346 4221 5024 5579 5943 110 117 135 141 143 0.0 0.0 B06AA Enzymes - - - - - 10 5 8 10 11 0.0 0.0 B06AA03 hyaluronidase - - - - - 10 5 8 10 11 0.0 0.0 B06AC Drugs used in hereditary angioedema 3346 4221 5024 5579 100 111 126 130 plasma derived (1.4 TU) 2354 2779 3448 4042 63 72 88 90 icatibant (30 mg) 992 1442 1576 1537 1601 65 73 87 90 99 0.0 0.0 B06AC04 conestat alfa (3.5 TU) 32 <5 - i DDD 33 % gruppens DDD. Reseptregisteret viser at i 2019 av minst ACE inh ibitors/ARBs (C09) in 2000 -2019. Source: Norwegian Drug Wholesales Statistics. Figure 4.4.2 Proportion of the population (prevalence, %) who had dispensed ACE -inhibitors, plain (C09A), ACE -inhibitors, combinations (C09B), 2005 -2019. Source: Norwegian Prescription Database 020406080100120140160180200220240260280300320 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018DDD/1000 inhabitants/dayACE-inhibitors + angiotensin II antagonists Calcium channel blockers Beta blocking agents Diuretics Anithypertensives Year 0123456 2005 2007 2009 2011 2013 2015 2017 2019Proportion (%) of the populationARBs plain ARBs combinations ACE-I plain ACE-I combinations Reseptregisteret v Det mest brukte middel et er atorvastatin som i totalt for av andel brukere fra 2015 t 2019. Av andre lipidsenkende midler er det Source: Norwegian Drug Wholesales Statistics 020406080100120140160 2000 2002 2004 2006 2008 2010 2012 2014 2016 Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 C CARDIOVASCULAR SYSTEM C01 CARDIA C THERAPY 10.80 10.29 10.04 9.63 9.47 108 892 110 226 109 552 109 092 107 577 21.1 20.2 C01A CARDIAC GLYCOSIDES 1.42 1.26 1.14 1.02 0.96 12 900 11 878 11 153 10 482 10 012 2.5 1.9 C01AA Digitalis glycosides 1.42 1.26 1.14 1.02 0.96 12 900 11 878 11 153 10 482 10 012 2.5 1.9 C01AA04 digitoxin (0.1 mg) 0.05 0.04 0.03 0.02 0.02 657 525 398 322 244 0.1 0.1 C01AA05 digoxin (0.25 mg) 1.37 1.22 1.11 1.00 0.94 12 279 11 377 10 769 10 167 9 778 2.4 1.8 C01B ANTIARRHYTHMICS, CLASS I AND III 2.20 2.25 2.34 2.39 2.52 15 234 16 006 16 810 17 401 18 265 3.0 3.4 C01BA Antiarrhythmics, class Ia 0.02 0.02 0.02 0.02 0.02 91 100 100 99 102 0.0 0.0 C01BA01 disopyramide (0.4 g) 0.02 0.02 0.02 0.02 0.02 89 96 96 94 98 0.0 0.0 C01BB Antiarrhythmics, class Ib 0.00 0.00 0.01 0.01 0.01 33 37 39 45 43 0.0 0.0 C01BB02 mexiletine (0.8 g) 0.00 0.00 0.01 0.01 0.01 33 37 39 45 42 0.0 0.0 C01BC Antiarrhythmics, class Ic 1.18 1.16 1.19 1.17 1.19 7 755 7 890 8 152 8 194 8 353 1.5 1.6 C01BC03 propafenone (0.3 g) 0.00 0.00 0.00 5 <5 0.0 - C01BC04 flecainide (0.2 g) 1.18 1.16 1.18 1.17 1.19 7 750 7 885 8 145 8 190 8 349 1.5 1.6 C01BD Antiarrhythmics, class III 1.00 1.06 1.13 1.19 1.31 7 717 8 315 8 871 9 391 10 124 1.5 1.9 C01BD01 amiodarone (0.2 g) 0.75 0.77 0.79 0.81 0.87 5 978 6 232 6 551 6 813 7 270 1.2 1.4 C01BD07 dronedarone (0.8 g) 0.25 0.29 0.34 0.38 0.43 1 924 2 253 2 520 2 792 3 128 0.4 0.6 C01C 21 930 25 874 27 586 29 484 29 342 4.3 5.5 C01CA Adrenergic and dopaminergic agents 0.38 0.37 0.38 0.39 0.40 21 930 25 874 27 586 29 484 29 342 4.3 5.5 C01CA01 etilefrine (50 mg) 0.00 0.00 0.00 0.00 59 58 45 0.0 0.0 C01CA03 norepinephrine (6 mg) 0.05 0.05 0.05 0.05 0.05 <5 C01CA06 phenylephrine (4 mg) 0.01 0.01 0.01 midodrine (30 mg) 0.00 0.00 0.00 0.00 54 69 72 115 0.0 0.0 C01CA24 epinephrine (0.5 mg) 0.23 0.22 0.22 0.23 0.23 21 812 25 752 27 455 29 352 29 177 4.2 5.5 CARDIAC DISEASES 6.77 6.37 6.14 62 794 60 017 57 5.79 5.55 62 794 60 017 54 875 52 919 12.2 9.9 C01DA02 glyceryl trinitrate (2.5 mg SL/5mg O/TD) 1.24 1.19 1.17 1.11 1.05 48 662 46 507 44 297 42 413 40 747 9.4 7.7 C01DA08 isosorbide dinitrate 0.07 isosorbide mononitrate (40 mg) 5.44 5.11 4.97 4.68 4.50 25 701 24 237 23 752 22 774 22 006 5.0 4.1 C01E OTHER CARDIAC PREPARATIONS 0.03 0.03 0.04 0.04 0.05 84 172 286 289 373 0.0 0.1 C01EB Other cardiac preparations 0.03 0.03 0.04 0.04 0.05 84 172 286 289 373 0.0 0.1 C01EB09 ubidecarenone - - - - - 10 22 0.0 C01EB10 adenosine (15 mg) 0.02 0.02 0.02 0.02 (40 mg) 0.00 0.00 0.00 0.00 0.00 5 6 10 7 11 0.0 0.0 45 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 C01EB17 ivabradine (10 mg) 0.01 0.01 0.02 0.02 0.03 59 141 249 241 305 0.0 0.1 C01EB18 ranolazine (1.5 g) 0.00 0.00 0.00 0.00 C02 ANTIHYPERTENSIVES 4.06 4.01 4.05 3.71 3.75 16 820 17 147 17 723 17 686 16 774 3.3 3.2 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING 1.30 1.25 1.29 1.25 1.40 6 468 6 644 7 025 7 169 7 787 1.3 1.5 C02AB Methyldopa 0.01 0.00 0.00 0.00 0.00 (levorotatory) (1 g) 0.01 0.00 0.00 0.00 46 40 41 0.0 0.0 C02AC Imidazoline receptor agonists 1.29 1.25 1.29 1.24 1.39 6 419 6 592 6 982 7 132 7 749 1.2 1.5 C02AC01 clonidine (0.45 mg) 0.02 0.02 0.02 0.03 0.04 100 125 200 282 514 0.0 0.1 C02AC02 guanfacine (3 mg) 0.01 0.04 0.05 0.07 96 417 477 638 0.1 C02AC05 moxonidine (0.3 mg) 1.27 1.22 1.23 1.16 1.29 6 320 6 373 6 367 6 377 6 600 1.2 1.2 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 2.69 2.67 2.67 2.37 2.26 10 486 10 610 10 818 10 630 9 064 2.0 1.7 C02CA Alpha -adrenoreceptor antagonists 2.69 2.67 2.67 2.37 2.26 10 486 10 610 10 818 10 630 9 064 2.0 1.7 C02CA01 prazosin (5 mg) 0.01 0.01 0.01 0.02 0.02 79 95 140 145 122 0.0 0.0 C02CA04 doxazosin (4 mg) 2.68 2.66 2.66 2.35 2.24 10 410 10 517 10 681 10 488 8 943 2.0 1.7 C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 0.03 0.03 0.03 0.04 0.04 360 383 383 411 427 0.1 0.1 C02DB Hydrazinophthalazine derivatives 0.03 0.03 0.03 0.04 0.04 312 330 322 363 370 0.1 0.1 C02DB02 hydralazine (0.1 g) 0.03 0.03 0.03 0.04 0.04 312 330 322 363 370 0.1 0.1 C02DC Pyrimidine derivatives 0.00 0.00 0.00 0.00 (20 mg) 0.00 0.00 0.00 0.00 0.00 62 50 63 0.0 C02K OTHER ANTIHYPERTENSIVES 0.04 0.05 0.05 0.06 0.06 268 304 0.00 0.00 0.00 (40 mg) 0.00 0.00 0.00 0.00 10 7 0.0 0.0 C02KX Antihypertensives for pulmonary arterial hypertension 0.04 0.05 0.05 0.05 0.06 258 294 317 328 354 0.1 0.1 C02KX01 bosentan (0.25 g) 0.02 0.02 0.02 0.01 0.01 117 111 106 103 112 0.0 0.0 C02KX02 ambrisentan (7.5 mg) 0.01 0.01 0.01 0.01 0.01 55 55 58 47 53 0.0 0.0 C02KX04 macitentan (10 mg) 0.01 0.02 0.02 0.02 0.03 87 114 144 155 168 0.0 0.0 C02KX05 riociguat (4. 5 mg) 0.00 0.00 0.00 0.01 0.01 11 19 21 DIURETICS 35.24 33.62 32.01 31.70 30.80 180 977 28 447 7.3 5.3 C03AA Thiazides, plain 1.95 1.87 1.84 1.79 1.65 12 993 12 857 12 495 13 253 11 874 2.5 2.2 C03AA03 hydrochlorothiazide (25 mg) 1.95 1.87 1.84 1.79 1.65 12 993 12 857 12 492 13 250 11 870 2.5 2.2 C03AB Thiazides and potassium in combination 4.03 3.64 3.30 2.98 2.66 24 716 22 519 20 465 18 795 16 630 4.8 3.1 C03AB01 bendroflumethiazide and potassium (2.5 mg) 4.03 3.64 3.30 2.98 2.66 24 716 22 519 20 465 18 795 16 630 4.8 3.1 46 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 plain 0.00 0.00 0.00 0.00 (25 mg) 0.00 0.00 0.00 0.00 22.44 118 668 116 446 114 641 23.2 21.5 C03CA Sulfonamides, plain 24.19 23.33 22.52 22.70 22.44 119 815 118 174 115 668 116 446 114 641 23.2 21.5 C03CA01 furosemide (40 mg) 12.72 11.93 11.15 11.24 82 939 79 694 75 970 74 596 78 887 16.1 14.8 C03CA02 bumetanide (1 mg) 11.47 11.41 11.37 11.85 11.20 41 465 42 921 44 130 46 219 44 135 8.0 8.3 C03D POTASSIUM -SPARING AGENTS 1.63 1.68 1.72 1.84 2.00 20 004 21 421 22 492 24 209 26 290 3.9 4.9 C03DA Aldosterone antagonists 1.63 1.68 1.72 1.84 2.00 19 982 21 406 22 476 24 196 26 275 3.9 4.9 C03DA01 spironolactone (75 mg) 1.48 1.51 1.54 1.60 1.67 18 795 20 091 20 980 22 160 23 591 3.6 4.4 C03DA04 eplerenone (50 mg) 0.15 0.17 0.18 0.24 0.33 1 339 1 489 1 671 2 236 2 918 0.3 0.6 C03DB Other potassium - sparing agents 0.00 0.00 0.00 0.00 23 16 18 16 (10 mg) 0.00 0.00 0.00 0.00 16 21 0.0 0.0 C03E DIURETICS AND POTASSIUM -SPARING AGENTS IN COMBINATION 3.43 3.08 2.61 2.36 1.99 18 854 16 977 15 279 13 339 11 099 3.7 2.1 C03EA Low -ceiling diuretics and potassium -sparing agents 3.43 3.08 2.61 2.36 1.99 18 854 16 977 15 279 13 339 11 099 3.7 2.1 C03EA01 hydrochlorothiazide and potassium -sparing agents (1 UD) 3.43 3.08 2.61 2.36 1.99 18 854 16 977 15 279 13 339 11 099 3.7 2.1 C03X OTHER DIURETICS 0.00 0.01 0.02 0.04 0.05 55 78 160 187 224 0.0 0.0 C03XA Vasopressin antagonists 0.00 0.01 0.02 0.04 0.05 55 78 160 187 224 0.0 0.0 C03XA01 tolvaptan (30 mg) 0.00 0.01 0.02 0.04 0.05 55 78 160 187 224 0.0 0.0 C04 PERIPHERAL VASODILATORS 0.09 0.08 0.07 0.06 0.06 VASODILATORS 0.09 0.08 0.07 0.09 0.08 0.07 0.08 0.07 631 565 AGENTS 35.87 35.33 34.76 34.07 33.84 373 078 375 379 605 382 270 72.2 71.7 369 672 372 376 704 379 602 71.6 71.2 C07AA Beta blocking agents, non-selective 1.64 1.54 1.51 1.41 1.36 21 003 20 165 20 491 21 170 22 064 4.1 4.1 C07AA03 pindolol (15 mg) 0.00 0.00 0.00 0.00 (0.16 g) 0.82 0.83 0.86 0.82 0.84 15 740 15 274 15 992 17 116 18 383 3.1 3.5 C07AA06 timolol (20 mg) 0.00 0.00 0.00 0.00 11 sotalol (0.16 g) 0.81 0.70 0.64 0.57 0.51 5 228 4 768 4 346 3 872 3 484 1.0 0.7 C07AA12 nadolol (0.16 g) 0.01 0.01 0.01 0.02 0.02 122 139 163 189 206 0.0 0.0 C07AB Beta blocking agents, selective 30.83 30.51 30.01 29.52 29.39 330 834 333 820 337 155 338 918 64.0 C07AB02 metoprolol (0.15 g) 24.31 24.09 23.86 496 283 411 285 653 288 054 53.7 54.1 47 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 C07AB03 atenolol (75 mg) 3.71 3.50 3.14 2.74 2.74 26 316 24 654 23 277 21 435 18 868 5.1 3.5 C07AB07 bisoprolol (10 mg) 2.81 2.91 3.01 3.10 3.21 30 299 31 582 33 069 34 311 35 632 5.9 6.7 C07AB12 nebivolol (5 mg) 0.00 0.00 0.01 0.01 0.02 22 41 79 98 127 0.0 0.0 C07AG Alpha and beta blocking agents 2.70 2.64 2.62 2.56 2.56 21 960 21 956 22 064 22 019 22 439 4.3 4.2 C07AG01 labetalol (0.6 g) 0.18 0.18 0.18 0.18 0.18 2 671 2 789 2 819 2 963 3 134 0.5 0.6 C07AG02 carvedilol (37.5 mg) 2.51 2.45 2.44 2.38 2.38 19 314 19 189 19 267 19 077 19 335 3.7 3.6 C07B BETA BLOCKING AGENTS AND THIAZIDES 0.70 0.65 0.62 0.58 0.53 3 729 3 563 3 342 3 113 2 883 0.7 0.5 C07BB Beta blocking agents, selective, and thiazides 0.70 0.65 0.62 0.58 0.53 3 729 3 563 3 342 3 113 2 883 0.7 0.5 C07BB07 bisoprolol and thiazides (1 UD) 0.70 0.65 0.62 0.58 0.53 3 725 3 556 3 336 3 105 2 875 0.7 0.5 C07BB12 BLOCKERS 57.74 58.48 57.95 58.78 61.57 241 894 249 493 256 070 260 260 264 002 46.8 49.6 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH 131 318 134 703 137 090 155 136 163 575 25.4 30.7 C08CA02 felodipine (5 mg) 3.70 3.48 3.36 3.40 3.58 13 945 13 522 12 982 14 561 14 804 2.7 2.8 C08CA03 isradipine (5 mg) 0.07 0.07 0.07 0.02 446 422 351 275 <5 0.1 - C08CA05 nifedipine (30 mg) 8.89 9.45 9.98 7.72 5.77 42 101 46 124 50 280 47 653 25 203 8.2 4.7 C08CA06 nimodipine P) 0.00 0.00 0.00 41 31 45 35 C08CA13 lercanidipine (10 mg) 10.33 10.57 10.79 11.63 12.95 42 239 43 626 44 738 51 137 54 170 8.2 10.2 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 2.55 2.33 2.38 2.22 2.14 16 236 15 746 15 374 15 121 14 918 3.1 2.8 C08DA Phenylalkylamine derivatives 1.88 1.69 1.75 1.60 1.56 12 401 11 965 11 662 11 357 11 261 2.4 2.1 C08DA01 verapamil (0.24 g) 1.88 1.69 1.75 1.60 1.56 12 401 11 965 11 662 11 357 11 261 2.4 2.1 C08DB Benzothiazepine derivatives 0.67 0.64 0.63 0.62 0.58 3 941 3 850 3 763 3 820 3 742 0.8 0.7 C08DB01 diltiazem (0.24 g) 0.67 0.64 0.63 0.62 0.58 3 941 3 850 3 763 3 820 3 742 0.8 0.7 C09 AGENTS 856 135 138 648 138 734 26.1 C09AA 44.05 856 135 26.1 26.0 C09AA01 captopril (50 mg) 0.36 0.30 0.27 0.24 0.20 1 535 1 381 1 339 1 205 1 094 0.3 0.2 C09AA02 enalapril (10 mg) 10.23 10.12 9.97 9.77 9.87 45 640 46 041 46 333 46 453 46 507 8.8 8.7 C09AA03 lisinopril (10 mg) 4.93 4.69 4.46 4.29 4.19 22 235 21 466 20 709 20 334 19 418 4.3 3.6 C09AA04 perindopril (4 mg) 0.00 0.00 0.01 0.01 0.01 24 39 52 60 80 0.0 0.0 C09AA05 ramipril (2.5 mg) 28.94 29.06 29.34 29.76 30.22 65 938 67 562 69 406 71 098 72 069 12.8 13.5 C09AA10 trandolapril (2 mg) 0.00 41 0.0 48 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 COMBINATIONS 5.52 5.27 5.12 4.78 4.58 31 299 30 217 29 243 28 185 27 004 6.1 5.1 C09BA ACE inhibitors and diuretics 5.23 4.97 4.77 4.44 4.18 29 646 28 485 337 26 093 24 630 5.7 4.6 C09BA02 enalapril and diuretics (1 UD) 3.19 3.07 2.97 2.80 2.69 18 210 17 658 17 149 16 553 15 866 3.5 3.0 C09BA03 lisinopril and diuretics (1 UD) 2.04 1.90 1.80 1.64 1.50 11 448 10 836 10 189 9 561 8 777 2.2 1.7 C09BB ACE inhibitors and calcium channel blockers 0.29 0.30 0.35 0.34 0.40 1 669 1 755 1 930 2 125 2 418 0.3 0.5 C09BB02 enalapril and 1 669 1 755 1 930 2 125 2 418 0.3 0.5 C09C ANGIOTENSIN 539 66 606 67 344 69 440 71 294 12.7 13.4 C09CA02 eprosartan (0.6 g) 0.21 0.20 0.17 0.15 0.12 1 183 1 105 988 902 830 0.2 0.2 C09CA03 valsartan (80 mg) 8.12 8.79 9.51 9.73 10.34 32 325 35 101 38 060 40 080 40 005 6.3 7.5 C09CA04 irbesartan (0.15 g) 4.54 4.37 4.28 4.12 4.09 18 445 18 209 17 853 17 579 17 232 3.6 3.2 C09CA06 candesartan (8 mg) 26.69 28.64 30.63 33.14 37.10 102 232 110 321 118 609 129 744 141 509 19.8 26.6 C09CA07 telmisartan (40 mg) 1.38 1.36 1.34 1.40 1.40 5 657 5 705 5 680 5 794 5 840 1.1 1.1 medoxomil (20 mg) 0.29 0.28 0.30 0.30 0.30 1 555 1 542 1 538 1 644 1 700 0.3 0.3 C09D 11.54 11.27 11.04 10.63 10.14 64 608 64 474 63 337 61 870 58 886 12.5 11.1 C09DA02 eprosartan and diuretics (1 UD) 0.23 0.21 0.20 0.18 0.16 1 267 1 201 1 113 1 024 945 0.3 0.2 C09DA03 valsartan and diuretics (1 UD) 4.80 26 698 26 633 26 833 26 530 24 757 23 578 301 21 177 19 678 4.8 3.7 C09DA06 10.21 10.25 10.18 57 400 58 597 59 488 60 366 59 966 11.1 11.3 C09DA07 telmisartan and diuretics (1 UD) 0.63 0.58 0.55 0.53 0.50 3 548 3 414 3 266 3 131 2 970 0.7 0.6 C09DA08 olmesartan medoxomil and diuretics (1 UD) 0.19 0.18 0.17 0.17 0.16 1 020 992 972 973 928 0.2 0.2 C09DB Angiotensin II receptor blockers (ARBs) and calcium channel blockers 4.38 4.90 5.18 5.40 6.45 26 972 29 272 31 687 34 464 38 960 5.2 7.3 C09DB01 0.06 0.05 0.06 0.07 315 336 321 372 427 0.1 0.1 49 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 C09DX Angiotensin 5.33 24 276 32 713 4.86 21 559 23 861 26 003 28 023 29 852 4.2 5.6 C09DX03 0.05 0.14 0.27 0.47 417 921 1 682 2 871 0.5 C09X OTHER AGENTS ACTING ON THE RENIN - ANGIOTENSIN SYSTEM 0.01 0.01 0.01 0.00 0.00 40 35 32 10 8 0.0 0.0 C09XA Renin -inhibitors 0.01 0.01 0.01 0.00 0.00 40 35 32 10 8 0.0 0.0 C09XA02 aliskiren (0.15 g) 0.01 0.01 0.01 0.00 0.00 40 35 32 10 8 0.0 0.0 C10 LIPID MODIFYING AGENTS 128.62 131.90 135.61 112.54 147.66 530 553 524 558 729 566 333 99.8 232 429 192 106 174 850 48.9 32.8 C10AA02 lovastatin C10AA03 pravastatin (30 mg) 3.23 3.12 2.99 2.88 2.76 18 617 18 317 17 903 17 497 16 597 3.6 3.1 C10AA04 fluvastatin (60 mg) 1.30 1.28 1.18 1.15 1.14 7 590 7 731 7 469 5 152 5 202 1.5 1.0 C10AA05 atorvastatin (20 mg) 70.72 75.30 82.29 59.46 94.98 237 283 264 578 329 576 349 027 45.9 65.5 C10AA07 rosuvastatin (10 mg) 4.01 5.36 6.24 7.35 8.90 15 939 20 448 25 959 30 921 36 645 3.1 6.9 C10AA08 pitavastatin (2 mg) 0.00 0.00 0.00 0.00 48 30 26 0.0 0.0 C10AB Fibrates 0.05 0.05 0.05 0.05 0.05 311 301 316 329 329 0.1 0.1 C10AB02 bezafibrate (0.6 g) 0.00 0.00 0.00 0.00 0.01 42 36 36 39 49 0.0 0.0 C10AB04 gemfibrozil (1.2 g) 0.01 0.01 0.01 0.01 0.01 74 68 67 61 57 0.0 0.0 C10AB05 fenofibrate (0.2 g) 0.03 0.03 0.04 0.04 0.03 195 197 215 230 223 0.0 0.0 C10AC Bile acid sequestrants 0.15 0.15 0.16 0.16 0.17 2 754 3 011 3 277 3 412 3 488 0.5 0.7 C10AC01 colestyramine (14 g) 0.08 0.08 0.09 0.09 0.10 2 328 2 763 2 858 0.4 0.5 C10AC02 colestipol (20 g) 0.02 0.01 0.01 0.01 0.01 256 242 216 196 189 0.1 0.0 derivatives 0.00 0.00 0.00 0.00 15 13 10 acid (2 g) 0.00 0.00 0.00 modifying agents 4.50 5.05 5.58 7.65 8.06 29 683 33 353 38 964 53 420 56 626 5.8 10.6 C10AX06 omega -3-triglycerides incl. other esters and acids (4 UD) 0.51 0.53 0.56 0.56 0.56 4 400 4 480 4 725 4 813 4 716 0.9 0.9 C10AX09 ezetimibe (10 mg) 3.98 4.45 4.91 6.91 7.23 25 884 29 42 0 34 729 49 074 52 118 5.0 9.8 C10AX12 0.00 0.03 0.04 0.07 0.10 45 217 317 484 664 0.0 0.1 50 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 C10AX14 alirocumab (5.4 mg) 0.00 0.04 0.06 0.11 0.17 10 185 280 474 665 0.0 0.1 C10B LIPID MODIFYING AGENTS . COMBINATIONS 1.07 2.14 2.66 2.79 3.41 8 136 14 974 20 260 21 745 24 468 1.6 4.6 C10BA HMG CoA reductase inhibitors in combination with other lipid modifying agents 1.07 2.14 2.66 2.79 3.41 8 136 14 974 20 260 21 745 24 468 1.6 4.6 629 4 652 0.8 0.9 1.94 4 136 10 871 15 847 17 293 20 021 0.8 3.8 C10BA06 rosuvastatin and ezetimibe (1 UD) - - - - - <5 - 51 4.5 Dermatologiske midler i AT C gruppe J01. 53 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 D DERMATOLOGICALS - - - - - D01 ANTIFUNGALS FOR DERMATOLOGICAL USE - - - - - 141 400 145 187 150 144 153 601 161 220 27.4 30.3 D01A ANTIFUNGALS FOR TOPICAL USE - - - - - 124 070 127 061 132 033 134 332 142 726 24.0 26.8 D01AA Antibiotics - - - - - 32 13 27 41 33 0.0 0.0 D01AA01 nystatin - - - - - 32 13 27 41 33 0.0 0.0 D01AC Imidazole and triazole derivatives - - - - - 99 330 102 356 107 077 109 065 117 744 19.2 22.1 D01AC01 clotrimazole - - - - - 9 703 10 096 10 505 10 533 11 342 1.9 2.1 D01AC02 miconazole - - - - - 2 313 2 321 2 309 2 381 2 330 0.5 0.4 D01AC03 econazole - - - - - 949 975 1 016 1 035 1 177 0.2 0.2 D01AC08 ketoconazole - - - - - 18 825 19 256 20 378 21 874 24 981 3.6 4.7 D01AC20 imidazoles/triazoles in combination with corticosteroids - - - - - 72 618 74 981 78 325 78 596 84 038 14.1 15.8 D01AE Other antifungals for topical use - - - - - 28 407 28 410 28 823 29 125 29 029 5.5 5.5 D01AE02 methylrosaniline - - - - - 908 812 873 586 221 0.2 0.0 D01AE14 ciclopirox - - - - - 3 824 4 645 4 773 4 976 4 978 0.7 0.9 D01AE15 terbinafine - - - - - 19 116 19 117 19 520 19 822 20 306 3.7 3.8 D01AE16 amorolfine - - - - - 5 032 4 335 4 152 4 212 4 023 1.0 0.8 D01B ANTIFUNGALS FOR SYSTEMIC USE 1.16 1.22 1.24 1.28 1.22 21 816 22 551 22 760 24 057 23 256 4.2 4.4 D01BA Antifungals for systemic use 1.16 1.22 1.24 1.28 1.22 21 816 22 551 22 760 24 057 23 256 4.2 4.4 D01BA01 griseofulvin (0.5 g) 0.00 0.00 0.00 0.00 33 23 20 0.0 0.0 D01BA02 terbinafine (0.25 g) 1.16 1.22 1.24 1.28 1.22 21 799 22 533 22 733 24 038 23 243 4.2 4.4 D05 ANTIPSORIATICS - - - - - 30 301 30 801 31 250 30 297 30 874 5.9 5.8 D05A ANTIPSORIATICS FOR TOPICAL USE - - - - - 28 530 28 920 29 303 28 441 29 061 5.5 5.5 D05AA Tars - - - - - 1 299 1 550 1 917 1 940 2 194 0.3 0.4 D05AC Antracen derivatives - - - - - 10 <5 7 7 5 0.0 0.0 D05AC01 dithranol - - - - - 10 <5 7 7 5 0.0 0.0 D05AX Other antipsoriatics for topical use - - - - - 27 416 27 610 27 683 26 768 27 199 5.3 5.1 D05AX02 calcipotriol - - - - - 20 116 369 471 333 0.0 0.1 D05AX03 calcitriol - - - - - 1 406 1 284 1 162 1 022 956 0.3 0.2 D05AX52 calcipotriol, combinations - - - - - 26 546 26 701 26 676 25 818 26 336 5.1 4.9 D05B ANTIPSORIATICS FOR SYSTEMIC USE 0.18 0.18 0.18 0.18 0.18 2 360 2 446 2 519 2 463 2 464 0.5 0.5 D05BA Psoralens for systemic use 0.00 0.00 0.00 0.00 11 16 methoxsalen (10 mg) 0.00 0.00 0.00 0.00 17 11 16 15 15 treatment of 277 2 2 412 2 443 0.4 (35 0.18 2 361 2 442 2 412 2 443 0.4 0.5 54 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 D05BX Other antipsoriatics for systemic use - - - - - 71 78 66 38 7 0.0 0.0 D05BX51 fumaric acid derivatives, combinations - - - - - 71 78 66 38 7 0.0 0.0 D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE - - - - - 114 332 111 663 108 688 106 031 106 769 22.1 20.0 D06A ANTIBIOTICS FOR TOPICAL USE - - - - - 57 378 56 016 54 255 53 256 54 360 11.1 10.2 D06AA Tetracycline and derivatives - - - - - 3 340 3 230 3 226 3 276 3 636 0.7 0.7 D06AA02 chlortetracycline - - - - - 26 16 29 28 17 0.0 0.0 D06AA03 oxytetracycline - - - - - 3 315 3 214 3 198 3 248 3 619 0.6 0.7 D06AX Other antibiotics for topical use - - - - - 54 247 52 966 51 217 50 163 50 923 10.5 9.6 D06AX01 fusidic acid - - - - - 50 693 48 979 47 857 47 490 49 608 9.8 9.3 D06AX05 bacitracin - - - - - 2 138 2 357 2 893 2 805 1 341 0.4 0.3 D06AX09 mupirocin - - - - - 98 47 43 39 49 0.0 0.0 D06AX13 retapamulin - - - - - 1 552 1 813 640 0 0 0.3 0.0 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE - - - - - 58 986 57 534 56 248 54 554 54 144 11.4 10.2 D06BA Sulfonamides - - - - - 3 313 3 124 2 866 2 893 2 603 0.6 0.5 D06BA01 silver sulfadiazine - - - - - 3 313 3 124 2 866 2 893 2 603 0.6 0.5 D06BB Antivirals - - - - - 36 191 35 673 35 270 34 585 32 831 7.0 6.2 D06BB03 aciclovir - - - - - 15 254 14 818 15 101 15 302 14 465 3.0 2.7 D06BB04 podophyllotoxin - - - - - 12 623 12 096 10 834 10 353 9 624 2.4 1.8 D06BB06 penciclovir - - - - - 1 087 958 871 691 560 0.2 0.1 D06BB10 imiquimod - - - - - 7 993 8 494 9 299 8 973 8 698 1.6 1.6 D06BB12 sinecatechins - - - - - 169 75 0 0 0 0.0 0.0 D06BB53 aciclovir, combinations - - - - - 0 0 0 32 133 0.0 0.0 D06BX Other chemothera - peutics - - - - - 20 174 19 386 18 720 17 664 19 305 3.9 3.6 D06BX01 metronidazole - - - - - 14 666 14 082 13 311 12 426 13 908 2.8 2.6 D06BX02 ingenol mebutate - - - - - 5 571 5 363 5 459 5 275 5 440 1.1 1.0 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS - - - - - 390 663 406 760 420 091 424 136 434 154 75.6 81.5 D07A CORTICOSTEROIDS, PLAIN - - - - - 336 817 349 112 360 719 361 928 369 300 65.2 69.3 D07AA Corticosteroids, weak (group I) - - - - - 32 883 34 121 36 466 36 146 39 765 6.4 7.5 D07AA02 hydrocortisone - - - - - 32 883 34 121 36 466 36 146 39 765 6.4 7.5 D07AB Corticosteroids, moderately potent (group II) - - - - - 114 463 117 426 124 714 125 571 128 189 22.2 24.1 D07AB02 hydrocortisone butyrate - - - - - 90 268 92 705 98 183 99 175 110 928 17.5 20.8 D07AB08 desonide - - - - - 25 654 26 249 28 161 27 855 19 569 5.0 3.7 D07AC Corticosteroids, potent (group III) - - - - - 169 883 176 406 176 748 173 574 182 629 32.9 34.3 D07AC01 betamethasone - - - - - 50 585 58 525 55 767 54 129 53 421 9.8 10.0 55 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 D07AC03 desoximetasone - - - - - 14 876 12 571 11 848 10 660 12 208 2.9 2.3 D07AC04 fluocinolone acetonide - - - - - 7 312 5 773 5 634 5 132 5 936 1.4 1.1 D07AC08 fluocinonide - - - - - 477 446 376 362 365 0.1 0.1 D07AC13 mometasone - - - - - 100 745 98 164 102 116 102 281 115 156 19.5 21.6 D07AC17 fluticasone - - - - - 5 704 8 791 8 661 7 759 3 622 1.1 0.7 D07AD Corticosteroids, very potent (group IV) - - - - - 69 390 71 624 74 810 76 790 69 790 13.4 13.1 D07AD01 clobetasol - - - - - 69 390 71 624 74 810 76 790 69 790 13.4 13.1 D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS - - - - - 26 806 32 087 32 979 37 187 37 083 5.2 7.0 D07BB Corticosteroids, moderately potent, combinations with antiseptics - - - - - 10 013 9 621 4 673 6 995 9 1.9 0.0 D07BB02 desonide and antiseptics - - - - - 10 013 9 621 4 673 6 995 9 1.9 0.0 D07BC Corticosteroids, potent, combinations with antiseptics - - - - - 17 796 23 369 28 949 30 910 37 077 3.4 7.0 D07BC01 betamethasone and antiseptics - - - - - 12 283 19 354 26 980 28 898 34 338 2.4 6.4 D07BC02 fluocinolone acetonide and antiseptics - - - - - 6 371 4 786 2 260 2 135 2 960 1.2 0.6 D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS - - - - - 26 063 26 192 26 831 25 974 27 865 5.1 5.2 D07CA Corticosteroids, weak, combinations with antibiotics - - - - - 25 992 25 707 26 181 25 437 27 828 5.0 5.2 D07CA01 hydrocortisone and antibiotics - - - - - 25 992 25 707 26 181 25 437 27 828 5.0 5.2 D07CC Corticosteroids, potent, combinations with antibiotics - - - - - 77 514 687 563 39 0.0 0.0 D07CC01 betamethasone and antibiotics - - - - - 76 513 684 562 37 0.0 0.0 D07X CORTICOSTEROIDS, OTHER COMBINATIONS - - - - - 29 011 30 276 31 931 32 026 33 261 5.6 6.2 D07XA Corticosteroids, weak, other combinations - - - - - 10 5 11 <5 0.0 D07XA01 hydrocortisone - - - - - 10 5 11 <5 0.0 D07XC Corticosteroids, potent, other combinations - - - - - 29 001 30 271 31 920 32 022 33 261 5.6 6.2 D07XC01 betamethasone - - - - - 29 001 30 271 31 920 32 022 33 261 5.6 6.2 D10 ANTI -ACNE PREPARATIONS - - - - - 75 653 78 061 82 095 83 202 85 751 14.6 16.1 D10A ANTI -ACNE PREPARATIONS FOR TOPICAL USE - - - - - 67 313 68 595 71 573 70 960 72 251 13.0 13.6 D10AD Retinoids for topical use in acne - - - - - 40 391 43 437 46 115 47 702 50 432 7.8 9.5 D10AD01 tretinoin - - - - - 3 113 3 253 3 483 3 608 4 134 0.6 0.8 D10AD03 adapalene - - - - - 7 719 7 161 6 883 6 789 7 364 1.5 1.4 D10AD51 tretinoin, combinations - - - - - 4 942 9 127 10 042 10 111 10 663 1.0 2.0 D10AD53 adapalene, combinations - - - - - 26 587 26 519 28 445 29 909 31 280 5.2 5.9 56 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 D10AE Peroxides - - - - - 2 736 2 630 3 390 3 939 4 193 0.5 0.8 D10AE01 benzoyl peroxide - - - - - 2 736 2 630 3 390 3 939 4 193 0.5 0.8 D10AF Antiinfectives for treatment of acne - - - - - 16 533 15 651 14 791 11 270 8 527 3.2 1.6 D10AF01 clindamycin - - - - - 16 503 15 619 14 758 11 245 8 478 3.2 1.6 D10AF02 erythromycin - - - - - 31 33 35 26 51 0.0 0.0 D10AX Other anti -acne preparations for topical use - - - - - 15 938 14 338 14 562 15 006 15 613 3.1 2.9 D10AX03 azelaic acid - - - - - 15 934 14 334 14 554 15 003 15 612 3.1 2.9 D10B ANTI -ACNE PREPARATIONS FOR SYSTEMIC USE 1.03 1.15 1.24 1.40 1.53 12 523 14 285 15 925 17 959 19 924 2.4 3.7 D10BA Retinoids for treatment of acne 1.03 1.15 1.24 1.40 1.53 12 523 14 285 15 925 17 959 19 924 2.4 3.7 D10BA01 isotretinoin (30 mg) 1.03 1.15 1.24 1.40 1.53 12 523 14 285 15 925 17 959 19 924 2.4 3.7 D11 OTHER DERMATOLOGICAL PREPARATIONS - - - - - 27 571 32 631 38 672 41 048 43 883 5.3 8.2 D11A OTHER DERMATOLOGICAL PREPARATIONS - - - - - 27 571 32 631 38 672 41 048 43 883 5.3 8.2 D11AC Medicated shampoos - - - - - 1 809 2 134 2 237 1 921 2 253 0.4 0.4 D11AC03 selenium compounds - - - - - 1 809 2 134 2 237 1 921 2 253 0.4 0.4 D11AF Wart and anti -corn preparations - - - - - 2 857 2 884 3 214 3 010 333 0.6 0.1 D11AH Agents for dermatitis, excluding corticosteroids 0.07 0.07 0.09 0.08 0.09 16 458 17 758 19 667 20 505 23 057 3.2 4.3 D11AH01 tacrolimus - - - - - 10 394 10 859 11 229 11 511 12 090 2.0 2.3 D11AH02 pimecrolimus - - - - - 5 747 6 543 8 054 8 630 10 640 1.1 2.0 D11AH04 alitretinoin (20 mg) 0.07 0.07 0.09 0.08 0.09 733 853 967 973 1 041 0.1 0.2 D11AH05 dupilumab (21.4 mg) 0.00 0.00 0 0 0 6 19 0.0 0.0 D11AX Other dermatologicals 0.07 0.07 0.07 0.06 0.07 6 705 10 323 14 238 16 363 19 140 1.3 3.6 D11AX01 minoxidil - - - - - 358 397 469 597 644 0.1 0.1 D11AX10 finasteride (1 mg) 0.07 0.07 0.07 0.06 0.07 541 515 519 511 560 0.1 0.1 D11AX16 eflornithine - - - - - 685 790 934 1 019 1 086 0.1 0.2 D11AX18 diclofenac - - - - - 249 368 406 304 261 0.1 0.1 D11AX21 brimonidine - - - - - 2 489 1 954 1 805 1 405 1 518 0.5 0.3 D11AX22 ivermectin - - - - - 840 4 655 8 311 10 395 13 068 0.2 2.5 57 4.6 G Urogenitalsystem genitalia er den st\u00f8rste av under gruppen e i gruppe G (70 % av all DDD). Reseptregisteret viser at i 2019 fikk 22 % av ut siden 2015, men 2018 til 2019 ser vi en \u00f8kning p\u00e5 rundt 1 % anbefalt (G03AC08). p -piller og p transdermal hormonal contraceptives 2010 -2019 . Source: Norwegian Drug Wholesales Statistics 020000400006000080000100000120000140000160000180000200000220000240000260000280000 2010 2012 Year 59 Figure 4.6.2 Sales of IUDs (G02BA03) and contraceptive implants (G03AC08) 2010 -2019 Source: Norwegian Drug Wholesales Statistics Figure 4.6.3 Number of Norwegian women in age groups 10 -49 years who had dispensed at least one hormonal contraceptive in 2019 according to the following categories: Intrauterine contraceptives (G02BA), vaginal rings (G02BB), progestogens and estrogens, se quential preparations (G03AB), mini pills, injections and implants (G03AC) and progestogens and estrogens, fixed combinations (incl. TD 00040 00050 00060 00070 000 2010 2012 Intrauterine devices (IUDs) (G02BA03) Contraceptive implants (G03AC08)Number of IUDs/ s.c. implants Year 020000400006000080000100000120000140000 10 - 19 20 - 29 30 - 39 40 - 49 Intrauterine contraceptives (IUDs) Intravaginal contraceptives (vaginal ring) Progestogens and estrogens, sequential preparations Progestogens (mini pills, injections and implants) Progestogens and estrogens, fixed combinations 60 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 G GENITO URINARY SYSTEM 586 40 070 42 519 41 124 40 941 7.5 7.7 G01A ANTIINFECTIVES 0.84 38 586 40 070 42 519 41 124 40 941 7.5 7.7 G01AA Antibiotics 0.06 0.06 0.06 0.05 0.05 23 983 24 308 23 450 22 820 21 954 4.6 4.1 G01AA10 clindamycin (0.1g) 0.06 0.06 0.06 0.05 0.05 23 983 24 308 23 450 22 820 21 954 4.6 4.1 G01AC Quinoline derivatives 0.00 0.01 0.02 0.02 11 1 928 6 558 7 965 8 153 0.0 1.5 G01AC05 dequalinium (20 mg) 0.00 0.00 0.01 0.02 0.02 11 1 928 6 558 7 965 8 153 0.0 1.5 G01AD Organic acids - - - - - 16 12 10 11 6 0.0 0.0 G01AD02 acetic acid - - - - - 16 12 10 11 6 0.0 0.0 G01AF Imidazole derivatives 0.90 0.83 0.76 0.77 0.77 16 267 15 785 15 115 13 005 13 657 3.2 2.6 G01AF01 metronidazole (0.5 g) 0.03 0.03 0.02 0.02 0.02 7 378 6 968 6 303 6 261 6 257 1.4 1.2 G01AF02 clotrimazole (0.1 g) 0.82 0.77 0.69 0.69 0.68 8 021 7 976 7 989 5 936 6 574 1.6 1.2 G01AF05 econazole (0.1 g) 0.05 0.04 0.05 0.06 0.07 1 168 1 127 1 127 1 034 1 122 0.2 0.2 0.00 0.00 (90 mg) 0.00 0.00 0.00 0.00 0.00 8 7 9 0.0 0.0 G02 OTHER GYNECOLOGICALS 49 301 50 823 52 144 55 340 54 026 9.5 10.1 G02A UTEROTONICS 0.01 0.01 0.01 0.01 0.01 10 7 11 <5 6 0.0 0.0 G02AD Prostaglandins 0.01 0.01 0.01 0.01 0.01 2015 2016 2017 2018 2019 G02B CONTRACEPTIVES FOR TOPICAL USE 46 915 48 551 49 912 53 116 51 838 9.1 9.7 G02BA Intrauterine contraceptives 28 972 31 358 34 139 38 443 38 191 5.6 7.2 G02BA03 plastic IUD with progestogen, numbers of IUD 45 202 49 304 54 975 60 423 59 914 28 972 31 358 34 139 38 443 38 191 5.6 7.2 G02BB Intravaginal contraceptives 18 259 17 547 16 170 15 083 13 982 3.5 2.6 G02BB01 vaginal ring with progestogen and estrogen, given in DDD/day 12 333 12 002 11 303 10 535 10 283 18 259 17 547 16 170 15 083 13 982 3.5 2.6 DDD/1000 inhabitants/day 2015 2016 2017 2019 G02C OTHER GYNECOLOGICALS 0.13 0.12 0.11 0.11 0.11 2 444 2 331 2 296 2 295 2 256 0.5 0.4 G02CB Prolactine inhibitors 0.13 0.12 0.11 0.11 0.11 2 279 2 315 2 293 2 295 2 256 0.4 0.4 G02CB01 bromocriptine (5 mg) 0.05 0.05 0.05 0.04 0.04 797 728 654 595 473 0.2 0.1 G02CB03 cabergoline (0.5 mg) 0.04 0.04 0.04 0.04 0.05 1 320 1 424 1 503 1 579 1 684 0.3 0.3 61 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 G02CB04 quinagolide (65 mcg) 0.03 0.03 0.03 0.02 0.02 200 206 175 162 151 0.0 0.0 G02CX Other gynecologicals - - - - - 165 16 <5 0.0 G02CX04 Cimicifugae rhizoma - - - - - 165 16 <5 0.0 DDD/day 2015 2016 2017 2018 2019 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 583 927 593 953 594 870 594 129 602 681 113.0 113.1 G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE 350 607 353 941 351 197 345 926 347 090 67.9 65.1 G03AA Progestogens and estrogens, fixed combinations 200 375 199 067 196 432 188 200 189 457 238 577 236 034 230 419 222 612 219 882 46.2 41.3 G03AA07 levonorgestrel and ethinylestradiol 119 078 125 213 126 943 123 786 127 860 145 951 150 143 152 705 149 303 150 374 28.3 28.2 G03AA09 desogestrel and ethinylestradiol 35 451 30 730 22 689 41 679 37 097 31 982 28 788 26 039 8.1 4.9 G03AA12 drospirenone and ethinylestradiol 39 201 37 413 34 822 33 762 33 332 48 906 46 233 43 520 41 128 40 504 9.5 7.6 G03AA13 norelgestromin and ethinylestradiol 5 778 5 602 5 247 5 033 4 922 8 751 8 394 7 926 7 630 7 351 1.7 1.4 G03AA14 nomegestrol and estradiol 867 835 794 837 429 1 152 1 095 1 068 1 080 1 025 0.2 0.2 G03AA16 dienogest and ethinylestradiol 54 226 102 306 0.1 G03AB Progestogens and estrogens, sequential preparations 9 425 8 462 7 737 6 829 6 373 11 539 10 426 9 293 8 116 7 635 2.2 1.4 G03AB04 norethisterone and ethinylestradiol 8 161 7 249 6 576 5 742 5 231 9 765 8 750 7 727 6 684 6 057 1.9 1.1 G03AB08 dienogest and estradiol 1 264 1 213 1 160 1 087 1 142 1 796 1 694 1 577 1 441 1 590 0.4 0.3 G03AC Progestogens 119 628 128 200 132 116 134 848 138 200 23.2 25.9 G03AC01 norethisterone (oral) 3 120 2 990 2 740 2 470 2 340 4 909 4 625 4 256 3 823 3 673 1.0 0.7 G03AC06 medroxyprogesterone (parenteral) 13 180 12 830 12 190 11 540 11 200 18 083 17 296 16 340 15 329 14 679 3.5 2.8 G03AC08 etonogestrel (number of s.c. implants) 14 100 23 030 25 510 29 820 30 191 12 689 19 677 23 778 27 216 27 999 2.5 5.3 G03AC09 desogestrel (oral) 56 190 59 250 60 880 62 010 64 730 87 457 90 935 92 421 92 912 95 886 16.9 18.0 G03AD Emergency contra - ceptives 390 350 340 330 310 285 151 141 115 102 0.1 0.0 G03AD01 levonorgestrel (1.5 mg) 200 80 90 110 100 71 64 56 56 45 0.0 0.0 G03AD02 ulipristal (30 mg) 190 270 250 220 210 216 88 85 60 58 0.0 0.0 G03B ANDROGENS 6 850 8 190 9 170 8 740 9 010 12 268 14 554 15 427 15 997 16 387 2.4 3.1 G03BA 3-oxoandrosten (4) derivatives 6 850 8 190 9 160 8 740 9 000 12 264 14 550 15 422 15 997 16 386 2.4 3.1 G03BA03 testosterone (0.12 g O,R/18 mg P/ 60 mg SL/ 0 mg TD gel/ 3 mg TD) 6 850 8 190 9 160 8 740 9 000 12 264 14 550 15 422 15 997 16 386 2.4 3.1 G03BB 5-androstanon (3) derivatives 0 0 10 0 10 5 8 9 6 7 0.0 0.0 G03BB01 mesterolone (50 mg) 0 0 10 0 10 5 8 9 6 7 0.0 0.0 62 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/day 2015 2016 2017 2018 2019 G03C ESTROGENS 45 500 45 940 47 960 48 780 51 760 138 256 144 129 150 015 156 072 163 866 26.8 30.8 G03CA Natural and semisynthetic estrogens, plain 40 240 40 750 42 990 44 100 47 190 131 613 137 669 143 976 150 342 158 505 25.5 29.8 G03CA01 ethinylestradiol (0.025 mg) 50 20 40 30 30 22 13 17 12 9 0.0 0.0 G03CA03 estradiol (50 mcg TD/ 1 mg TD mg O/ 25 mcg V/ 7.5 mcg vaginal ring) 21 890 23 260 26 060 27 950 31 490 123 120 129 932 136 672 142 825 149 693 23.8 28.1 G03CA04 estriol (2 mg O/0.2 mg V) 18 300 17 470 16 890 16 120 15 670 9 956 9 242 8 853 9 411 11 176 1.9 2.1 G03CA57 conjugated estrogens (0.625 mg) 0 0 0 0 0 <5 5 <5 <5 0.0 - G03CX Other estrogens 5 260 5 190 4 970 4 680 4 570 7 504 7 301 6 897 6 528 6 137 1.5 1.2 G03CX01 tibolone (2.5 mg) 5 260 5 190 4 970 4 680 4 570 7 504 7 301 6 897 6 528 6 137 1.5 1.2 G03D PROGESTOGENS 7 590 7 810 8 220 8 860 10 170 38 822 38 079 39 183 39 586 39 083 7.5 7.3 G03DA Pregnen (4) derivatives 4 670 5 070 5 380 6 070 7 430 15 507 15 875 16 568 17 737 18 184 3.0 3.4 G03DA02 medroxyprogesterone (5 mg O/7 mg P) 2 260 2 220 2 310 2 700 3 820 6 510 6 469 6 869 7 303 7 041 1.3 1.3 G03DA04 progesterone (30 mg O/5 mg P/90 mg V) 2 410 2 850 3 070 3 370 3 610 9 174 9 584 9 934 10 675 11 399 1.8 2.1 G03DB Pregnadien derivatives 90 90 130 180 220 172 191 241 388 561 0.0 0.1 G03DB01 dydrogesterone (10 mg) 30 90 130 0 0 64 221 379 0.0 0.1 G03DB08 dienogest (2 mg) 90 90 100 90 90 171 190 177 167 182 0.0 0.0 G03DC Estren derivatives 2 830 2 650 2 710 2 610 2 520 23 943 22 767 23 274 22 376 21 400 4.6 4.0 G03DC02 norethisterone (5 mg) 2 830 2 650 2 710 2 610 2 520 23 943 22 767 23 274 22 376 21 400 4.6 4.0 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 31 390 31 100 29 650 30 770 31 610 42 974 42 769 41 514 42 210 43 995 8.3 8.3 G03FA Progestogens and estrogens, fixed combinations 23 970 23 830 22 740 23 560 24 180 33 672 33 661 32 749 33 086 34 509 6.5 6.5 G03FA01 norethisterone and estrogen 23 200 23 050 21 970 22 760 23 490 32 779 32 742 31 823 32 146 33 772 6.4 6.3 G03FA12 medroxyprogesterone and estrogen 770 780 770 800 670 997 1 014 1 027 1 053 1 035 0.2 0.2 G03FA14 dydrogesterone and estrogen 20 64 0.0 G03FB Progestogens and estrogens, sequential preparations 7 420 7 270 6 910 7 210 7 430 10 359 10 196 9 801 10 129 10 571 2.0 2.0 G03FB05 norethisterone and estrogen 7 420 7 270 6 910 7 210 7 420 10 359 10 196 9 801 10 129 10 547 2.0 2.0 G03FB08 dydrogesterone and estrogen 0 0 0 0 10 31 0.0 63 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/day 2015 2016 2017 2018 2019 G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS 2 634 2 712 2 029 1 537 1 367 10 672 10 733 9 047 8 573 8 165 2.1 1.5 G03GA Gonadotropins 1 104 1 182 1 249 1 007 987 6 932 7 143 7 587 7 743 7 636 1.3 1.4 G03GA01 chorionic gonadotrophin (250 U) 330 360 390 110 60 655 639 736 91 46 0.1 0.0 G03GA02 human menopausal gonadotrophin (75 U) 290 330 330 320 350 2 494 2 832 2 849 2 782 2 796 0.5 0.5 G03GA04 urofollitropin (75 U) 10 0 0 20 30 81 5 <5 225 357 0.0 0.1 G03GA05 follitropin alfa (75 U) 270 280 380 420 460 2 627 2 812 3 532 4 000 4 197 0.5 0.8 G03GA06 follitropin beta (75 U) 170 180 110 80 20 2 000 2 086 1 324 851 226 0.4 0.0 G03GA07 lutropin alfa (75 U) 0 <5 - G03GA08 choriogonadotropin alfa (0.25 mg) 29 29 29 36 38 6 005 6 240 6 467 7 067 7 022 1.2 1.3 G03GA09 corifollitropin alfa (0.15 mg) 1 1 2 2 1 313 352 486 469 192 0.1 0.0 G03GA10 follitropin delta (12 mcg) 3 7 9 98 220 274 0.1 G03GA30 combinations 4 2 5 12 19 69 34 96 215 294 0.0 0.1 G03GB Ovulation stimulants, synthetic 1 530 1 530 780 530 380 4 732 4 489 1 935 1 031 707 0.9 0.1 G03GB02 clomifene (9 mg) 1 530 1 530 780 530 380 4 732 4 489 1 935 1 031 707 0.9 0.1 G03H ANTIANDROGENS 11 510 11 310 11 050 10 560 10 630 15 321 14 968 14 553 13 982 13 806 3.0 2.6 G03HA Antiandrogens, plain 70 80 80 90 110 199 221 255 312 364 0.0 0.1 G03HA01 cyproterone (0.1 g) 70 80 80 90 110 199 221 255 312 364 0.0 0.1 G03HB Antiandrogens and estrogens 11 440 11 230 10 970 10 470 10 520 15 127 14 749 14 301 13 672 13 446 2.9 2.5 G03HB01 cyproterone and estrogen 11 440 11 230 10 970 10 470 10 520 15 127 14 749 14 301 13 672 13 446 2.9 2.5 G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 650 787 866 468 578 1 346 1 903 2 062 1 155 1 608 0.3 0.3 G03XA Antigonadotropins and similar agents 10 10 10 10 10 42 46 46 44 39 0.0 0.0 G03XA01 danazol (0.6 g) 10 10 10 10 10 42 46 46 44 39 0.0 0.0 G03XB Progesterone receptor modulators 320 527 596 268 298 965 1 559 1 766 894 844 0.2 0.2 G03XB01 mifepristone (0.2 g) 40 37 36 38 <5 <5 <5 - - G03XB02 ulipristal (5 mg) 280 490 560 230 260 961 1 557 1 765 893 843 0.2 0.2 G03XC Selective estrogen receptor modulators 320 250 260 190 180 339 298 250 217 194 0.1 0.0 G03XC01 raloxifene (60 mg) 320 250 260 190 180 339 298 250 217 194 0.1 0.0 G03XX Other sex hormones and modulators of the genital system 90 533 0.1 G03XX01 prasterone (6.5 mg) 90 533 15.31 144 301 165 551 174 799 184 268 28.0 34.6 64 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 G04BA Acidifiers <5 <5 5 <5 6 - 0.0 and incontinence 9.70 10.09 10.48 10.81 11.58 59 257 62 109 65 824 69 472 73 627 11.5 13.8 G04BD04 oxybutynin (3.9 mg TD/15 mg O) 0.01 0.17 0.19 0.22 0.24 1 882 2 364 2 839 3 499 3 929 0.4 0.7 G04BD07 tolterodine (4 mg) 1.18 1.08 0.98 0.86 0.74 8 622 7 939 7 389 6 550 5 714 1.7 1.1 G04BD08 solifenacin (5 mg) 3.40 3.32 3.18 3.11 3.28 17 576 17 047 16 400 16 145 15 881 3.4 3.0 G04BD10 darifenacin (7.5 mg) 0.55 0.45 0.44 0.38 0.35 2 454 2 187 2 011 1 803 1 605 0.5 0.3 G04BD11 fesoterodine (4 mg) 2.00 1.90 1.81 1.72 1.65 10 029 9 437 8 942 8 483 8 162 1.9 1.5 G04BD12 mirabegron (50 mg) 2.56 3.18 3.88 4.51 5.31 24 299 28 867 34 219 39 629 45 113 4.7 8.5 DDD/day 2015 2016 2017 2018 2019 G04BE Drugs used in erectile dysfunction 12 999 14 093 15 577 17 687 19 917 87 401 94 327 101 982 107 704 113 372 16.9 21.3 G04BE01 alprostadil (0.02 mg) 204 186 196 184 182 3 134 3 169 3 091 3 280 3 296 0.6 0.6 G04BE03 sildenafil (50 mg) 5 652 6 283 7 264 8 071 8 906 39 750 44 279 49 803 54 309 56 199 7.7 10.6 G04BE08 tadalafil (10 mg) 6 166 6 659 7 136 8 523 9 879 45 287 48 390 50 838 53 660 57 012 8.8 10.7 G04BE09 vardenafil (10 mg) 963 950 943 818 821 8 096 8 256 8 188 6 931 6 635 1.6 1.3 G04BE10 avanafil (0.1 g) 14 64 98 0 0 286 1 224 1 606 0.0 0.3 G04BE30 fentolamin, combinations 14 15 24 27 31 335 403 636 727 796 0.1 0.2 G04BX Other urologicals 53 65 66 74 73 113 229 378 491 451 0.0 0.1 G04BX01 magnesium hydroxide (0.5 g) 16 19 18 17 15 14 23 17 20 19 0.0 0.0 G04BX14 dapoxetine (30 mg) 0 2 6 9 8 37 139 294 394 347 0.0 0.1 G04BX15 pentosan polysulfate sodium (0.3 g) 34 41 38 44 46 58 60 61 72 75 0.0 0.0 G04BX16 tiopronin (0.8 g) 3 3 4 4 4 <5 <5 5 5 <5 - - DDD/1000 inhabitants/day 2015 2016 2017 2018 2019 G04C DRUGS BENIGN PROSTATIC HYPERTROPHY 11.99 13.25 13.81 14.47 15.33 78 579 83 917 89 368 94 665 100 212 15.2 18.8 G04CA Alpha -adrenoreceptor antagonists 9.25 10.54 11.18 11.87 12.89 66 025 71 252 76 632 81 729 87 838 12.8 16.5 G04CA01 alfuzosin (7.5 mg) 0.00 0.00 0.00 18 0.0 G04CA02 tamsulosin (0.4 mg) 6.83 7.30 7.59 7.85 8.28 50 322 52 615 55 027 57 370 60 594 9.7 11.4 G04CA03 terazosin (5 mg) 0.07 0.07 0.06 0.05 0.05 502 509 421 395 350 0.1 0.1 G04CA52 tamsulosin and dutasteride (1 caps) 2.35 3.14 3.43 3.84 4.39 18 364 21 617 24 463 27 008 30 043 3.6 5.6 G04CA53 tamsulosin and solifenacin (1 caps) 0.00 0.03 0.08 0.13 0.17 25 348 703 1 134 1 407 0.0 0.3 G04CB Testosterone -5-alpha reductase inhibitors 2.74 2.70 2.64 2.60 2.44 17 549 17 492 17 414 17 467 17 248 3.4 3.2 G04CB01 finasteride (5 mg) 2.59 2.57 2.52 2.50 2.35 16 641 16 687 16 763 16 869 16 698 3.2 3.1 G04CB02 dutasteride (0.5 mg) 0.15 0.13 0.12 0.10 0.09 962 846 686 637 705 0.2 0.1 65 4.7 med henholdsvis 40 % og 56 % av all DDD i gruppe H. Reseptregisteret viser at i 2019 fikk rundt 10 % av befolkningen i 2019 fikk minst ett legemiddel fra ATC gruppe kvinner (5 % i 2019) enn for menn (4.2 % i 2019). Bruken \u00f8ker med \u00f8kende alder, i 2019 fikk 4.7.1 Proportion of the population (prevalence ) who had dispensed at least one glucocorticosteroid (H02AB) according to age groups 2005 salget n\u00e6r doblet fra 2000 til 2019 ) f\u00e5r utlevert et thyroideapreparat . 020406080100 0 - 9 years 10 - 19 years 20 - 39 years 40 - 69 years 70 years and aboveProportion () of the population age groups2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 67 Figure. 4.7.2. Proportion of the population (prevalence ) who had dispensed a thyroid preparation (H03AA2) according to age groups in selected years. Source: Norwegian Prescription Database 1. \u00d8ymar K, Bruun Mikalsen I, Nag T, et Men years 30-59 years 60 years and aboveProportion ( ) of the population 2007 2011 2015 2019 68 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 1.83 1.85 1.92 1.86 1.91 26 947 26 687 27 881 27 529 26 181 5.2 4.9 H01A 079 2 091 2 087 2 133 2 148 0.4 0.4 H01AC01 somatropin (2 U) 0.45 0.47 0.51 0.51 0.52 2 042 2 046 2 083 2 130 2 148 0.4 H01AC03 mecasermin pituitary lobe hormones and analogues 0.01 0.01 0.01 0.01 0.01 35 40 42 41 50 0.0 0.0 H01AX01 pegvisomant (10 mg) 0.01 0.01 0.01 0.01 0.01 35 40 42 41 50 0.0 0.0 H01B POSTERIOR PITUITARY LOBE HORMONES 1.04 1.03 1.07 1.01 1.05 18 930 18 399 19 303 18 602 17 326 3.7 3.3 H01BA Vasopressin and 997 12 026 2.3 11 662 11 996 12 026 2.3 0.22 0.16 0.18 7 078 6 737 7 320 6 607 5 302 1.4 1.0 H01BB02 oxytocin (15 U) 0.20 0.20 0.22 0.16 0.18 7 078 6 737 7 320 6 607 5 302 1.4 1.0 6 487 6 7 042 6 954 1.2 1.3 H01CA Gonadotropin -releasing hormones 0.13 0.13 0.10 0.10 0.08 3 031 2 954 2 632 2 483 2 184 0.6 0.4 H01CA02 nafarelin (0.4 mg) 0.13 0.13 0.10 0.10 0.08 3 031 2 954 2 632 2 483 2 184 0.6 0.4 H01CB Somatostatin and analogues 0.19 0.20 0.21 0.21 0.22 895 927 944 987 997 0.2 0.2 H01CB02 octreotide (0.7 mg) 0.13 0.13 0.13 0.12 0.11 638 616 617 607 576 0.1 0.1 H01CB03 lanreotide (3 mg) 0.06 0.07 0.08 0.09 0.10 291 329 351 397 445 pasireotide (1.2 mg) 0.00 0.00 0.00 0.00 0.00 11 11 13 0.0 0.0 H01CC Anti -gonadotropin - releasing hormones 0.01 0.01 0.02 0.02 0.02 2 685 3 082 3 650 4 053 4 233 0.5 0.8 H01CC01 ganirelix (0.25 mg) 0.01 0.01 0.02 0.02 0.02 2 607 3 011 3 071 3 495 3 844 0.5 H01CC02 cetrorelix (0.25 mg) 0.00 0.00 0.00 0.00 753 640 CORTICOSTEROIDS FOR SYSTEMIC USE 19.69 19.77 19.86 19.76 19.87 231 293 233 848 242 825 256 115 44.8 48.1 H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN 19.69 19.77 19.86 19.76 19.87 231 055 233 616 240 195 242 824 256 114 44.7 48.1 69 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 0.42 1 563 1 612 0.3 H02AA02 0.42 1 490 866 602 255 887 44.7 48.0 H02AB01 betamethasone ( 1.5 mg O,P/0.4 mg P (depot)) 1.38 1.29 1.23 1.20 1.17 2 669 2 982 3 476 3 984 4 301 0.5 0.8 H02AB02 dexamethasone (1.5 mg) 2.28 2.47 2.69 2.84 3.06 7 268 8 837 10 446 11 688 13 801 1.4 2.6 H02AB04 methylprednisolone (7.5 mg O/20 mg P) 1.26 1.19 1.06 0.93 0.81 9 769 9 093 7 919 6 941 (10 mg) 13.16 13.21 13.26 13.19 13.17 177 416 181 260 187 335 191 453 200 577 34.3 37.6 H02AB07 prednisone (10 mg) 0.02 0.02 0.02 0.01 0.01 303 294 268 114 69 0.1 0.0 H02AB08 triamcinolone (7.5 mg) 0.47 0.46 0.45 0.43 0.45 37 521 35 086 34 710 32 421 35 504 7.3 6.7 H02AB09 hydrocortisone (30 mg) 0.22 0.22 0.24 0.25 0.26 700 827 948 989 1 090 0.1 0.2 H02AB10 cortisone (37.5 mg) 0.49 0.50 0.49 0.49 0.52 3 006 3 130 3 254 3 351 3 418 0.6 0.6 H02AB13 deflazacort (15 mg) 0.01 0.01 0.01 0.01 0.01 45 51 55 59 64 0.0 0.0 H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS - - - - - 418 402 107 <5 <5 0.1 - H02BX Corticosteroids for systemic use, combinations - - - - - 418 402 107 <5 26.12 27.68 207 068 212 089 216 620 220 398 224 401 H03A THYROID PREPARATIONS 25.17 26.30 25.38 26.73 26.83 202 677 218 325 39.1 200 938 205 630 209 382 212 354 216 028 38.9 40.5 H03AA02 liothyronine sodium (0.06 mg) 0.30 0.35 0.40 0.41 0.56 6 206 7 273 8 412 9 883 10 348 1.2 1.9 H03AA05 thyroid gland preparations 0.50 0.73 0.73 0.91 0.93 2 662 3 407 4 144 4 885 5 6 924 7 103 7 525 8 175 8 617 1.3 1.6 H03BA Thiouracils 0.13 0.12 0.10 0.11 0.12 629 557 559 552 570 0.1 0.1 H03BA02 (0.1 0.13 0.12 0.10 0.11 0.12 629 559 552 570 0.1 0.1 -containing imidazole derivatives 0.60 0.61 0.63 0.70 0.73 6 484 6 729 7 157 7 814 8 246 1.3 1.6 H03BB01 carbimazole (15 mg) 0.60 0.61 0.63 0.70 0.73 6 484 6 729 7 157 7 814 8 246 1.3 1.6 H03C IODINE THERAPY - - - - - 12 7 <5 5 <5 0.0 - H03CA Iodine therapy - - - - - 12 7 <5 5 <5 0.0 - H04 PANCREATIC HORMONES 0.02 0.02 0.01 0.01 0.02 5 398 5 588 5 427 5 353 5 693 1.0 1.1 H04A GLYCOGENOLYTIC HORMONES 0.02 0.02 0.01 0.01 0.02 5 398 5 588 5 427 5 353 5 693 1.0 1.1 H04AA Glycogenolytic hormones 0.02 0.02 0.01 0.01 0.02 5 398 5 588 5 427 5 353 5 693 1.0 1.1 H04AA01 glucagon (1 mg) 0.02 0.02 0.01 0.01 0.02 5 398 5 588 5 427 5 353 5 693 1.0 1.1 70 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 H05 CALCIUM HOMEOSTASIS 0.19 0.22 0.25 0.25 0.26 1 559 1 827 2 096 2 139 2 239 0.3 0.4 H05A PARATHYROID HORMONES AND ANALOGUES 0.09 0.11 0.14 0.14 0.14 720 931 1 151 1 133 1 179 0.1 0.2 H05AA Parathyroid hormones and analogues 0.09 0.11 0.14 0.14 0.14 720 931 1 151 1 133 1 179 0.1 0.2 H05AA02 teriparatide (20 mcg) 0.09 0.11 0.14 0.14 0.13 720 931 1 151 1 123 1 149 0.1 0.2 H05AA03 parathyroid hormone (0.1 mg) 0.00 0.00 0.00 0 0 <5 22 31 0.0 0.0 H05B ANTI -PARATHYROID AGENTS 0.10 0.11 0.11 0.12 0.12 839 896 945 1 006 1 060 0.2 0.2 H05BA Calcitonin preparations 0.00 0.00 0.00 synthetic) (100 U) 0.00 8 7 8 6 H05BX Other anti -parathyroid agents 0.10 0.11 0.11 0.12 0.12 831 889 937 1 001 1 057 0.2 0.2 H05BX01 cinacalcet (60 mg) 0.07 0.08 0.08 0.08 734 782 0.1 0.2 H05BX02 paricalcitol (2 mcg) 0.03 0.03 0.03 0.03 0.03 309 341 333 336 361 0.1 0.1 H05BX04 etelcalcetide (2.1 virussykdommer. B J utgj\u00f8r 8, 2 % av de totale legemiddelkostnadene i 2019 er redusert 2 mens det ses en liten \u00f8kning i salget av de andre legemiddelgruppene i gruppe J, m\u00e5lt i DDD. Antibakterielle midler til systemisk bruk Fra antibiotikabruken med 30 m\u00e5lt i DDD fra 2012 ti l utgangen av 2020. Figur 4.8.1 viser at det i , at 23 % av norske mot antibiotikaresi stens i helsetjenesten1. Fenoksymetylpenicillin sto for 25 % av antibiotikareseptene og mer i Reseptregisteret i 2019. Disse tre midlene sto for mer enn 50 % av antibiotikareseptene og 54 % av alle forekomst av kombinasjonspreparater bruk antibacterials use (J01) in 2000-2019 The total of J01 includes all shown specifically in the figure. Source: Norwegian Drug Wholesales Statistics Figur e 4.8.2 Proportion of users (prevalence) of antibacterials for systemic use (ATC group J01, excl. methenamine) in 2019 by age and gender. Source: Norwegian Prescription Database 0510152025 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018DDD/1000 inhabitants/dayJ01 J01C J01A J01F J01E Year 0 5 10 15 20 25 30 35 40 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75+ AgeWomen MenProportion (%) of the population 74 1) Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 J ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE 18.87 17.40 008 1 109 722 1 063 315 1 026 325 1 046 196.4 J01A TETRACYCLINES 3.38 3.16 3.01 2.86 2.96 181 380 168 809 159 385 152 173 158 962 35.1 29.8 J01AA Tetracyclines 3.38 3.16 3.01 2.86 2.96 181 380 168 809 159 385 152 173 158 962 35.1 29.8 J01AA02 doxycycline (0.1 g) 1.96 1.82 1.69 1.61 1.67 141 617 131 272 122 266 115 433 121 112 27.4 22.7 J01AA04 lymecycline (0.6 g) 0.96 0.94 0.95 561 23 337 24 396 24 801 26 525 4.8 J01AA06 oxytetracycline (1 g) 0.00 0.00 0.00 0.00 26 29 J01AA07 tetracycline (1 g) 0.45 0.40 0.36 0.32 0.31 18 062 16 804 15 267 14 239 13 852 3.5 2.6 J01AA08 minocycline (0.2 g) 0.00 0.00 0.00 0.00 0.00 28 23 J01C BETA -LACTAM ANTI - BACTERIALS, PENICILLINS 7.59 7.35 6.99 6.87 7.12 769 281 750 891 730 187 713 965 735 182 138.0 J01CA Penicillins with extended spectrum 2.73 2.62 2.47 2.46 2.53 319 429 311 008 298 397 299 130 303 783 61.8 57.0 J01CA01 ampicillin (6 g) 0.04 0.04 0.04 0.05 0.05 50 62 54 66 55 0.0 0.0 J01CA04 amoxicillin (1.5 g) 0.92 0.88 0.87 0.84 0.89 132 447 125 992 119 990 117 650 118 029 25.6 22.2 J01CA08 pivmecillinam (0.6 g) 1.76 1.69 1.56 1.57 1.58 200 847 198 004 190 781 194 098 199 160 38.9 37.4 J01CA11 mecillinam (1.2 g) 0.01 0.01 0.01 0.00 0.00 10 16 18 6 14 0.0 0.0 J01CE Beta -lactamase sensitive penicillins 3.88 3.73 3.61 3.43 3.56 417 025 404 417 483 373 320 388 028 80.7 72.8 J01CE01 benzylpenicillin (3.6 g) 0.22 0.23 0.23 0.24 0.23 120 149 166 209 214 0.0 0.0 J01CE02 phenoxymethylpenicillin (2 g) 3.66 3.50 3.38 3.18 3.33 416 0.00 87 60 57 resistant penicillins 0.89 0.90 0.84 0.90 0.93 105 990 105 128 103 589 105 680 109 543 20.5 20.6 J01CF01 dicloxacillin (2 g) 0.73 0.74 0.70 0.74 0.76 104 241 103 820 103 272 105 556 109 423 20.2 20.5 J01CF02 cloxacillin (2 g) 0.16 0.17 0.13 0.16 0.17 2 211 1 624 379 105 123 0.4 0.0 J01CF05 flucloxacillin (2 g) 0.00 0.00 0.00 0.00 0.00 29 78 73 0.0 J01CR Combinations of penicillins, incl. beta - lactamase inhibitors 0.08 0.10 0.07 0.08 0.10 770 1 017 1 652 2 829 4 595 0.2 0.9 J01CR02 amoxicillin and beta - lactamase inhibitor (1.5 g) 0.01 0.01 0.02 0.03 0.04 695 916 1 588 2 762 4 519 0.1 0.9 J01CR05 piperacillin and beta - lactamase inhibitor (14 g) 0.08 0.09 0.05 0.05 0.05 79 104 66 70 83 0.0 0.0 J01D OTHER BETA -LACTAM ANTIBACTERIALS 0.43 0.42 0.38 0.39 0.37 17 366 14 827 13 449 12 545 12 151 3.4 2.3 J01DB First -generation cephalosporins 0.21 0.20 0.17 0.18 0.17 16 071 13 968 12 546 11 728 11 322 3.1 2.1 J01DB01 cefalexin (2 g) 0.12 0.10 0.09 0.09 0.07 16 055 13 951 12 529 11 708 11 311 3.1 2.1 J01DB03 cefalotin (4 g) 0.09 0.09 0.08 0.07 0.00 16 19 17 22 7 0.0 0.0 J01DB04 cefazolin (3 g) 0.01 0.03 0.09 5 0.0 J01DC Second -generation cephalosporins 0.04 0.04 0.03 0.03 0.03 93 97 72 75 68 0.0 0.0 J01DC02 cefuroxime (0.5 g O/3 g P) 0.04 0.04 0.03 0.03 0.03 93 97 72 75 68 0.0 0.0 76 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 J01DD Third -generation cephalosporins 0.15 0.15 0.15 0.16 0.15 1 171 740 785 717 711 0.2 0.1 J01DD01 cefotaxime (4 g) 0.12 0.12 0.12 0.12 0.12 789 363 305 169 191 0.2 0.0 J01DD02 ceftazidime (4 g) 0.01 0.01 0.01 0.01 0.01 69 68 75 55 34 0.0 0.0 J01DD04 ceftriaxone (2 g) 0.02 0.02 0.02 0.02 0.02 313 312 412 494 484 0.1 0.1 J01DF Monobactams 0.00 0.00 0.00 18 10 0.0 0.0 J01DH Carbapenems 0.02 0.03 0.03 0.03 0.03 86 73 86 71 67 0.0 0.0 J01DH02 meropenem (3 g) 0.02 0.03 0.02 0.02 0.02 49 58 63 53 49 0.0 0.0 J01DH03 ertapenem (1 g) 0.00 0.00 0.00 0.00 18 cilastatin 121 722 434 125 601 131 238 23.4 24.6 J01EA Trimethoprim and derivatives 0.42 0.38 0.35 0.34 0.36 72 69 823 66 833 121 14.0 (0.4 0.35 72 69 823 68 0.49 0.53 0.57 54 153 57 183 58 807 64 637 69 732 10.5 13.1 J01EE01 sulfamethoxazole and trimethoprim 0.46 0.47 0.49 0.53 0.57 54 153 57 183 58 807 64 637 69 732 10.5 13.1 J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 1.51 1.33 1.18 1.05 1.04 242 351 217 006 187 736 163 664 158 725 46.9 29.8 J01FA Macrolides 1.20 1.04 0.93 0.80 0.80 190 236 168 977 145 999 123 066 118 620 36.8 22.3 J01FA01 erythromycin (2 g O/1 g O,P) 0.68 0.60 0.54 0.44 0.45 101 160 92 247 82 929 67 900 66 917 19.6 12.6 J01FA02 spiramycin (3 g) 0.00 0.00 0.00 0.00 0.00 1 307 1 0.18 0.14 0.13 0.11 0.11 24 078 18 856 15 730 13 280 12 498 4.7 2.4 J01FA10 azithromycin (0.3 g) 0.33 0.30 0.26 0.24 0.24 69 382 61 238 49 933 43 852 40 980 13.4 7.7 J01FF Lincosamides 0.31 0.28 0.25 0.25 0.25 59 149 53 932 46 587 44 856 44 181 11.5 8.3 J01FF01 clindamycin (1.2 g O/1.8 g P) 0.31 0.28 0.25 0.25 0.25 59 149 53 932 46 587 44 856 44 181 11.5 8.3 J01G AMINOGLYCOSIDE ANTIBACTERIALS 0.08 0.08 0.09 0.09 0.10 J01GB Other aminoglycosides 0.08 0.08 0.09 0.09 0.10 214 215 185 198 0.0 0.0 J01GB01 tobramycin (0.24 g P/ 0.3 g inhal.sol./ 0.112 g inhal.powder) 0.02 0.02 0.02 0.01 0.01 177 168 172 140 158 0.0 0.0 J01GB03 gentamicin (0.24 g) 0.06 0.06 0.07 0.08 0.09 24 32 32 33 (1 g) 0.00 0.00 0.00 0.00 0.00 13 15 20 13 12 0.0 0.0 77 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 J01M QUINOLONE ANTIBACTERIALS 0.60 0.53 0.45 0.41 0.36 58 859 53 197 45 649 42 077 37 406 11.4 7.0 J01MA Fluoroquinolones 0.60 0.53 0.45 0.41 0.36 58 859 53 197 45 649 42 077 37 406 11.4 7.0 J01MA01 ofloxacin (0.4 g) 0.01 0.01 0.01 0.01 0.01 1 312 1 083 941 832 849 0.3 0.2 J01MA02 ciprofloxacin (1 g O/0.8 g P) 0.58 0.51 0.43 0.33 56 847 51 047 43 221 39 387 34 464 11.0 (0.5 g) 0.00 0.00 0.00 0.00 60 83 82 0.0 0.0 J01MA14 moxifloxacin (0.4 g) 0.01 0.01 0.01 0.01 0.01 940 1 247 1 600 1 939 2 154 0.2 0.4 J01X OTHER ANTIBACTERIALS 4.41 147 60 756 12.4 11.4 J01XA Glycopeptide antibacterials 0.02 0.02 0.02 0.02 0.02 44 47 43 43 47 0.0 0.0 J01XA01 vancomycin (2 g) 0.02 0.02 0.02 0.02 0.02 44 47 42 43 47 0.0 0.0 J01XB Polymyxins 0.00 0.01 0.01 0.01 0.01 94 111 111 104 126 0.0 0.0 J01XB01 colistin (3 MU inhal/9 MU P) 0.00 0.01 0.01 0.01 0.01 94 111 111 104 126 0.0 0.0 J01XC Steroid antibacterials 0.00 0.00 0.00 (1.5 g) 326 326 359 0.1 0.1 J01XD Imidazole derivatives 0.04 0.03 0.04 0.04 0.04 34 30 27 31 36 0.0 0.0 J01XD01 metronidazole (1.5 g) 0.04 0.03 0.04 0.04 0.04 34 30 27 31 36 0.0 0.0 J01XE Nitrofuran derivatives 0.34 0.31 0.28 0.25 0.24 36 527 36 830 37 003 30 853 31 831 7.1 6.0 J01XE01 nitrofurantoin (0.2 g) 0.34 0.31 0.28 0.25 0.24 36 527 36 830 37 003 30 853 31 831 7.1 6.0 J01XX Other antibacterials 4.00 4.10 4.12 4.09 3.41 33 306 34 356 35 522 36 348 34 000 6.5 6.4 J01XX01 fosfomycin (8 g) 0.00 0.00 0.00 0.00 (hippurat 2 g) 3.99 4.09 4.11 4.08 3.39 33 030 34 039 35 183 35 980 33 618 6.4 6.3 J01XX08 linezolid (1.2 g) 0.01 0.01 0.01 0.01 0.01 275 305 314 339 340 0.1 0.1 0.85 1.19 0.59 0.61 1.48 25 11 8 8 11 0.0 0.0 J02AB02 ketoconazole (0.2 g) 0.85 1.19 0.59 0.61 1.48 25 11 8 8 11 1.73 1.68 1.69 1.56 1.91 530 401 365 348 382 0.1 0.1 J02AC03 voriconazole (0.4 g) 2.76 2.83 2.27 2.31 3.10 103 105 97 96 111 0.0 0.0 J02AC04 posaconazole (0.3 g) 2.96 2.93 2.74 2.71 3.19 101 120 106 111 139 0.0 J02AC05 isavuconazole (0.2 g) 0.08 0.34 0.73 <5 16 31 J02AX Other antimycotics for systemic use 2.45 2.80 2.68 2.72 3.06 8 10 10 20 20 0.0 0.0 J02AX04 caspofungin <5 <5 - - Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/1000 inhabitants/Year 2015 2016 2017 2018 2019 J02AX05 0.74 1.15 <5 7 g) 0.19 1.47 0.96 1.71 1.99 82.37 0.02 0.03 0.00 <5 <5 - J04AA01 4-aminosalicylic acid (12 J04AB05 rifapentine (0.11 g) 1.62 7.15 6.59 6.20 6.87 36 272 319 322 349 0.0 0.1 J04AB30 capreomycin J04AC01 isoniazid (0.3 g) 4.11 10.34 9.74 8.99 9.20 115 J04AD Thiocarbamide derivatives 0.40 0.29 0.68 0.35 0.18 6 6 J04AD01 protionamide (0.75 g) 0.40 0.29 0.68 0.35 0.18 6 6 11 9 6 0.0 0.0 J04AK Other drugs for treatment of tuberculosis 8.06 5.91 5.11 5.03 4.76 233 204 177 160 152 0.1 J04AK01 pyrazinamide (1.5 g) 1.68 1.25 0.93 0.96 0.88 41 46 40 40 28 0.0 ethambutol (1.2 g) 6.38 4.66 3.89 3.82 3.68 219 181 162 145 142 bedaquiline mg) 0.29 0.25 0.21 <5 <5 <5 18.19 13.37 11.60 10.19 J04AM05 rifampicin, pyrazinamide and isoniazid (6 UD) 2.59 2.01 1.23 1.08 0.68 129 126 95 76 54 0.0 0.0 J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid (4 UD) 1.32 1.85 1.95 1.71 1.48 68 101 128 126 97 0.0 0.0 J04B DRUGS FOR TREATMENT OF LEPRA 29.17 29.11 28.96 448 475 485 of lepra 29.17 29.11 28.96 g) 0.09 0.11 0.43 0.44 mg) 29.08 29.00 28.53 27.34 31.16 445 470 476 467 491 0.1 0.1 79 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/1000 inhabitants/Year 2015 2016 2017 0.03 0.07 0.02 <5 <5 <5 6 0.26 0.11 0.18 J05AB14 valganciclovir (0.9 g) 8.15 8.33 9.78 8.47 9.67 371 377 439 409 472 0.1 0.1 J05AD Phosphonic acid derivatives 0.20 0.21 0.21 0.16 foscarnet 811 605 399 269 g) 51.66 34.18 20.00 12.92 228 0.0 J05AE10 darunavir (1.2 g) 9.73 8.45 6.18 4.89 3.95 218 200 148 124 94 0.0 0.0 J05AF Nucleoside 0.69 0.48 0.41 15 14 19 15 18 0.0 0.0 J05AF02 didanosine (0.4 g) 0.11 5 3.65 3.20 2.70 3.41 9.54 94 84 75 103 (0.6 g) 3.48 3.44 3.37 2.91 0.34 0.29 <5 <5 J05AF09 emtricitabine (0.2 410 J05AF11 telbivudine (0.6 g) 0.08 0.05 <5 <5 0 0.0 J05AF13 tenofovir alafenamide (25 mg) 4.20 6.15 4.35 121 18.31 13.99 11.26 197 375 0.1 J05AG01 nevirapine (0.4 g) 9.13 7.46 5.94 5.04 5.53 147 126 99 89 83 0.0 0.0 J05AG03 efavirenz (0.6 g) 6.53 3.92 2.50 2.24 1.97 119 76 46 38 36 0.0 0.0 J05AG04 etravirine (0.4 g) 1.74 1.67 1.22 1.18 1.07 29 28 24 18 20 0.0 0.0 J05AG05 rilpivirine (25 mg) 0.91 0.94 1.60 3.27 13.03 14 19 31 85 239 0.0 ) 0.06 <5 2987 0.3 0.6 J05AH01 zanamivir (20 mg) 0.06 0.01 52 25 0.0 80 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/1000 inhabitants/Year 2015 2016 2017 2018 2019 J05AH02 oseltamivir (0.15 4.92 4.50 1923 3571 2987 380 88 36 J05AP03 boceprevir (2.4 g) 0.05 <5 - J05AP05 simeprevir (0.15 1.04 0.08 0.03 69 5 <5 0.0 J05AP07 daclatasvir (60 mg) 2.67 3.86 0.54 129 235 47 0.0 J05AP08 sofosbuvir (0.4 g) 6.28 6.33 1.24 - J05AP09 dasabuvir (0.5 g) 0.17 4.77 1.17 0.60 0.03 12 299 105 54 5 0.0 0.0 J05AP51 sofosbuvir and ledipasvir (1 UD) 9.06 4.18 0.46 1.15 6.99 534 312 29 98 620 0.1 0.1 J05AP53 ombitasvir, paritaprevir and ritonavir (2 UD) 0.19 4.92 1.20 0.61 0.03 13 312 107 55 6 0.0 0.0 J05AP54 elbasvir and grazoprevir (1 0.42 0.32 <5 30 27 0.0 J05AR Antivirals 3.53 J05AR02 lamivudine and abacavir (1 UD) 16.46 10.22 7.35 9.75 195 262 4.27 2.75 1.72 265 259 104 52 37 0.1 0.0 J05AR10 lopinavir and ritonavir (0.8 g) 11.20 6.62 4.18 2.63 2.32 212 145 89 62 43 cobicistat (1 UD) 2.28 4.31 alafenamide (1 UD) 891 945 713 0.1 81 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/1000 inhabitants/Year 2015 (3 g) 0.33 0.30 0.19 0.17 0.14 25 18 13 9 5 0.0 0.0 J05AX08 raltegravir (0.8 (0.6 g) 0.34 0.27 0.23 0.30 0.23 8 7 6 7 6 0.0 0.0 J05AX12 dolutegravir (50 mg) 7.04 10.21 13.75 19.06 44.55 246 413 793 0.0 0.2 J05AX18 letermovir (0.48 g) 0.15 6 0.0 82 4.9 L Antineoplastiske og immunmodulerende midler L01 Antineoplastiske legemiddelstatistikk utgj\u00f8r (m\u00e5lt pasienter kan tilbys I bare interferon beta (L03AB) og glatiramer acetate (L03AX13) tilgjengelige, legemidlene er i -60 \u00e5r som behand les. 83 Figur e 4.9. Sales of drugs in ATC -groups L03 and L04 indicated for treatment of multiple sclerosis; interferon beta (L03AB Source: Norwegian Drug Wholesales Statistics. 00,20,40,60,811,2 2000 2002 2004 2006 2008 2010 2012 2014 Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 gram of active ingredient/year ATC 2015 2016 2017 2018 2019 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS 8 243 8 784 9 955 10 466 11 488 1.6 2.2 L01A ALKYLATING AGENTS 1 436 1 242 1 247 1 252 1 326 0.3 0.3 L01AA Nitrogen mustard analogues 797 649 599 541 622 0.2 0.1 L01AA01 cyclophosphamide 15 438 1 839 18 728 17 952 19 088 231 214 223 227 304 0.0 0.1 L01AA02 chlorambucil 67 54 41 35 35 122 106 84 79 68 0.0 0.0 L01AA03 melphalan 174 153 148 125 150 352 215 175 144 155 0.1 0.0 L01AA06 ifosfamide 9 808 11 382 10 943 10 786 11 105 L01AA07 trofosfamide 1 725 1 680 1 668 1 700 1 348 106 119 123 98 104 0.0 0.0 L01AA09 bendamustine 501 556 447 7 5 0.0 0.0 L01AB01 busulfan 57 52 64 80 54 6 5 <5 7 5 0.0 0.0 L01AB02 treosulfan 1 431 2 196 2 577 2 947 4 061 L01AC Ethylene imines L01AC01 thiotepa 9 10 12 21 16 L01AD Nitrosoureas 117 126 125 117 122 0.0 0.0 L01AD01 carmustine 94 55 50 38 47 L01AD02 lomustine 160 156 158 129 143 117 126 125 117 122 0.0 0.0 L01AD04 streptozocin 183 349 248 203 144 L01AX Other alkylating agents 575 526 593 659 645 0.1 0.1 L01AX03 temozolomide 4 876 4 205 5 181 5 879 5 575 574 525 593 659 645 0.1 0.1 L01AX04 dacarbazine 1 480 1 182 1 134 1 001 960 <5 <5 - L01B ANTIMETABOLITES 1 869 1 920 2 525 2 625 3 200 0.4 0.6 L01BA Folic acid analogues 53 44 25 17 <5 0.0 - L01BA01 methotrexate 5 464 6 427 8 463 6 399 9 825 53 41 25 17 <5 0.0 - L01BA03 raltitrexed 66 80 12 6 L01BA04 pemetrexed 1 620 1 646 1 210 1 256 2 566 <5 L01BB Purine analogues 515 519 500 510 498 0.1 0.1 L01BB02 mercaptopurine 5 963 5 904 6 181 6 048 5 931 441 463 459 473 449 0.1 0.1 L01BB03 tioguanine 167 142 95 106 135 56 36 43 53 56 0.0 0.0 L01BB04 cladribine 3 2 3 3 4 L01BB05 fludarabine 100 97 87 90 110 65 54 38 35 45 0.0 0.0 L01BB06 clofarabine 1 0 0 1 L01BB07 nelarabine 3 8 L01BC Pyrimidine analogues 1 302 1 357 2 002 2 098 2 701 0.3 0.5 L01BC01 cytarabine 8 332 9 322 8 455 8 918 8 671 <5 <5 5 <5 <5 - - 85 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 gram of active ingredient/year ATC 2015 2016 2017 2018 2019 L01BC02 fluorouracil 63 594 58 829 61 987 64 856 69 357 146 116 98 68 166 0.0 0.0 L01BC05 gemcitabine 11 869 12 382 14 024 14 189 14 062 <5 13 15 0 0 - 0.0 L01BC06 capecitabine 220 647 223 728 215 430 209 256 253 557 1 145 1 184 1 215 1 175 1 292 0.2 0.2 L01BC07 azacitidine 543 669 811 827 <5 0.0 - L01BC08 decitabine 8 16 33 33 26 0 0 <5 0 0 0.0 0.0 L01BC52 fluorouracil, combinations 1 20 23 34 0 43 651 784 1 171 0.0 0.2 L01BC53 tegafur, combinations 26 30 24 36 28 <5 <5 6 5 5 - 0.0 L01BC59 trifluridine, combinations 78 268 258 24 74 73 0.0 L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS 1 351 1 346 1 235 1 201 973 0.3 0.2 L01CA Vinca alkaloids and analogues 888 893 792 765 528 0.2 0.1 L01CA01 vinblastine 22 23 22 21 18 L01CA02 vincristine 13 13 12 13 <5 <5 <5 vindesine L01CA04 vinorelbine 591 578 529 485 399 887 890 789 765 528 0.2 0.1 L01CA05 vinflunine 47 60 61 14 1 L01CB Podophyllotoxin derivatives 441 433 430 438 444 0.1 0.1 L01CB01 etoposide 3 781 3 749 3 627 3 630 3 844 441 433 430 438 444 0.1 0.1 L01CB02 teniposide 20 22 22 14 3 L01CD Taxanes 23 25 15 <5 <5 0.0 - L01CD01 paclitaxel 4 459 4 559 4 459 4 121 4 630 20 16 9 <5 <5 0.0 - L01CD02 docetaxel 854 898 909 867 <5 9 6 0 <5 - - L01CD04 cabazitaxel 10 3 10 34 38 L01CX Other plant alkaloids and natural products L01CX01 trabectedin 0 0 0 0 0 L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES 17 16 14 6 0 0.0 0.0 L01DA Actinomycines L01DA01 dactinomycin 0 0 0 0 0 L01DB Anthracyclines and related substances 17 15 14 <5 0 0.0 0.0 L01DB01 doxorubicin 575 601 564 0 - 52 52 60 44 L01DB03 epirubicin 1 289 1 315 1 127 1 006 988 14 10 7 0 0 0.0 0.0 L01DB06 idarubicin 5 6 6 5 5 <5 <5 <5 0 0.0 L01DB07 mitoxantrone 4 5 4 3 3 L01DB11 pixantrone 1 1 86 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 gram of active ingredient/year ATC 2015 2016 2017 2018 2019 L01DC Other cytotoxic antibiotics <5 0 <5 0 0.0 L01DC01 bleomycin 56 700 50 550 47 250 42 450 39 300 <5 0 <5 0 0.0 L01DC03 mitomycin 55 51 53 56 60 <5 L01X OTHER ANTINEOPLASTIC AGENTS 4 102 4 729 5 438 5 764 6 445 0.8 1.2 L01XA Platinum compounds 13 20 19 <5 0.0 - L01XA01 cisplatin 644 631 618 600 607 L01XA02 carboplatin 5 6 105 6 058 5 979 6 296 <5 6 7 0 0 - 0.0 L01XA03 oxaliplatin 1 833 1 864 1 899 1 835 1 978 9 14 12 0 <5 0.0 - L01XB Methylhydrazines 84 105 126 94 102 0.0 0.0 L01XB01 procarbazine 635 663 680 503 680 84 105 126 94 102 0.0 0.0 L01XC Monoclonal antibodies 105 238 216 115 63 0.0 0.0 L01XC02 rituximab 10 579 13 305 13 552 14 155 13 660 51 177 161 55 11 0.0 0.0 L01XC03 trastuzumab 6 038 6 232 6 794 6 798 6 221 23 28 21 34 21 0.0 0.0 L01XC05 gemtuzumab ozogamicin 10 10 L01XC06 cetuximab 742 1 1 166 993 <5 <5 - L01XC07 bevacizumab 4 078 3 902 4 030 3 997 4 227 9 12 7 <5 <5 0.0 - L01XC08 panitumumab 836 9 <5 L01XC10 ofatumumab 34 32 27 4 L01XC11 ipilimumab 101 10 27 37 81 <5 - - 9 23 24 30 L01XC13 pertuzumab 360 837 1 055 1 085 1 491 <5 <5 L01XC14 trastuzumab emtansine 6 9 70 obinutuzumab 14 53 226 330 L01XC17 nivolumab 34 472 1 027 1 663 2 074 11 19 19 21 23 0.0 0.0 L01XC18 pembrolizumab 8 327 885 1 017 <5 <5 2 3 L01XC21 ramucirumab 10 14 34 12 30 L01XC23 elotuzumab 2 daratumumab 28 Sensitizers used in photodynamic/radiation therapy 7 5 <5 47 193 0.0 0.0 L01XD03 methyl aminolevulinate 1 202 1 325 1 259 1 026 1 140 6 5 <5 37 141 0.0 0.0 L01XD04 aminolevulinic acid 140 158 289 490 453 <5 11 53 - 0.0 L01XE Protein kinase inhibitors 2 032 2 346 2 905 3 205 3 622 0.4 0.7 87 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 gram of active ingredient/year ATC 2015 2016 2017 2018 2019 L01XE01 imatinib 55 620 62 640 62 232 63 186 68 466 499 539 577 577 607 0.1 0.1 L01XE02 gefitinib 2 693 2 130 1 815 4 035 4 710 59 42 36 93 95 0.0 0.0 L01XE03 erlotinib 2 831 2 868 3 227 2 084 1 298 154 131 138 86 48 0.0 0.0 L01XE04 sunitinib 1 122 1 003 848 1 229 1 030 213 192 177 253 187 0.0 0.0 L01XE05 sorafenib 5 936 6 899 4 838 5 174 7 146 79 90 76 74 90 0.0 0.0 L01XE06 dasatinib 1 589 1 740 2 039 2 379 2 601 68 80 95 106 123 0.0 0.0 L01XE07 lapatinib 6 426 4 305 2 373 1 323 1 155 40 30 18 6 14 0.0 0.0 L01XE08 nilotinib 16 890 16 940 16 475 17 110 17 972 106 106 108 113 108 0.0 0.0 L01XE09 temsirolimus 1 0 0 0 0 L01XE10 everolimus 435 396 304 284 335 316 296 238 210 239 0.1 0.0 L01XE11 pazopanib 21 384 22 512 22 806 16 614 20 970 189 201 212 159 225 0.0 0.0 L01XE12 vandetanib 405 174 159 78 33 11 <5 <5 <5 <5 0.0 - L01XE13 afatinib 136 264 294 201 236 31 48 49 38 37 0.0 0.0 L01XE14 bosutinib 193 406 274 882 1 462 <5 6 5 15 19 - 0.0 L01XE15 vemurafenib 10 618 7 190 4 140 3 454 7 620 59 38 23 20 50 0.0 0.0 L01XE16 crizotinib 3 180 4 302 4 521 3 807 2 367 34 54 54 39 24 0.0 0.0 L01XE17 axitinib 95 111 68 44 38 59 66 43 24 23 0.0 0.0 L01XE18 ruxolitinib 585 1 010 1 404 1 773 2 014 86 143 213 262 320 0.0 0.1 L01XE21 regorafenib 665 595 769 585 665 71 64 77 59 68 0.0 0.0 L01XE23 dabrafenib 4 330 5 592 6 480 6 400 5 115 111 144 164 162 126 0.0 0.0 L01XE24 ponatinib 48 51 92 120 145 6 7 14 16 17 0.0 0.0 L01XE25 trametinib 0 24 44 44 35 <5 106 155 156 126 - 0.0 L01XE26 cabozantinib 55 249 566 898 1 213 <5 33 78 135 172 - 0.0 L01XE27 ibrutinib 5 300 10 387 14 045 19 324 22 408 60 115 153 207 234 0.0 0.0 L01XE28 ceritinib 878 1 823 2 273 1 508 743 12 18 21 13 8 0.0 0.0 L01XE29 lenvatinib 1 13 15 43 49 <5 5 7 14 25 - 0.0 L01XE31 nintedanib 1 125 5 280 9 339 13 311 19 167 29 84 132 194 276 0.0 0.1 L01XE33 palbociclib 97 1 129 6 147 7 520 7 090 12 86 442 463 426 0.0 0.1 L01XE34 tivozanib <5 6 9 0.0 L01XE36 alectinib 1 378 5 242 15 187 9 32 55 0.0 L01XE38 cobimetinib 1 40 52 151 <5 10 10 41 0.0 L01XE39 midostaurin 73 62 <5 5 0.0 L01XE41 binimetinib 28 0 6 0.0 L01XE42 ribociclib 7 594 20 668 143 317 0.1 L01XE43 <5 L01XE46 encorafenib 126 6 0.0 L01XE47 dacomitinib 1 <5 - 88 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 gram of active ingredient/year ATC 2015 2016 2017 2018 2019 L01XX Other antineoplastic agents 1 921 2 096 2 268 2 401 2 591 0.4 0.5 L01XX01 amsacrine 47 39 61 37 28 L01XX02 asparaginase 4 600 3 200 2 850 3 640 2 380 L01XX05 hydroxycarbamide 432 410 453 570 475 390 512 300 550 520 1 636 1 757 1 866 2 009 2 163 0.3 0.4 L01XX14 tretinoin 137 98 178 114 133 22 15 32 22 24 0.0 0.0 L01XX17 topotecan 2 2 1 1 1 14 23 17 18 19 0.0 0.0 L01XX19 irinotecan 3 409 3 416 3 671 3 443 3 574 9 6 5 0 0 0.0 0.0 L01XX23 mitotane 7 800 9 600 7 300 4 750 5 800 15 15 14 13 15 0.0 0.0 L01XX24 pegaspargase 2 291 1 916 1 695 1 216 390 L01XX25 bexarotene 1 200 1 275 1 035 998 720 13 13 11 9 8 0.0 0.0 L01XX27 arsenic trioxide 3 4 8 3 6 L01XX32 bortezomib 28 32 34 38 45 30 30 33 35 32 0.0 0.0 L01XX35 anagrelide 103 102 104 103 108 203 206 218 215 224 0.0 0.0 L01XX41 eribulin 2 2 2 1 1 <5 - L01XX42 panobinostat 0 9 10 4 4 <5 25 26 12 12 - 0.0 L01XX43 vismodegib 269 202 340 307 361 12 12 22 21 25 0.0 0.0 L01XX44 aflibercept olaparib 2 822 7 750 8 893 8 372 <5 27 53 62 69 - 0.0 L01XX47 idelalisib 684 1 251 978 1 401 1 368 18 26 26 27 23 0.0 0.0 L01XX50 ixazomib 12 240 192 <5 <5 <5 0.0 - L01XX52 venetoclax 1 605 2 094 9 45 0.0 DDD/1000 inhabitants/year 2015 2016 2017 2018 2019 L02 ENDOCRINE THERAPY 2 245 2 258 2 298 2 247 2 357 27 821 28 869 31 639 32 537 33 413 5.4 6.3 L02A HORMONES AND RELATED AGENTS 577 560 554 545 554 10 398 10 452 10 640 10 832 11 026 2.0 2.1 L02AB Progestogens 6 6 6 7 5 138 138 130 162 144 0.0 0.0 L02AB01 megestrol (0.16 g) 6 6 6 7 5 138 138 130 162 144 0.0 0.0 L02AE Gonadotropin releasing hormone analogues 571 554 548 538 549 10 260 10 315 10 513 10 671 10 882 2.0 2.0 L02AE01 buserelin (1.2 mg) 3 2 2 1 1 495 387 335 252 127 0.1 0.0 L02AE02 leuprorelin (0.134 mg depot inj./ 0.06 mg implant) 229 198 172 151 142 3 139 2 786 2 467 2 236 2 090 0.6 0.4 L02AE03 goserelin (0.129 mg) 339 353 373 385 405 6 599 7 001 7 312 7 689 8 072 1.3 1.5 L02AE04 triptorelin (0.134 mg depot inj./ 0.1 mg P) 0 1 1 1 1 131 241 479 573 670 0.0 0.1 L02AE05 histrelin (0.137 mg) 89 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/1000 inhabitants/year ATC 2015 2016 2017 2018 2019 L02B HORMONE ANTAGONISTS AND RELATED AGENTS 1 668 1 698 1 744 1 702 1 803 21 821 22 834 25 548 26 485 27 256 4.2 5.1 L02BA Anti -estrogens 279 304 333 337 347 4 609 4 958 5 439 5 544 5 675 0.9 1.1 L02BA01 tamoxifen (20 mg) 255 272 288 287 301 4 338 4 612 4 963 5 062 5 214 0.8 1.0 L02BA03 fulvestrant (8.3 mg) 24 32 45 50 46 292 376 522 521 487 0.1 0.1 L02BB Anti -androgens 765 743 737 681 721 7 081 6 985 7 007 7 020 6 884 1.4 1.3 L02BB01 flutamide (0.75 g) 6 4 4 3 2 108 85 82 64 55 0.0 0.0 L02BB03 bicalutamide (50 mg) 734 707 694 634 672 6 313 6 116 6 041 5 945 5 762 1.2 1.1 L02BB04 enzalutamide (0.16 g) 25 32 39 44 47 826 938 1 093 1 188 1 219 0.2 0.2 L02BG Aromatase inhibitors 556 584 614 630 684 9 813 10 626 12 995 13 880 14 668 1.9 2.8 L02BG03 anastrozole (1 mg) 59 50 41 34 35 1 028 843 757 652 574 0.2 0.1 L02BG04 letrozole (2.5 mg) 445 480 521 542 592 8 128 9 079 11 537 12 524 13 348 1.6 2.5 L02BG06 exemestane (25 mg) 52 54 52 54 57 983 1 015 974 1 041 1 078 0.2 0.2 L02BX Other hormone antagonists and related agents 68 67 60 54 51 1 415 1 401 1 273 1 180 1 147 0.3 0.2 L02BX02 degarelix (2.7 mg) 43 46 44 40 38 806 872 837 786 778 0.2 0.2 L02BX03 abiraterone (1 g) 25 21 16 14 13 660 581 473 430 398 0.1 0.1 L03 IMMUNOSTIMULANTS 205 200 177 168 164 6 306 6 819 6 431 6 432 6 510 1.2 1.2 L03A IMMUNOSTIMULANTS 205 200 177 168 164 6 306 6 819 6 431 6 432 6 510 1.2 1.2 L03AA Colony stimulating factors 4 159 4 909 4 775 4 932 5 169 0.8 1.0 L03AA02 filgrastim (0.35 mg) 4 4 4 4 4 593 583 588 594 671 0.1 0.1 L03AA13 pegfilgrastim (0.3 mg) 47 55 61 23 47 3 138 3 605 3 947 1 811 3 208 0.6 0.6 L03AA14 lipegfilgrastim (0.3 mg) 9 13 5 45 24 676 956 370 3 086 1 997 0.1 0.4 L03AB Interferons 1 375 1 210 952 763 668 0.3 0.1 L03AB01 interferon alfa natural (2 MU) 0 8 0.0 L03AB03 interferon gamma (40 mcg) 1 1 1 1 1 10 13 10 9 8 0.0 0.0 L03AB04 interferon alfa -2a (2 MU) 1 1 1 19 19 21 0.0 L03AB05 interferon alfa -2b (2 MU) 1 1 1 1 1 34 36 40 27 22 0.0 0.0 L03AB07 interferon beta -1a (4.3 mcg) 66 55 44 37 33 592 461 372 323 273 0.1 0.1 L03AB08 interferon beta -1b (4 MU) 18 12 9 6 5 321 211 134 95 65 0.1 0.0 L03AB10 peginterferon alfa -2b (7.5 mcg) 4 3 2 2 1 71 51 50 40 28 0.0 0.0 L03AB11 peginterferon alfa -2a (26 mcg) 6 7 5 5 6 319 315 214 184 203 0.1 0.0 L03AB13 peginterferon beta -1a (8.9 mcg) 0 3 3 2 2 11 149 135 100 75 0.0 0.0 L03AC Interleukins L03AC01 aldesleukin (0.2 mg) 0 0 0 0 90 DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/1000 inhabitants/year ATC 2015 2016 2017 2018 2019 L03AX Other immunostimulants 789 723 722 761 685 0.2 0.1 L03AX03 BCG vaccine (1.8 mg) 7 8 8 8 9 14 13 5 8 5 0.0 0.0 L03AX13 glatiramer acetate (20 mg) 40 36 33 34 31 775 710 717 753 680 0.2 0.1 L03AX16 plerixafor (16.8 mg) 0 0 0 0 0 L04 IMMUNOSUPPRESSANTS 4 509 4 907 5 229 5 473 5 743 61 188 64 946 68 190 71 244 74 825 11.8 14.0 L04A IMMUNOSUPPRESSANTS 4 509 4 907 5 229 5 473 5 743 61 188 64 946 68 190 71 244 74 825 11.8 14.0 L04AA Selective immunosuppressants 603 679 712 737 731 9 551 10 333 10 851 11 856 12 234 1.9 2.3 L04AA06 mycophenolic acid (2 g) 218 225 233 238 248 4 668 4 925 5 164 5 375 5 473 0.9 1.0 L04AA10 sirolimus (3 mg) 11 12 12 12 12 242 272 295 297 293 0.1 0.1 L04AA13 leflunomide (20 mg) 98 104 102 98 81 2 142 2 225 2 256 2 238 2 121 0.4 0.4 L04AA18 everolimus (1.5 mg) 48 52 49 53 54 484 487 481 508 480 0.1 0.1 L04AA23 natalizumab (10 mg) 56 58 58 60 61 <5 <5 L04AA24 abatacept (27 mg) 10 11 11 10 9 222 258 283 268 215 0.0 0.0 L04AA25 eculizumab (64 mg) 17 18 18 18 22 0.0 0.0 L04AA26 belimumab (25 mg) 3 3 3 3 4 L04AA27 fingolimod (0.5 mg) 71 79 82 82 77 1 238 1 329 1 411 1 380 1 263 0.2 0.2 L04AA28 belatacept (12.5 mg) 0 1 1 1 1 <5 <5 <5 - L04AA29 tofacitinib (10 mg) 1 24 33 87 835 672 0.1 L04AA31 teriflunomide (14 mg) 55 73 78 81 78 1 069 1 362 1 427 1 465 1 358 0.2 0.3 L04AA32 apremilast (60 mg) 0 1 1 1 0 9 35 27 15 6 0.0 0.0 L04AA33 vedolizumab (5.4 mg) 15 38 61 78 96 <5 - L04AA34 alemtuzumab (0.13 mg) 18 23 22 21 10 L04AA36 ocrelizumab (3.29 mg) 0 1 L04AA37 baricitinib (4 mg) 1 2 16 28 56 553 0.1 L04AA40 cladribine (0.34 mg) 14 39 182 510 0.0 0.1 L04AB Tumor necrosis factor alpha (TNF -) inhibitors 1 510 1 671 1 814 1 979 2 187 15 163 15 647 16 505 16 764 20 473 2.9 3.8 L04AB01 etanercept (7 mg) 281 279 329 377 343 5 551 5 737 7 350 8 196 7 228 1.1 1.4 L04AB02 infliximab (3.75 mg) 656 801 920 1 086 <5 <5 <5 <5 - - L04AB04 adalimumab (2.9 mg) 271 257 256 255 500 4 699 4 448 4 376 4 430 10 828 0.9 2.0 L04AB05 certolizumab pegol (14 mg) 177 214 195 157 131 3 506 4 262 3 646 2 990 2 577 0.7 0.5 L04AB06 golimumab (1.66 mg) 125 120 114 104 86 2 040 1 848 1 684 1 514 1 308 0.4 0.3 L04AC Interleukin inhibitors 102 129 173 198 195 1 408 1 848 2 673 3 062 3 002 0.3 0.6 L04AC01 daclizumab (5 mg) 1 0 14 5 L04AC02 basiliximab (40 mg) 0 0 0 0 0 L04AC03 anakinra (0.1 g) 7 8 9 8 10 170 189 197 208 270 0.0 0.1 L04AC05 ustekinumab (0.54 mg) 58 67 69 80 78 764 830 814 805 752 0.2 0.1 L04AC07 tocilizumab (20 mg) 36 37 41 42 38 455 521 608 618 543 0.1 0.1 L04AC08 canakinumab (2.7 mg) 1 2 2 4 4 13 23 24 37 37 0.0 0.0 91 DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 DDD/1000 inhabitants/year ATC 2015 2016 2017 2018 2019 L04AC10 secukinumab (10 mg) 1 16 51 64 64 22 371 1 102 1 430 1 368 0.0 0.3 L04AC11 siltuximab (37 mg) 0 0 0 0 L04AC12 brodalumab (15 mg) 0 0 15 85 0.0 L04AC13 ixekizumab (2.9 mg) 1 22 0.0 L04AD Calcineurin inhibitors 291 298 310 320 337 5 979 6 203 6 274 6 449 6 612 1.2 1.2 L04AD01 ciclosporin (0.25 g) 129 125 118 110 108 3 156 3 130 2 954 2 893 2 788 0.6 0.5 L04AD02 tacrolimus (5 mg) 162 173 192 210 229 2 889 3 132 3 383 3 628 3 886 0.6 0.7 L04AX Other immunosuppressants 2 003 2 130 2 220 2 239 2 294 41 473 43 579 45 478 47 018 48 044 8.0 9.0 L04AX01 azathioprine (0.15 g) 313 320 312 300 276 7 896 8 280 8 280 8 214 8 003 1.5 1.5 L04AX02 thalidomide (0.1 g) 6 4 2 1 2 238 200 90 63 63 0.1 0.0 L04AX03 methotrexate (2.5 mg) 1 665 1 777 1 865 1 890 1 967 31 709 33 357 35 139 36 511 37 749 6.1 7.1 L04AX04 lenalidomide (10 mg) 14 23 33 39 39 434 612 810 987 957 0.1 0.2 L04AX05 pirfenidone (2.4 g) 3 3 3 4 5 65 69 78 98 120 0.0 0.0 L04AX06 pomalidomide (3 mg) 2 3 4 5 5 99 130 178 191 202 0.0 0.0 L04AX07 dimethyl fumarate (0.48 g) 66 68 63 62 63 1 273 1 235 1 160 1 213 1 180 0.3 0.2 92 4.10 M Muskler og pakninger. 93 Figure 4.10 Proportion of the populations (prevalence % of most prescribed antirheumatic products, non -steroids (NSAID s, M01A )) Database. 1. https://legemiddelverket.no/nyheter/nye -anbefalinger -for-diklofenak 94 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 M MUSCULO -SKELETAL Acetic acid derivatives and related substances 8.97 8.18 7.75 7.16 6.74 376 889 349 105 341 369 324 883 307 675 73.0 57.7 M01AB01 indometacin (0.1 g) 0.06 0.07 0.06 0.06 0.07 1 179 1 220 1 282 1 302 1 466 0.2 0.3 M01AB02 sulindac (0.4 (0.1 g) 7.97 7.25 6.85 6.31 5.92 357 614 330 952 323 120 307 370 290 645 69.2 54.6 M01AB15 ketorolac (30 mg) 0.03 0.03 0.03 0.04 0.04 20 18 25 48 35 0.0 0.0 M01AB55 diclofenac, combinations (0.1 g) 0.91 0.83 0.80 0.75 0.71 21 482 19 774 19 896 18 773 17 808 4.2 3.3 M01AC Oxicams 1.56 1.36 1.19 1.07 0.73 40 897 35 293 31 649 27 443 23 545 7.9 4.4 M01AC01 piroxicam (20 mg) 1.00 0.86 0.75 0.69 0.56 32 479 28 375 25 189 21 552 19 409 6.3 3.6 M01AC06 meloxicam (15 mg) 0.55 0.50 0.44 0.38 0.17 8 740 7 051 6 577 5 991 4 349 1.7 0.8 acid derivatives 95 355 105 672 99 739 94 126 93 013 18.5 17.5 M01AE03 ketoprofen (0.15 g) 0.62 0.54 0.49 0.45 0.43 4 492 4 252 3 766 3 559 3 432 0.9 0.6 M01AE14 dexibuprofen (0.8 g) 0.00 0.00 0.00 0.00 (75 mg) 0.00 0.00 0.00 0.00 24 26 0.0 0.0 M01AE52 naproxen and esomeprazole (0.5 g) 6.50 7.93 9.17 9.96 11.04 99 701 123 511 142 741 154 154 173 107 19.3 32.5 M01AG Fenamates 0.01 0.01 0.01 0.01 0.01 417 454 494 484 616 0.1 0.1 M01AG02 tolfenamic acid (0.3 g) 0.01 0.01 0.01 0.01 0.01 417 454 494 484 616 0.1 0.1 M01AH Coxibs 4.11 4.26 4.71 4.99 5.55 97 949 96 372 104 773 112 423 19.0 21.1 M01AH01 14 296 14 942 16 566 2.9 3.1 M01AH04 parecoxib (60 mg) 0.01 0.01 0.01 0.01 <5 <5 <5 3.43 3.84 4.10 4.54 84 192 83 452 87 661 90 827 97 099 16.3 18.2 M01AX Other antiinflammatory and antirheumatic agents, non -steroids 4.03 3.85 3.69 3.38 2.99 32 466 31 596 30 244 28 000 24 546 6.3 4.6 M01AX01 nabumetone (1 g) 0.26 0.21 0.20 0.17 0.16 2 886 2 427 2 175 1 935 1 753 0.6 0.3 M01AX05 glucosamine (1.5 g) 3.77 3.64 3.50 3.21 2.83 28 918 28 405 27 221 25 322 22 116 5.6 4.2 M01C SPECIFIC ANTI - RHEUMATIC AGENTS 0.01 0.01 0.00 0.00 0.00 66 64 49 35 29 0.0 0.0 M01CB Gold preparations 0.01 0.01 0.00 0.00 0.00 61 59 42 29 22 0.0 aurothiomalate (2.4 mg) 0.00 0.00 0.00 0.00 24 (6 mg) 0.00 0.00 0.00 0.00 0.00 42 35 29 18 16 0.0 0.0 95 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 Penicillamine and similar agents 0.00 0.00 0.00 0.00 5 7 (0.5 g) 0.00 0.00 0.00 0.00 0.00 RELAXANTS 0.86 0.81 0.86 0.84 0.89 7 501 8 272 8 991 10 310 11 347 1.5 2.1 M03A MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS 0.14 0.14 0.14 0.13 0.12 M03AB Choline derivatives 0.14 0.14 0.14 0.13 0.12 M03AB01 suxamethonium (0.1 g) 0.14 0.14 0.14 0.13 0.12 M03B RELAXANTS, CENTRALLY ACTING AGENTS 0.73 0.67 0.73 0.72 0.77 5 749 5 868 5 883 6 164 6 358 1.1 1.2 M03BA Carbamic acid esters 0.06 0.05 0.05 401 387 0.1 0.1 M03BA02 carisoprodol (1.4 g) 0.06 0.05 0.05 0.04 0.04 401 (1.5 g) 0.00 0.00 0.00 0.00 0.00 21 41 44 57 91 Other centrally acting agents 0.67 0.62 0.68 0.67 0.72 5 159 5 347 5 430 5 716 5 892 1.0 1.1 M03BX01 baclofen (50 mg O) 0.65 0.61 0.66 0.66 0.71 5 075 5 269 5 357 5 637 5 819 1.0 1.1 M03BX02 tizanidine (12 mg) 0.01 0.01 0.02 0.01 0.01 107 105 103 108 105 0.0 0.0 M04 ANTIGOUT PREPARATIONS 4.42 4.50 4.95 4.87 4.96 53 499 56 374 59 343 61 965 64 438 10.4 12.1 M04A ANTIGOUT PREPARATIONS 4.42 4.50 4.95 4.87 4.96 53 499 56 374 59 343 61 965 64 438 10.4 12.1 M04AA Preparations inhibiting uric acid production 3.76 3.80 4.22 4.23 4.20 48 333 50 525 53 155 55 688 58 024 9.4 10.9 M04AA01 allopurinol (0.4 g) 3.73 3.76 4.18 4.15 4.11 48 141 50 261 52 795 55 177 57 435 9.3 10.8 M04AA03 febuxostat (80 mg) 0.02 0.03 0.05 0.08 0.09 218 300 438 648 736 0.0 0.1 M04AB Preparations increasing uric acid excretion 0.21 0.20 0.20 0.19 0.19 1 924 1 878 1 788 1 752 1 710 0.4 0.3 M04AB01 probenecid (1 g) 0.21 0.20 0.20 0.19 0.19 1 924 1 878 1 788 1 748 1 702 0.4 0.3 M04AB05 lesinurad (0.2 g) 0.00 0.00 <5 8 0.0 M04AC Preparations with no effect on uric acid metabolism 0.44 0.50 0.53 0.45 0.57 7 054 8 293 9 200 9 575 9 870 1.4 1.9 M04AC01 colchicine (1 mg) 0.44 0.50 0.53 0.45 0.57 7 054 8 293 9 200 9 575 9 870 1.4 1.9 M05 DRUGS FOR TREATMENT OF BONE DISEASES 10.20 9.78 9.52 9.43 9.43 62 023 63 305 64 868 66 175 67 014 12.0 12.6 M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION 10.20 9.78 9.52 9.43 9.43 62 023 63 305 64 868 66 175 67 014 12.0 12.6 M05BA Bisphosphonates 8.15 7.98 7.75 7.56 7.33 57 321 57 490 57 746 57 407 56 785 11.1 10.7 M05BA02 clodronic acid (1.6 g O/1.5 g 10 7 9 5 5 <5 0.0 0.0 M05BA04 alendronic acid (10 mg) 8.02 7.88 7.65 7.46 7.24 52 364 52 152 51 864 50 714 49 788 10.1 9.3 M05BA06 ibandronic acid (5 mg O/6 mg P) 0.05 0.04 0.04 0.03 0.03 659 618 597 556 488 0.1 0.1 M05BA07 risedronic acid (5 mg) 0.07 0.05 0.04 0.04 0.04 403 327 309 280 264 0.1 0.1 M05BA08 zoledronic acid (4 mg) 0.01 0.01 0.02 0.02 0.02 4 345 4 921 5 613 6 475 6 856 0.8 1.3 96 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 M05BX Other drugs affecting bone structure and mineralization 2.05 1.80 1.77 1.87 2.11 5 198 6 410 7 906 9 608 10 998 1.0 2.1 M05BX04 denosumab (0.33 mg) 2.05 1.80 1.77 1.87 2.11 5 198 6 410 7 906 9 608 10 998 1.0 2.1 97 4.11 N Nervesystemet *** Grossistbasert m\u00e5lt i befolkningen utlevert et NSAID, 11 % 4.11: Proportion of the population (prevalence, %) having dispensed various analgesics in the period 2010 -2019. Anti -inflammatory 3 N\u00f8kkeltall. Grossistbasert of the populationM01A N02A N02B Year 99 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 NERVOUS 19.72 19.82 19.28 18.77 19.05 550 559 406 563 551 560 703 562 199 106.6 105.5 N02AA 42 022 48 789 193 62 111 67 118 8.1 12.6 N02AA01 morphine (0.03 g P/0. 1 g O) 1.05 1.11 1.08 1.06 1.12 7 572 7 951 8 200 8 068 8 722 1.5 1.6 N02AA03 hydromorphone (20 mg O) 0.19 0.24 0.19 0.18 0.18 127 137 123 60 12 0.0 0.0 N02AA05 oxycodone (75 mg O) 2.05 2.20 2.40 2.42 2.49 34 405 40 730 48 755 53 411 57 732 6.7 10.8 N02AA08 dihydrocodeine (0.15 g) 0.01 0.01 0.01 0.01 0.01 35 42 37 34 39 0.0 0.0 N02AA55 oxycodone and naloxone 0.27 0.28 0.30 0.32 0.33 5 713 6 521 7 246 7 726 8 380 1.1 1.6 N02AB Phenylpiperidine derivatives 1.54 1.56 1.50 1.46 1.43 12 732 12 920 12 405 11 975 11 564 2.5 2.2 N02AB01 ketobemidone (50 mg) 0.14 0.11 0.08 0.08 0.07 4 252 4 146 3 604 3 241 2 889 0.8 0.5 N02AB02 pethidine (0.4 g) 0.03 0.03 0.02 0.02 0.02 1 180 1 112 948 976 856 0.2 0.2 N02AB03 fentanyl (1.2 mg TD/ 0.6 mg N/SL) 1.37 1.43 1.40 1.36 1.34 7 753 8 058 8 180 8 036 8 070 1.5 1.5 N02AC Diphenylpropylamine derivatives - - - - - 12 0.0 N02AC04 dextropropoxyphene 0.00 - - - 0.00 0.00 0.00 0.00 (0.2 g) 0.00 0.00 0.00 0.00 derivatives 0.70 0.73 0.78 0.77 0.77 17 814 18 354 18 403 17 999 17 972 3.5 3.4 N02AE01 buprenorphine (1.2 mg) 0.70 0.73 0.78 0.77 0.77 17 814 18 354 18 403 17 999 17 972 3.5 3.4 N02AG Opioids in combination with antispasmodics 0.05 0.04 0.05 0.05 0.05 1 766 1 719 1 688 1 546 1 511 0.3 0.3 N02AG02 ketobemidone and antispasmodics 0.05 0.04 0.05 0.05 0.05 1 765 1 719 1 688 1 546 1 511 0.3 0.3 N02AJ Opioids in combination with non -opioid analgesics 9.60 9.24 8.41 8.04 8.28 374 911 369 278 932 18 21 29 0.0 0.0 N02AJ13 tramadol and paracetamol 0.13 0.14 0.09 0.10 0.11 10 499 10 761 6 698 6 878 7 354 2.0 1.4 N02AX Other opioids 4.26 4.42 4.56 4.46 4.38 204 523 217 509 228 155 229 799 221 267 39.6 41.5 N02AX02 tramadol (0,3 g) 4.18 4.30 4.40 4.27 4.17 215 712 225 070 226 103 217 038 39.4 40.7 N02AX06 tapentadol (0 .4 g) 0.08 0.11 0.16 0.19 0.20 2 006 2 822 4 613 5 304 5 970 0.4 1.1 N02B Other analgesics 581 86.5 113.5 N02BA Salicylic acid and derivatives 0.18 0.16 0.13 0.13 0.18 1 074 1 086 1 261 1 195 1 258 0.2 0.2 N02BA01 acetylsalicylic acid 0.18 0.16 0.13 0.13 0.18 1 071 1 082 1 257 1 191 1 254 0.2 0.2 N02BB Pyrazolones 1.54 1.45 1.35 1.27 1.17 1 144 1 318 1 550 1 551 1 521 0.2 0.3 N02BB02 metamizole sodium (3 g) 0.00 0.00 0.00 0.00 0.0 N02BB51 phenazone, combinations excl. psycholeptics 1.54 1.45 1.35 1.27 1.17 1 103 1 269 1 485 1 492 1 448 0.2 0.3 100 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 Anilides 38.55 40.44 42.25 44.01 46.55 444 981 560 287 602 394 86.1 0.1 0.1 N02BG Other analgesics and antipyretics 0.03 0.32 0.04 0.04 0.06 344 326 472 541 841 0.1 0.2 N02BG10 cannabinoids 0.03 0.32 0.04 0.04 0.06 340 326 472 540 840 0.1 0.2 N02C ANTIMIGRAINE 3.98 ergotamine, combinations with psycholeptics 0.00 0.00 0.00 366 Selective serotonin (5HT1) agonists 3.60 3.70 3.87 3.91 4.02 101 029 103 715 111 321 114 869 121 160 19.6 22.7 N02CC01 sumatriptan (50 mg O/ 6 mg P/ 20 mg N) 1.64 1.58 1.70 1.72 1.79 52 591 51 695 58 093 59 989 64 377 10.2 12.1 N02CC02 naratriptan (2.5 mg) 0.06 0.07 0.07 0.09 0.09 2 109 2 242 2 485 2 847 3 171 0.4 0.6 N02CC03 zolmitriptan (2.5 mg) 0.70 0.78 0.81 0.79 0.78 16 229 20 268 19 321 19 236 19 838 3.1 3.7 N02CC04 rizatriptan (10 mg) 0.67 0.71 0.73 0.75 0.80 27 936 30 355 31 217 32 744 34 523 5.4 6.5 N02CC05 almotriptan (12.5 mg) 0.07 0.07 0.07 0.08 0.07 2 889 2 916 2 934 3 022 3 214 0.6 0.6 N02CC06 eletriptan (40 mg) 0.45 0.48 0.48 0.48 0.48 12 332 12 796 13 275 13 650 14 317 2.4 2.7 N02CC07 frovatriptan (2.5 mg) 0.00 0.00 0.00 0.00 N02CD Calcitonin gene -related peptide (CGRP) antagonists 0.02 0.16 399 1 488 0.3 N02CD01 erenumab (2.5 mg) 0.02 0.16 399 1 468 galcanezumab (4 mg) 0.00 antimigraine preparations 0.38 0.39 0.41 0.43 0.43 4 622 4 762 4 844 5 343 5 489 0.9 1.0 N02CX01 pizotifen (1.5 mg) 0.01 0.01 0.01 0.00 0.00 58 50 45 35 31 0.0 0.0 N02CX02 clonidine (0.1 mg) 0.38 0.39 0.41 0.43 0.43 4 567 4 714 4 802 5 308 5 458 0.9 1.0 N03 ANTIEPILEPTICS 16.73 16.95 17.58 17.91 18.45 122 561 127 262 131 955 136 190 142 623 23.7 26.8 N03A ANTIEPILEPTICS 16.73 16.95 17.58 17.91 18.45 122 561 127 262 131 955 136 190 142 623 23.7 26.8 N03AA Barbiturates and d erivatives 0.53 0.51 0.49 0.46 0.30 2 175 2 087 2 006 1 901 1 825 0.4 0.3 N03AA02 phenobarbital (0.1 g) 0.51 0.49 0.47 0.44 0.28 1 829 1 744 1 630 1 519 1 387 0.4 0.3 N03AA03 primidone (1.25 g) 0.02 0.02 0.02 0.02 0.02 358 355 385 391 445 0.1 0.1 N03AB Hydantoin derivatives 0.25 0.23 0.21 0.19 0.17 1 436 1 281 1 118 1 022 981 0.3 0.2 N03AB02 phenytoin (0.3 g) 0.25 0.22 0.21 0.19 0.16 1 436 1 281 1 118 1 022 981 0.3 0.2 0.02 0.02 0.02 0.03 0.03 224 266 289 294 305 0.0 0.1 N03AD01 ethosuximide (1.25 g) 0.02 0.02 0.02 0.03 0.03 224 266 289 294 305 0.0 0.1 101 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 N03AE Benzodiazepine derivatives 0.37 0.33 0.28 0.25 0.23 9 856 8 702 7 198 6 416 5 885 1.9 1.1 N03AE01 clonazepam (8 mg) 0.37 0.33 0.28 0.25 0.23 9 856 8 702 7 198 6 416 5 885 1.9 1.1 N03AF Carboxamide derivatives 1.83 1.79 1.74 1.70 1.75 15 671 15 310 14 894 14 432 14 218 3.0 2.7 N03AF01 carbamazepine (1 g) 1.24 1.17 1.11 1.03 0.99 12 723 12 256 11 495 10 461 9 734 2.5 1.8 N03AF02 oxcarbazepine (1 g) 0.49 0.50 0.50 0.50 0.55 2 635 2 703 2 968 3 387 3 732 0.5 0.7 N03AF03 rufinamide (1.4 g) 0.02 0.02 0.01 0.01 0.01 96 94 90 83 78 0.0 0.0 N03AF04 eslicarbazepine (0.8 g) 0.08 0.10 0.12 0.15 0.19 383 461 590 783 955 0.1 0.2 N03AG Fatty acid derivatives 1.80 1.79 1.79 1.79 1.79 15 211 15 249 15 197 15 072 14 939 2.9 2.8 N03AG01 valproic acid (1.5 g) 1.78 1.78 1.78 1.78 1.78 15 137 15 167 15 118 15 014 14 859 2.9 2.8 N03AG03 aminobutyric acid (1 g) 0.00 0.00 0.00 0.00 16 14 8 17 0.0 0.0 N03AG04 vigabatrin (2 g) 0.01 0.01 0.01 0.01 0.01 85 85 87 78 90 0.0 0.0 N03AG06 tiagabine (30 mg) 0.00 0.00 0.00 0.00 0.00 Other antiepileptics 11.92 12.28 13.04 13.50 14.19 91 243 109 602 117 023 17.7 22.0 N03AX03 sultiame (0.4 g) 0.02 0.02 0.03 0.03 0.03 238 277 323 343 347 0.1 0.1 N03AX09 lamotrigine (0.3 g) 4.12 4.18 4.36 4.38 4.54 28 531 29 235 30 145 30 746 31 739 5.5 N03AX10 felbamat (2.4 g) 0.00 0.00 0.00 topiramate (0.3 g) 0.30 0.30 0.31 0.31 0.32 3 954 4 174 4 617 4 814 5 751 0.8 1.1 N03AX12 gabapentin (1.8 g) 2.68 2.76 2.97 3.23 3.58 35 539 39 417 42 711 46 051 50 467 6.9 9.5 N03AX14 levetiracetam (1.5 g) 1.47 1.52 1.60 1.68 1.76 8 529 9 244 9 761 10 306 10 896 1.7 2.0 N03AX15 zonisamide (0.2 g) 0.18 0.17 0.17 0.16 0.17 638 639 623 611 604 0.1 N03AX16 pregabalin (0.3 g) 3.03 3.15 3.39 3.46 3.49 20 712 21 852 23 571 24 468 24 994 4.0 4.7 N03AX17 stiripentol (1 g) 0.01 0.01 0.01 0.01 0.01 27 30 33 34 40 0.0 0.0 N03AX18 lacosamide (0.3 g) 0.10 0.10 0.12 0.13 0.16 555 625 703 770 935 0.1 0.2 N03AX21 retigabine (0.9 g) 0.00 0.00 0 0.0 0.0 N03AX22 perampanel (0.9 g) 0.03 0.04 0.04 0.05 0.05 254 303 360 361 406 0.1 0.1 N03AX23 brivaracetam (8 mg) 0.01 0.04 0.06 0.08 89 201 289 347 0.1 N03AX24 cannabidiol - - - - drugs 4.11 4.32 23 693 4.0 4.5 N04A Anticholinergic agents 0.18 0.17 0.16 0.15 0.15 2 252 2 119 2 071 1 990 1 906 0.4 0.4 N04AA Tertiary amines 0.18 0.17 0.16 0.15 0.15 2 236 2 103 2 055 1 979 1 899 0.4 0.4 N04AA01 trihexyphenidyl (10 mg) 0.01 0.01 0.01 0.01 0.01 44 52 54 39 48 0.0 0.0 N04AA02 biperiden (10 mg) 0.17 0.16 0.15 0.14 0.14 2 189 2 049 2 000 1 939 1 852 0.4 0.4 0.00 0.00 0.00 Dopaminergic agents 3.93 3.99 4.06 4.13 4.17 18 546 19 443 20 262 21 150 21 850 3.6 4.1 N04BA Dopa and dopa derivatives 1.51 1.58 1.62 1.74 1.84 9 331 9 663 10 093 10 586 10 900 1.8 2.1 N04BA02 levodopa and decarboxylase inhibitor (0.6 g) 1.19 1.25 1.30 1.42 1.51 8 701 9 055 9 513 10 003 10 328 1.7 1.9 102 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 N04BA03 levodopa, decarboxylase inhibitor and comt inhibitor (0.45 g) 0.32 0.33 0.32 0.32 0.32 1 350 1 392 1 387 1 380 1 314 0.3 0.3 N04BB Adamantane derivatives 0.02 0.03 0.03 0.03 0.03 166 191 207 178 175 0.0 0.0 N04BB01 amantadine (0.2 g) 0.02 0.03 0.03 0.03 0.03 166 191 207 178 175 0.0 0.0 N04BC Dopamine agonists 1.24 1.19 1.18 1.16 1.13 12 154 12 849 13 281 13 773 14 142 2.4 2.7 mg) 0.65 0.61 0.59 0.56 0.53 2 930 2 957 2 923 2 914 2 800 0.6 0.5 N04BC05 pramipexole (2.5 mg) 0.48 0.47 0.49 0.49 0.50 8 906 9 577 10 013 10 581 11 126 1.7 2.1 N04BC06 cabergoline (3 mg) 0.01 0.01 0.01 0.00 88 91 80 61 0 0.0 0.0 N04BC07 apomorphine (20 mg) 0.01 0.02 0.02 0.02 0.03 30 45 62 60 66 0.0 0.0 N04BC09 rotigotine oxidase B inhibitors 1.15 1.19 1.21 1.19 1.16 4 011 4 134 4 304 4 302 4 171 0.8 0.8 N04BD01 selegiline (5 mg) 0.83 0.84 0.85 0.85 0.83 2 318 2 400 2 439 2 465 2 376 0.5 0.5 N04BD02 rasagiline (1 mg) 0.32 0.34 0.34 0.33 0.31 1 739 1 778 1 887 1 807 1 768 0.3 0.3 N04BD03 safinamide (75 mg) 0.00 0.01 0.02 0.01 0 10 101 86 68 0.0 0.0 N04BX Other dopaminergic agents 0.02 0.02 0.02 0.02 0.02 105 127 142 157 141 0.0 0.0 N04BX01 tolcapone (0.45 g) 0.00 0.00 0.00 0.00 8 6 5 0.0 0.0 N04BX02 entacapone (1 g) 0.02 0.02 0.02 0.02 0.02 98 118 134 151 136 0.0 0.0 N05 PSYCHOLEPTICS 71.91 71.08 69.58 22.0 24.7 N05AA Phenothiazines with aliphatic side -chain 0.21 0.19 0.17 0.15 0.14 17 572 16 472 15 331 13 921 10 482 3.4 2.0 N05AA01 chlorpromazine (0.3 g O,R/0.1 g P) 0.01 0.01 0.01 0.01 0.00 167 168 202 202 176 0.0 0.0 N05AA02 levomepromazine (0.3 g O/0.1 g P) 0.20 0.18 0.16 0.15 0.13 17 418 16 313 15 135 13 727 10 312 3.4 1.9 N05AB Phenothiazines with piperazine structure 0.32 0.26 0.29 0.27 0.27 10 514 9 382 9 108 8 690 8 394 2.0 1.6 N05AB02 fluphenazine (10 mg O/1 mg P) 0.00 0.00 0.00 17 14 7 N05AB03 perphenazine (30 mg O/10 mg P/7mg P (dep)) 0.26 0.26 0.24 0.23 0.22 1 707 1 659 1 577 1 507 1 454 0.3 0.3 N05AB04 Prochlorperazine (0.1 g O,R/50 mg P) 0.05 0.00 0.04 0.04 0.04 8 803 7 715 7 529 7 185 6 936 1.7 structure 0.00 0.00 0.00 30 Butyrophenone derivatives 0.23 0.23 0.22 0.20 0.18 3 878 3 998 3 835 3 628 3 750 0.8 0.7 N05AD01 haloperidol (8 mg O,P/ 3.3 mg P (depot )) 0.23 0.22 0.21 0.19 0.18 3 871 3 987 3 822 3 608 3 740 0.8 0.7 N05AD03 melperon (0.3 g) 0.00 0.00 0.00 0.00 11 18 10 0.0 0.0 N05AD08 droperidol (2.5 mg) 0.01 0.01 0.01 0.01 0.01 <5 5 - N05AE Indole derivatives 0.18 0.18 0.17 0.19 0.20 963 1 013 1 006 1 091 1 186 0.2 0.2 N05AE03 sertindole (16 mg) 0.02 0.02 0.01 0.01 0.01 110 96 79 72 65 0.0 0.0 103 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 N05AE04 ziprasidone (80 mg O/40 mg P) 0.14 0.12 0.11 0.11 0.11 677 639 586 550 560 0.1 0.1 N05AE05 lurasidone (60 mg) 0.02 0.04 0.05 0.06 0.08 189 291 347 476 576 0.0 0.1 N05AF Thioxanthene derivatives 1.07 1.01 0.95 0.87 0.83 20 893 20 308 19 329 17 745 16 803 4.0 3.2 N05AF01 flupentixol (6 mg O/4 mg P) 0.24 0.22 0.21 0.19 0.19 3 902 3 744 3 486 3 171 3 025 0.8 0.6 N05AF03 chlorprothixene (0.3 g O/50 mg P) 0.38 0.36 0.34 0.31 0.28 14 811 14 499 13 822 12 619 11 908 2.9 2.2 N05AF05 zuclopenthixol (30 mg O,P/ 15 mg P (depot)) 0.45 0.43 0.40 0.37 0.36 2 729 2 561 2 470 2 314 2 208 0.5 0.4 N05AG Diphenylbutylpiperidine derivatives 0.01 0.01 0.01 0.01 0.01 112 112 104 101 103 0.0 0.0 N05AG02 pimozide (4 mg) 0.01 0.01 0.01 0.01 0.01 111 109 101 97 100 0.0 0.0 N05AH 64 650 723 80 292 86 831 11.0 16.3 N05AH02 clozapine (0.3 g) 0.61 0.60 0.60 0.60 0.59 2 576 2 610 2 651 2 700 2 718 0.5 0.5 N05AH03 olanzapine (10 mg) 3.11 3.03 3.01 2.97 3.05 16 920 16 990 17 421 17 673 18 174 3.3 3.4 N05AH04 quetiapine (0.4 g) 2.53 2.65 2.82 2.89 3.02 39 948 47 818 55 638 63 125 69 337 7.7 13.0 N05AH05 asenapine (20 mg) 0.00 0.00 0.0 0.0 0.10 0.10 0.11 650 624 637 692 0.1 0.1 N05AN Lithium 1.23 1.21 1.18 1.17 1.19 7 580 7 570 7 628 7 639 7 797 1.5 1.5 N05AN01 lithium (24 mmol) 1.23 1.21 1.18 1.17 1.19 7 580 7 570 7 628 7 639 7 797 1.5 1.5 N05AX Other antipsychotics 1.78 1.77 1.78 1.80 1.84 14 345 14 612 14 943 14 999 15 532 2.8 2.9 N05AX08 risperidone (5 mg O/ 2.7 mg P (depot)) 0.69 0.67 0.64 0.62 0.62 8 264 8 305 8 141 8 040 8 225 1.6 1.5 N05AX12 aripiprazole (15 5 910 6 530 6 825 1.1 1.3 N05AX13 paliperidone (15 mg) 0.27 0.29 0.30 0.31 0.32 860 887 936 973 1 013 0.2 0.2 N05AX15 cariprazine (3 mg) 0.00 0 0 0 0 11 0.0 0.0 N05AX16 brexpiprazole (3 mg) 0.00 0 0 0 N05B Anxiolytics 14.91 14.01 13.10 12.41 12.03 262 535 258 789 247 153 244 452 50.8 45.9 N05BA 638 diazepam (10 5.44 5.02 5.18 109 998 105 594 106 454 21.3 20.0 mg) 5.85 5.68 5.39 5.20 4.71 135 729 137 340 136 950 135 934 131 846 26.3 24.7 N05BA06 lorazepam (2.5 mg) 0.03 0.03 0.03 0.04 0.04 70 98 142 148 164 0.0 0.0 N05BA08 bromazepam (10 N05BA09 clobazam (20 mg) 0.12 0.12 0.13 0.13 0.14 779 836 896 936 1 042 0.2 0.2 N05BA12 alprazolam (1 mg) 1.12 1.01 0.89 0.84 0.81 3 206 2 895 2 587 2 409 2 494 0.6 0.5 N05BB Diphenylmethane derivatives 1.33 1.17 1.05 1.02 0.98 34 044 31 107 29 716 29 178 29 986 6.6 5.6 N05BB01 hydroxyzine (75 g) 1.33 1.17 1.05 1.02 0.98 34 044 31 107 29 716 29 178 29 986 6.6 5.6 104 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 N05BE Azaspirodecanedione derivatives 0.20 0.18 0.17 0.16 0.16 2 273 2 248 2 119 2 053 2 138 0.4 0.4 N05BE01 buspirone (30 mg) 0.20 0.18 0.17 0.16 0.16 2 273 2 248 2 119 2 053 2 138 0.4 0.4 N05C HYPNOTICS AND SEDATIVES 45.58 45.83 45.17 44.53 46.78 424 789 431 014 899 82.2 83.9 N05CD Benzodiazepine derivatives 3.37 3.11 2.92 2.75 2.66 27 282 26 877 26 433 25 703 25 482 5.3 4.8 N05CD01 flurazepam (30 mg) 0.00 0.00 0.00 0.00 0.0 N05CD02 nitrazepam (5 mg) 2.97 2.73 2.57 2.41 2.32 21 518 20 328 19 139 17 915 17 146 4.2 3.2 N05CD03 flunitrazepam (1 mg) 0.17 0.14 0.11 0.10 0.09 961 790 645 559 516 0.2 0.1 N05CD05 triazolam (0.25 mg) 0.01 0.01 0.01 0.01 0.01 67 62 49 49 43 0.0 0.0 N05CD08 midazolam (15 mg) 0.21 0.23 0.23 0.23 0.24 5 220 6 217 7 125 7 702 8 300 1.0 1.6 N05CF Benzodiazepine related drugs 34.41 33.71 32.06 30.65 31.18 354 753 355 844 345 210 344 766 5.81 5.78 5.88 67 382 70 628 357 74 824 13.0 14.0 N05CH Melatonin receptor 032 82 748 94 753 101 659 114 056 14.7 21.4 N05CH01 melatonin (2 mg) 7.61 8.83 10.02 10.97 12.78 76 032 82 748 94 753 101 659 114 056 14.7 21.4 N05CM Other hypnotics and sedatives 0.19 0.18 0.17 0.16 0.16 2 145 2 122 1 961 1 948 1 849 0.4 0.4 N05CM02 clomethiazole (1.5 g) 0.17 0.16 0.15 0.14 0.14 1 971 1 945 1 835 1 824 1 707 0.4 0.3 N05CM05 scopolamine 0.00 0.00 - - - 61 65 41 25 19 0.0 0.0 N05CM06 propiomazine (25 mg) 0.01 0.01 0.01 0.01 0.01 108 105 77 97 121 0.0 0.0 N05CM18 dexmedetomidine (1 mg) 0.01 0.01 70.52 70.64 71.26 70.63 342 934 62.5 68 350 69 403 70 267 71 207 75 288 13.2 14.1 N06AA02 imipramine (0.1 g) 0.00 0.00 0.00 0.00 13 10 18 0.0 0.0 N06AA04 clomipramine (0.1 g) 0.23 0.21 0.19 0.17 0.17 2 342 2 216 2 122 1 953 1 835 0.5 0.3 N06AA05 opipramol (0.15 g) 0.00 0.00 0.00 0.00 0.0 N06AA06 trimipramine (0.15 g) 0.30 0.27 0.26 0.24 0.20 8 837 8 128 7 521 7 105 6 628 1.7 (75 mg) 2.70 2.72 2.73 2.68 2.93 53 891 55 869 57 811 59 416 64 298 10.4 12.1 N06AA10 nortriptyline (75 mg) 0.14 0.15 0.14 0.14 0.15 2 192 2 251 2 143 2 422 2 476 0.4 0.5 N06AA12 doxepin (0.1 g) 0.14 0.12 0.11 0.09 0.08 1 846 1 641 1 454 1 37.88 37.32 36.64 35.46 35.97 186 025 186 321 183 597 180 025 182 002 36.0 34.2 N06AB03 fluoxetine (20 mg) 2.26 2.52 2.36 2.29 2.25 12 142 12 232 12 055 11 817 12 097 2.4 2.3 N06AB04 citalopram (20 mg) 4.18 3.71 3.41 3.11 2.89 22 312 20 210 18 571 17 008 15 942 4.3 3.0 N06AB05 paroxetine (20 mg) 2.68 2.54 2.42 2.30 2.22 13 797 13 122 12 510 12 050 11 570 2.7 2.2 N06AB06 sertraline (50 mg) 7.53 7.49 7.94 8.06 8.79 30 095 32 444 34 076 35 157 38 158 5.8 7.2 N06AB08 fluvoxamine (0.1 g) 0.10 0.09 0.09 0.08 0.08 554 542 505 488 474 escitalopram (10 mg) 21.13 20.97 20.42 19.61 19.74 113 703 112 762 110 559 107 723 108 124 22.0 20.3 105 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 N06AF Monoamine oxidase inhibitors, non -selective 0.02 0.01 0.02 0.02 0.01 88 89 93 97 87 0.0 0.0 N06AF03 phenelzine (60 mg) 0.01 0.01 0.01 0.01 0.01 83 85 88 89 83 0.0 0.0 N06AF04 tranylcypromine (60 mg) 0.00 0.00 0.00 N06AG Monoamine oxidase A inhibitors 0.14 0.13 0.12 0.11 0.10 721 668 634 569 540 0.1 0.1 N06AG02 moclobemide (0.3 g) 0.14 0.13 0.12 0.11 0.10 721 668 634 569 540 antidepressants 16.49 16.67 17.08 17.26 17.90 107 779 112 616 115 819 118 415 123 086 20.9 23.1 N06AX01 oxitriptan - - - - - 203 95 90 78 58 0.0 0.0 N06AX02 tryptophan - - - - - 9 32 17 18 26 0.0 0.0 N06AX03 mianserin (60 mg) 1.80 1.52 1.44 1.29 1.34 25 419 24 219 23 176 22 033 21 432 4.9 4.0 N06AX05 trazodone (0.3 g) 0.00 0.00 0.00 (0.4 g) 0.00 0.00 0.00 0.00 26 25 mirtazapine (30 mg) 5.64 5.58 5.68 5.83 5.82 40 915 43 265 45 123 46 334 48 445 7.9 9.1 N06AX12 bupropion (0.3 g) 1.10 1.09 1.12 1.10 1.13 12 123 12 100 11 958 11 934 12 103 2.4 2.3 N06AX14 tianeptine (37.5 mg) 0.00 0.00 0.00 0.00 9 10 0.0 N06AX16 venlafaxine (0.1 g) 7.20 7.18 7.13 7.01 7.14 32 625 32 903 32 906 32 734 33 226 6.3 6.2 N06AX18 reboxetine (8 mg) 0.03 0.03 0.03 0.03 0.02 329 286 263 262 197 0.1 0.0 N06AX21 duloxetine (60 mg) 0.57 0.63 0.68 0.77 0.88 4 664 5 361 6 119 7 206 8 096 0.9 1.5 N06AX22 agomelatine (25 mg) 0.00 0.00 0.00 0.00 16 13 0.0 N06AX26 vortioxetine (10 mg) 0.14 0.64 1.00 1.24 1.56 1 381 5 041 7 126 8 703 10 809 0.3 2.0 N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS 9.25 9.90 10.83 11.42 12.68 39 627 42 365 45 899 48 609 52 711 7.7 9.9 N06BA Centrally acting sympathomimetics 9.21 9.87 10.79 11.40 12.65 39 231 41 988 45 520 48 281 52 382 7.6 9.8 N06BA01 amfetamine (15 mg) 0.12 0.12 0.14 0.13 0.13 378 315 348 327 335 0.1 0.1 N06BA02 dexamfetamine (15 mg) 0.69 0.75 0.83 0.90 0.97 2 009 2 282 2 589 2 861 3 233 0.4 0.6 N06BA04 methylphenidate (30 mg) 7.71 7.85 8.20 8.23 8.48 34 062 35 618 37 698 38 784 40 246 6.6 7.6 N06BA07 modafinil 0.06 0.06 0.07 N06BA09 0.27 0.27 0.26 0.25 0.28 3 630 3 669 3 707 3 621 3 812 0.7 0.7 N06BA12 lisdexamfetamine (30 mg) 0.36 0.80 1.29 1.82 2.70 2 115 3 908 5 884 8 217 11 933 0.4 2.2 N06BC Xanthine derivatives 0.02 0.02 0.01 0.00 0.00 321 304 300 269 263 0.1 0.1 N06BC01 caffeine (0.4 g) 0.02 0.02 0.01 0.00 0.00 321 304 300 269 263 0.1 0.1 N06BX Other psychostimulants and nootropics 0.03 0.02 0.03 0.02 0.02 93 92 98 78 85 0.0 0.0 N06BX03 piracetam (2.4 g) 0.03 0.02 0.02 0.02 0.02 72 75 81 64 71 0.0 0.0 N06BX13 idebenone (0.9 g) 0.00 0.00 0.00 0.00 0.00 17 14 14 0.0 0.0 N06D ANTI -DEMENTIA DRUGS 3.23 3.16 3.16 3.05 3.03 15 170 15 233 15 281 15 356 15 138 2.9 2.8 N06DA Anticholinesterases 2.36 2.28 2.32 2.25 2.24 12 597 12 572 12 630 12 729 12 570 2.4 2.4 N06DA02 donepezil (7.5 mg) 1.54 1.47 1.50 1.45 1.48 7 479 7 360 7 449 7 546 7 569 1.5 1.4 N06DA03 rivastigmine (9 mg) 0.78 0.78 0.79 0.77 0.74 5 239 5 344 5 380 5 404 5 214 1.0 1.0 N06DA04 galantamine (16 mg) 0.04 0.04 0.03 0.02 0.02 224 193 172 139 131 0.0 0.0 106 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 Other 0.87 0.84 0.80 0.79 3 646 3 821 3 818 3 685 3 540 0.7 0.7 N06DX01 Memantine (20 mg) 0.87 0.87 0.84 0.80 0.79 3 646 3 821 3 818 3 685 3 540 0.7 0.7 N07 OTHER NERVOUS SYSTEM DRUGS 12.15 12.47 12.91 12.88 13.10 41 860 40 271 38 745 37 137 35 785 8.1 6.7 N07A PARA - SYMPATHOMIMETICS 0.15 0.15 0.17 0.17 0.18 781 837 874 928 991 0.2 0.2 N07AA Anticholinesterases 0.13 0.14 0.15 0.15 0.16 621 692 737 770 825 0.1 0.2 N07AA02 pyridostigmine (0.18 g) 0.11 0.12 0.13 0.13 0.14 620 688 733 767 818 0.1 0.2 mg O/0. 5 mg P) 0.00 0.00 21 9 0 0.00 0.00 <5 - N07AX Other parasympathomimetics 0.02 0.01 0.02 0.02 0.02 140 139 137 158 165 0.0 0.0 N07AX01 pilocarpine (15 mg) 0.02 0.01 0.01 0.02 0.02 140 135 130 152 159 0.0 0.0 N07AX03 cevimeline (90 mg) 0.00 0.00 0.00 0.00 0 <5 7 6 6 0.0 0.0 N07B DRUGS USED IN ADDICTIVE DISORDERS 11.66 11.97 12.38 12.34 12.53 38 602 36 830 35 133 33 381 31 851 7.5 6.0 N07BA Drugs used in nicotine dependence 7.54 7.87 8.34 8.39 8.60 17 104 16 961 16 000 14 701 13 546 3.3 2.5 N07BA01 Nicotine (14 mg TD/30 mg gum) 7.05 7.40 7.90 7.99 8.23 993 1 191 1 168 1 284 1 287 0.2 0.2 N07BA03 Varenicline (2 mg) 0.49 0.47 0.45 0.40 0.37 16 175 15 833 14 902 13 506 12 329 3.1 2.3 N07BB Drugs used in alcohol dependence 0.52 0.49 0.47 0.44 0.41 13 682 12 143 11 498 11 158 10 729 2.7 2.0 N07BB01 disulfiram (200 mg) 0.39 0.39 0.37 0.34 0.31 4 225 4 247 4 146 4 003 3 788 0.8 0.7 N07BB03 acamprosate (2 g) 0.02 0.01 0.02 0.02 0.02 465 472 435 384 374 0.1 0.1 N07BB04 naltrexone (50 mg) 0.08 0.08 0.07 0.07 0.08 8 189 6 840 6 483 6 407 6 332 1.6 1.2 N07BB05 nalmefene (18 mg) 0.02 0.01 0.01 0.01 0.01 1 162 921 695 583 488 0.2 0.1 N07BC Drugs used in opioid dependence 3.61 3.60 3.56 3.50 3.52 8 117 8 010 7 933 7 791 7 829 1.6 1.5 N07BC01 buprenorphine (8 mg) 0.99 1.03 1.09 1.15 1.17 3 037 3 168 3 321 3 485 3 607 0.6 0.7 N07BC02 methadone (25 mg) 2.07 2.06 2.02 1.97 2.00 3 548 3 424 3 346 3 295 3 330 0.7 0.6 N07BC05 levomethadone (15 mg) 0.00 0.01 0.01 0.02 0.03 6 14 16 16 51 0.0 0.0 N07BC51 buprenorphine, combinations (8 mg) 0.55 0.51 0.44 0.37 0.33 2 198 2 018 1 774 1 455 1 286 0.4 0.2 N07C ANTIVERTIGO PREPARATIONS 0.00 0.00 0.00 0.34 0.35 0.36 0.38 0.39 2 153 2 210 2 300 2 388 2 424 0.4 0.5 N07XX Other nervous system drugs 0.34 0.35 0.36 0.38 0.39 2 153 2 210 2 300 2 388 2 424 0.4 0.5 N07XX02 riluzole (0.1 g) 0.04 0.05 0.05 0.05 0.05 301 336 353 359 351 0.1 0.1 107 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 N07XX04 sodium oxybate (7.5 mg) 0.01 0.02 0.02 0.02 0.02 103 116 142 141 151 0.0 0.0 N07XX05 amifampridine (40 mg) 0.00 0.00 0.00 0.00 8 13 18 0.0 0.0 N07XX06 tetrabenazine (0.1 g) 0.01 0.01 0.01 0.01 0.01 48 41 44 57 48 0.0 0.0 N07XX07 fampridine (20 mg) 0.27 0.28 0.28 0.30 0.30 1 690 1 703 1 751 1 796 1 819 0.3 0.3 N07XX08 <5 - N07XX11 0.0 N07XX59 dextromethorphan, combinations 0.00 0.00 0.00 8 9 8 insekticider og insektmidler P01 P har relativt stabil i perioden 2015 - 2019 i de \u00e5rene. Fra 2013 til salget av ivermektin tabletter er mer enn 5 fra 2018 til 2019, viser tall fra Grossistbasert HH, Soleng A. Increase of infestations, 2018. Euro Surveill. 2019;24(23):pii=190020. https://doi.org/10.2807/1560 - 7917.ES.2019.24.23.190020 109 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 P ANTIPARASITIC 0.79 89 211 87 278 86 800 87 630 87 487 17.3 16.4 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 0.24 0.23 0.22 0.21 0.22 57 467 55 655 53 658 52 535 52 598 11.1 9.9 P01AB Nitroimidazole derivatives 0.24 0.23 0.22 0.21 0.22 57 467 55 655 53 655 52 529 52 596 11.1 9.9 P01AB01 metronidazole (2 g) 0.24 0.23 0.22 0.21 0.22 57 451 55 641 53 649 52 508 0.00 0.00 0.00 0.58 0.58 0.59 594 6.3 6.6 P01BA Aminoquinolines 0.45 0.46 0.45 0.44 0.44 6 216 6 288 6 280 6 298 6 308 1.2 1.2 P01BA01 chloroquine (0.5 g) 0.00 0.00 0.00 0.00 hydroxychloroquine (0.516 g) 0.44 0.45 0.45 0.44 0.44 6 199 6 258 6 260 6 279 6 286 1.2 1.2 P01BA03 primaquine (15 mg) 0.00 0.00 0.00 0.00 10 10 15 0.0 0.0 P01BB Biguanides 0.12 0.12 0.13 0.12 0.13 23 467 23 563 25 145 27 088 27 080 4.5 5.1 P01BB51 proguanil, combinations 0.12 0.12 0.13 0.12 0.13 23 465 23 563 25 144 27 088 27 080 4.5 5.1 P01BC Methanolquinolines 0.01 0.01 0.01 0.01 0.01 2 769 2 436 2 323 2 336 2 110 0.5 0.4 P01BC01 quinine (1.5 g) 0.00 0.00 0.00 (1 g) 0.01 0.00 0.00 0.00 2 401 2 105 2 037 2 083 1 901 0.5 0.4 0,00 P02 ANTHELMINTICS 0.16 0.17 0.17 0.17 0.19 2 960 3 066 3 231 3 438 6 332 0.6 1.2 P02B ANTITREMATODALS 0.00 0.00 0.00 derivatives and related substances 0.00 0.00 0.00 0.00 66 65 56 (3 g) 0.00 0.00 0.00 0.00 56 63 83 0.0 0.0 P02C ANTINEMATODAL AGENTS 0.16 0.17 0.17 0.17 0.19 2 894 2 991 3 167 3 370 6 234 0.6 1.2 P02CA Benzimidazole derivatives 0.16 0.16 0.17 0.16 0.17 2 612 2 626 2 696 2 457 2 535 0.5 0.5 P02CA01 mebendazole (0.2 g) 0.16 0.16 0.17 0.16 0.17 2 277 2 261 2 294 2 065 2 026 0.4 0.4 P02CA03 albendazole (0.4 g) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 ivermectin (12 0.00 0.00 186 174 177 167 180 0.0 0.0 110 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 pyrvinium (0.35 g) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10 22 Salicylic acid derivatives 0.00 0.00 0.00 0.00 0.00 10 22 22 (2 g) 0.00 0.00 0.00 0.00 0.00 10 22 22 16 24 0.0 0.0 number of packages ATC 2015 2016 2017 2018 2019 P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS 486 68 693 50 164 47 209 82 741 2 779 3 211 3 561 3 681 4 977 0.5 0.9 P03A ECTOPARASITICIDES, INCL. SCABICIDES 84 486 68 693 50 164 47 209 82 741 2 779 3 211 3 561 3 681 4 977 0.5 0.9 P03AC Pyrethrines, incl. synthetic compounds 40 039 38 983 41 770 46 007 80 644 2 706 3 148 3 507 3 622 4 837 0.5 0.9 P03AC04 permethrin 40 039 38 983 41 770 46 007 80 644 2 706 3 148 3 507 3 622 4 837 0.5 0.9 P03AX Other ectoparasiticides, incl. scabicides 44 447 29 710 8 394 1 202 2 097 87 69 71 73 187 0.0 0.0 P03AX01 benzyl benzoate 33% 307 399 485 1 202 2 097 36 37 44 73 187 0.0 0.0 P03AX03 malathion 44 140 29 311 7 909 51 32 27 0 0 0.0 0.0 111 4.13 fastssatt kombinasjonspreparater, tabell 3.1 . Det er spesielt har \u00f8kt med 32 % m\u00e5lt i DDD 2015 til 2019. Reseptregistret gruppen 2015 til 2019. Grossistbasert legemiddelstatistikk viser at legemiddelstatistikk, inhalasjonspreparatene til har firedoblet seg fra 2015 til 2019. Figure 4.13 Sales of inhalation products for the treatment of obstructive lung disease (R03A and R03B) in 2015 -2019. Source: beta-2- adrenoreceptor Anticholinergics (R03AK)Adrenergics in (R03BA)Anticholinergics (R03BB)DDD/1000 inhabitants/day2015 2016 2017 2018 2019 113 Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 R RESPIRATORY SYSTEM R01 NASAL PREPARATIONS 54.44 57.03 62.20 63.12 67.56 416 518 254 80.7 97.3 R01A DECONGESTANTS 60.75 61.76 66.12 357 048 983 3 882 0.7 0.7 R01AA05 oxymetazoline (0.4 mg) 1.27 1.02 1.00 0.88 0.88 2 101 2 047 1 563 2 241 2 388 0.4 0.5 R01AA07 (0.8 mg) 30.21 32.77 36.63 37.41 39.52 1 671 1 503 0.3 0.3 R01AB Sympathomimetics, combinations excl. corticosteroids 2.07 2.05 1.99 1.83 1.90 495 480 435 382 403 0.1 0.1 R01AB06 xylometazoline (0.8 mg) 2.07 2.05 1.99 1.83 1.90 495 480 435 382 403 0.1 0.1 R01AC Antiallergic agents, excl. corticosteroids 1.03 0.96 1.08 0.98 1.11 42 319 42 169 46 164 45 902 50 805 8.2 9.5 R01AC01 cromoglicic acid (40 mg) 0.17 0.16 0.16 0.06 7 724 7 457 7 607 4 927 <5 - R01AC02 levocabastine (0.6 mg) 0.86 0.80 0.92 0.92 1.11 34 707 34 878 38 774 41 371 50 803 6.7 9.5 R01AC03 azelastine R01AD05 budesonide (0.2 mg) 2.48 2.31 2.21 2.02 2.30 26 320 25 023 25 004 20 345 18 032 5.1 3.4 R01AD08 fluticasone (0.2 mg) 1.82 1.83 1.81 1.65 1.63 21 422 21 199 21 209 20 341 21 776 4.2 4.1 R01AD09 mometasone (0.2 mg) 9.39 9.31 9.62 10.11 10.73 160 156 161 114 171 090 176 300 190 474 31.0 35.8 R01AD11 triamcinolone (0.22 mg) 0.37 0.31 0.30 0.28 0.28 6 357 6 023 5 719 5 523 5 608 1.2 1.1 R01AD12 fluticasone furoate (0.11 mg) 3.48 3.45 3.64 3.55 3.79 88 454 87 374 92 014 91 495 98 912 17.1 18.6 R01AD58 fluticasone, combinations 1.09 1.77 2.45 3.02 3.94 31 102 42 588 55 895 67 751 90 619 6.0 17.0 R01AX Other nasal preparations 0.02 0.02 0.02 0.02 0.03 1 332 1 482 1 923 2 047 2 123 0.3 0.4 R01AX03 ipratropium bromide (0.24 mg) 0.02 0.02 0.02 0.02 0.03 600 585 791 910 1 024 0.1 0.2 R01AX06 mupirocin - - - - - 732 899 1 134 1 137 1 099 0.1 0.2 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 1.23 1.22 1.44 1.36 1.44 92 556 97 245 105 358 106 138 112 359 17.9 21.1 R01BA Sympathomimetics 1.23 1.22 1.44 1.36 1.44 92 556 97 245 105 358 106 138 112 359 17.9 21.1 R01BA01 phenylpropanolamine (0.1 g) 1.23 1.22 1.44 1.36 1.44 92 554 97 241 105 358 106 138 112 359 17.9 21.1 R02 THROAT PREPARATIONS 0.77 1.18 1.07 1.14 1.16 601 860 959 718 859 0.1 0.2 R02A THROAT PREPARATIONS 0.77 1.18 1.07 1.14 1.16 601 860 959 718 859 0.1 0.2 R02AA Antiseptics 0.00 0.28 0.24 0.17 0.05 113 242 174 104 0.0 R02AA03 dichlorobenzyl alcohol (6 tab) 0.28 0.24 0.17 0.05 113 242 174 104 0.0 R02AX Other throat preparations 0.77 0.90 0.83 R02AX01 flurbiprofen (44 mg) 0.05 0.09 0.15 0.17 14 90 105 166 0.0 R02AX03 benzydamine (9 mg) 0.77 0.85 0.74 0.82 0.94 601 735 639 456 603 0.1 0.1 114 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 65.63 66.33 67.59 67.21 68.63 437 223 448 102 410 441 414 624 429 661 73.5 80.6 R03AA Alpha - and beta - adrenoreceptor agonists 0.01 0.01 0.01 0.01 0.01 122 68 52 55 32 0.0 0.0 R03AA01 Epinephrine (20 mg inhal.sol) 0.01 0.01 0.01 0.01 0.01 122 68 52 55 32 0.0 0.0 R03AC Selective beta -2- 322 384 54.9 60.5 R03AC02 salbutamol (0.8 12.38 12.32 12.88 239 798 255 957 288 784 46.4 54.2 R03AC03 terbutaline (2 mg aerosol/powder/ 20 mg solution) 1.55 1.47 1.35 1.24 1.32 28 386 27 455 25 686 23 882 22 509 5.5 4.2 R03AC04 fenoterol mg solution) 0.00 0.00 0.00 0.00 0.00 16 11 11 mg aerosol/powder 0.93 0.87 0.85 0.82 0.79 8 427 8 185 8 238 8 111 7 881 1.6 1.5 R03AC13 formoterol (24 mcg aerosol/powder) 1.05 162 11 282 10 731 9 958 9 400 2.4 1.8 R03AC18 indacaterol (0.15 mg) 1.25 1.02 0.86 0.74 0.63 7 525 6 114 5 163 4 402 3 775 1.5 0.7 R03AC19 olodaterol 0.09 0.10 0.11 0.11 0.12 817 927 1 029 1 070 1 114 0.2 0.2 R03AK Adrenergics in combination with corticosteroids 21.53 187 960 192 252 199 256 36.4 37.4 R03AK06 salmeterol and fluticasone 10.56 9.68 8.90 8.29 7.56 88 214 83 967 78 843 73 827 70 729 17.1 13.3 R03AK07 formoterol and budesonide 8.46 8.06 7.66 7.45 7.19 82 839 80 791 78 736 75 825 73 355 16.0 13.8 R03AK08 formoterol and beclometasone 0.74 1.20 1.61 1.90 2.19 8 761 13 249 17 061 20 625 23 854 1.7 4.5 R03AK10 vilanterol and fluticasone furoate 1.41 2.29 3.08 3.56 3.97 12 816 20 372 26 166 30 321 34 015 2.5 6.4 R03AK11 formoterol and 4 045 482 4 765 5 039 0.7 1.0 R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids 1.32 2.22 2.92 3.91 5.21 10 887 17 031 22 168 28 395 35 286 2.1 6.6 R03AL03 vilanterol and umeclidinium bromide 0.26 0.55 0.81 1.02 1.20 2 442 4 546 6 634 8 310 9 174 0.5 1.7 R03AL04 indacaterol and glycopyrronium bromide 0.96 1.06 1.04 1.00 0.89 7 447 7 618 7 435 6 766 5 956 1.4 1.1 R03AL05 formoterol and aclidinium bromide 0.07 0.29 and tiotropium bromide 0.03 0.32 0.70 0.98 1.27 440 3 086 5 969 7 631 9 040 0.1 1.7 R03AL07 formoterol and glycopyrronium and glycopyrronium bromide and beclometasone 0.02 0.39 0.85 337 3 221 6 270 1.2 115 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS 20.63 20.04 19.93 159 163 400 30.9 30.7 R03BA Glucocorticoids 7.30 7.48 7.97 7.66 7.74 97 203 99 473 103 028 102 566 103 183 18.8 19.4 R03BA01 beclometasone (0.8 mg) 0.15 0.14 0.14 0.13 0.14 3 692 3 652 3 817 3 889 3 860 0.7 0.7 R03BA02 budesonide (0.8 mg) 1.64 1.53 1.43 1.31 1.24 17 790 17 063 16 579 15 784 15 185 3.4 2.9 R03BA05 fluticasone (0.6 mg) 2.72 2.62 2.64 2.58 2.52 63 633 64 979 67 460 67 034 67 778 12.3 12.7 R03BA07 mometasone (0.4 mg) 0.06 0.05 0.04 0.04 0.04 431 392 348 348 331 0.1 0.1 R03BA08 ciclesonide (0.16 mg) 2.73 3.15 3.72 3.60 3.81 13 598 15 260 16 702 17 330 17 635 2.6 3.3 R03BB Anticholinergics 13.32 13.01 12.99 12.38 12.19 68 644 69 233 69 975 69 276 67 424 13.3 12.7 R03BB01 ipratropium bromide (0.12 mg powder/ aerosol/ 0.3 mg solution) 6.60 6.47 6.52 6.22 6.15 29 167 30 118 30 696 31 013 31 498 5.7 5.9 R03BB04 tiotropium bromide (10 mcg) 6.04 5.70 5.46 059 38 667 37 851 36 257 34 299 7.8 6.4 R03BB05 aclidinium bromide (0.644 mg) 0.37 0.36 0.37 0.33 0.28 2 976 3 048 2 929 2 575 2 210 0.6 0.4 R03BB06 glycopyrronium bromide (44 mcg) 0.31 0.27 0.25 0.22 0.19 2 251 1 905 1 705 1 506 1 283 0.4 0.2 mcg) 0.01 0.21 0.39 0.46 0.41 214 1 854 3 072 3 589 3 228 0.0 0.6 R03BC Antiallergic agents, excl. corticosteroids 0.01 0.01 0.00 0.00 210 10 28 35 0.1 0.0 R03BC01 cromoglicic acid (40 mg aerosol/ 80 mg powder/solution) 0.01 0.01 0.00 0.00 326 210 10 28 35 0.1 0.0 R03C ADRENERGICS FOR SYSTEMIC USE 0.23 0.19 0.16 0.11 0.08 20 578 13 869 4 772 3 573 2 585 4.0 0.5 R03CA Alpha - and beta - adrenoreceptor agonists 0.13 0.11 0.10 0.08 0.07 7 538 4 389 3 636 2 745 2 232 1.5 0.4 R03CA02 ephedrine (50 mg) 0.13 0.11 0.10 0.08 0.07 7 538 4 389 3 636 2 745 2 232 1.5 0.4 R03CC Selective beta -2- adrenoreceptor agonists 0.10 0.08 0.06 0.03 0.01 13 283 9 634 1 161 845 360 2.6 0.1 R03CC02 salbutamol (12 mg) 0.01 0.01 0.00 0.00 0.00 2 3 741 483 377 286 0.5 0.1 R03CC03 terbutaline (15 mg) 0.07 0.05 0.04 0.02 0.00 10 517 6 105 536 342 73 2.0 0.0 R03CC12 bambuterol (20 mg) 0.02 0.01 0.01 0.01 172 145 150 145 0 0.0 0.0 R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 5.58 5.48 5.41 5.46 5.56 39 982 39 686 39 924 39 922 40 875 7.7 7.7 R03DA Xanthines 0.60 0.47 0.43 0.37 0.32 2 677 2 316 2 017 1 873 1 611 0.5 0.3 R03DA04 theophylline (0.4 g) 0.60 0.47 0.43 0.37 0.32 2 667 2 305 2 006 1 864 1 604 0.5 0.3 R03DA05 aminophylline (0.6 g) 0.00 0.00 0.00 0.00 0.00 13 15 16 12 12 0.0 0.0 116 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 R03DC Leukotriene receptor antagonists 4.74 4.75 4.66 4.73 4.80 36 610 36 321 36 373 36 185 36 955 7.1 6.9 R03DC01 zafirlukast (40 mg) 0.00 0.00 0.00 0.00 15 13 0.0 R03DC03 montelukast (10 mg) 4.74 4.75 4.65 4.72 4.80 36 593 36 306 36 357 36 171 36 942 7.1 6.9 R03DX Other systemic drugs for obstructive airway diseases 0.24 0.26 0.32 0.37 0.43 1 764 2 147 2 691 3 066 3 636 0.3 0.7 R03DX05 omalizumab (16 mg) 0.08 0.12 0.15 0.17 0.21 752 1 122 1 519 1 812 2 214 0.2 0.4 R03DX07 roflumilast (0.5 mg) 0.15 0.14 0.15 0.15 0.14 1 012 977 997 981 946 0.2 0.2 R03DX08 reslizumab (7.1 mg) 0.00 0.01 0.00 <5 17 12 0.0 R03DX09 mepolizumab (3.6 mg) 0.01 0.02 0.04 0.06 61 197 247 443 0.1 R03DX10 benralizumab (0.54 mg) 0.00 0.01 34 78 0.0 R05 AND COLD PREPARATIONS 10.76 10.95 10.47 10.53 10.45 387 311 390 932 115 381 487 75.0 71.6 R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS 7.73 7.93 7.70 7.69 7.61 106 877 103 679 101 730 98 295 96 031 20.7 18.0 R05CA Expectorants 1.55 1.48 1.43 1.27 1.19 5 302 6 010 5 064 4 035 4 005 1.0 0.8 R05CA10 combinations 1.55 1.48 1.43 1.27 1.19 5 302 6 007 5 064 4 035 4 005 1.0 0.8 R05CB Mucolytics 6.18 6.45 6.27 6.42 6.42 102 335 98 519 97 444 95 089 92 861 19.8 17.4 R05CB01 acetylcysteine (0.5 g 98 794 94 871 303 90 768 88 822 19.1 16.7 R05CB02 bromhexine (24 mg) 1.59 1.60 1.51 1.47 1.45 4 157 4 300 4 689 4 926 4 487 0.8 0.8 R05CB13 dornase alfa (desoxyribonuclease) (2.5 mg) 0.02 0.02 0.02 0.02 0.02 155 156 165 182 191 0.0 0.0 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 2.53 2.50 2.25 2.31 2.31 271 828 275 066 273 933 271 068 268 764 52.6 50.4 R05DA Opium alkaloids and derivatives 2.53 2.50 2.25 2.31 2.31 271 828 275 066 273 933 271 764 52.6 50.4 R05DA01 ethylmorphine (50 mg) 1.39 1.38 1.34 1.29 1.26 262 841 266 227 265 341 262 514 g) 0.08 0.09 0.08 0.08 0.08 7 208 7 015 6 6 858 7 181 1.4 1.4 R05DA07 noscapine (0.125 g) 1.03 1.01 0.81 0.92 0.95 1 818 2 177 2 270 2 102 2 463 0.4 0.5 R05DA20 combinations 0.02 0.02 0.02 0.02 0.01 2 746 2 532 2 369 2 265 2 048 0.5 0.4 R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 0.50 0.52 0.52 0.53 0.53 51 620 55 023 55 933 56 945 57 425 10.0 10.8 R05FA Opium derivatives and expectorants 0.50 0.52 0.52 0.53 0.53 51 620 55 023 55 933 56 945 57 425 10.0 10.8 R05FA02 opium derivatives and expectorants 0.50 0.52 0.52 0.53 0.53 51 620 55 023 55 933 56 945 57 425 10.0 10.8 R06 ANTIHISTAMINES FOR SYSTEMIC 0.00 0.04 0.15 0.19 0.23 50 2 581 8 784 9 372 10 235 0.0 1.9 R06AA02 (2 mg) 0.00 0.00 0.00 0.00 13 27 19 0.0 0.0 R06AA09 doxylamine (25 mg) 0.03 0.15 0.19 0.23 0 2 535 8 741 9 303 10 186 0.0 1.9 117 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 R06AA52 diphenhydramine, combinations - - - - - 29 17 20 14 0.0 R06AB Substituted alkylamines 0.36 0.19 0.16 0.16 0.14 11 594 5 868 5 347 4 573 4 299 2.2 0.8 R06AB02 dexchlorpheniramine (6 mg) 0.36 0.19 0.16 0.16 0.14 11 594 5 868 5 347 4 573 4 299 2.2 0.8 R06AD Phenothiazine derivatives 4.39 4.32 4.16 4.09 4.15 71 388 72 539 72 702 74 509 78 985 13.8 14.8 R06AD01 alimemazine (30 mg) 3.07 3.07 2.98 2.96 3.04 65 271 66 312 66 923 68 852 73 109 12.6 13.7 R06AD02 promethazine (25 mg) 1.32 1.26 1.18 1.13 1.12 6 681 6 799 6 324 6 186 6 438 1.3 1.2 R06AD03 thiethylperazine (13 mg) 0.00 0.00 - - - 6 <5 0 0 35.30 35.64 37.43 285 596 288 008 298 541 55.3 56.0 R06AE03 cyclizine (0.1 g) 0.16 0.16 0.17 0.03 0.01 947 1 076 1 098 475 93 0.2 0.0 R06AE05 meclozine (50 mg) 0.77 0.65 0.76 0.86 0.86 3 202 3 378 3 838 4 355 5 046 0.6 1.0 R06AE07 cetirizine (10 mg) 33.50 34.00 34.29 34.68 36.49 281 318 281 412 286 302 283 122 293 295 54.5 55.1 R06AE09 levocetirizine (5 mg) 0.08 0.07 0.08 0.07 0.07 597 600 612 602 609 0.1 0.1 R06AX Other antihistamines for systemic use 29.30 30.75 33.84 35.88 41.21 285 917 311 25 20 14 R06AX13 loratadine (10 mg) 6.75 6.05 5.97 5.77 5.88 57 895 55 508 54 389 52 598 53 363 11.2 10.0 R06AX17 ketotifen (2 mg) 0.00 0.00 0.00 11 11 10 R06AX22 ebastine (10 mg) 1.78 1.82 1.97 1.97 2.19 11 024 11 836 12 808 13 182 14 694 2.1 2.8 R06AX26 fexofenadine (12 mg) 4.87 5.14 5.56 5.80 6.59 36 385 39 227 42 308 44 851 50 127 7.0 9.4 R06AX27 desloratadine (5 mg) 15.90 17.72 20.33 22.34 26.55 188 292 212 900 243 334 267 221 311 465 36.5 58.5 R06AX28 rupatadine (10 mg) 0.00 10 12 23 25 33 0.0 0.0 R07 OTHER RESPIRATORY SYSTEM PRODUCTS 0.00 0.00 0.01 0.01 0.01 18 39 49 57 65 0.0 0.0 R07A OTHER RESPIRATORY SYSTEM PRODUCTS 0.00 0.00 0.01 0.01 0.01 18 39 49 57 65 0.0 0.0 R07AX Other respiratory system products 0.00 0.00 0.01 0.01 0.01 10 26 41 45 49 0.0 0.0 R07AX02 ivacaftor (0.3 g) 0.00 0.00 0.00 0.00 15 ivacaftor and lumacaftor (4 tab) 0.00 0.00 0.00 0.01 og er rundt 61 000 i 2015 til rundt 97 i Med inkludert i hovedtabellen. Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 SENSORY ORGANS S01 659 110.3 121.0 S01A ANTIINFECTIVES - - - - - 246 270 240 135 243 441 238 050 243 137 47.7 45.6 S01AA Antibiotics - - - - - 243 185 236 834 239 977 234 627 239 489 47.1 45.0 S01AA01 chloramphenicol - - - - - 190 250 187 623 193 942 193 278 200 108 36.8 37.6 S01AA11 gentamicin - - - - - 37 31 17 24 22 0.0 0.0 S01AA12 tobramycin - - - - - 1 431 1 413 1 293 1 260 1 076 0.3 0.2 S01AA13 fusidic acid - - - - - 55 781 51 375 48 485 41 986 38 966 10.8 7.3 S01AA26 azithromycin - - - - - 6 268 5 796 5 330 4 876 4 564 1.2 0.9 S01AA30 combinations of different antibiotics - - - - - 5 758 6 263 6 446 8 651 9 932 1.1 1.9 S01AD Antivirals - - - - - 2 915 3 300 3 375 3 300 3 191 0.6 0.6 S01AD03 aciclovir - - - - - 2 915 3 300 3 374 3 299 3 188 0.6 0.6 S01AE Fluoroquinolones - - - - - 2 844 2 926 3 082 3 016 3 346 0.6 0.6 S01AE03 ciprofloxacin - - - - - 2 844 2 926 3 082 3 016 3 346 0.6 0.6 S01AX Other antiinfectives - - - - - 7 <5 5 7 13 0.0 0.0 S01AX18 povidone -iodine - - - - <5 10 - 0.0 S01B ANTIINFLAMMATORY AGENTS - - - - - 59 749 62 824 67 149 70 182 77 071 11.6 14.5 S01BA Corticosteroids, plain - - - - - 37 698 42 473 48 920 53 707 61 287 7.3 11.5 S01BA01 dexamethasone - - - - - 23 155 29 392 36 013 37 430 41 254 4.5 7.7 S01BA02 hydrocortisone - - - - - 0 0 60 4 618 7 419 0.0 1.4 S01BA04 prednisolone - - - - - 15 448 16 479 17 943 18 288 20 193 3.0 3.8 S01BA07 fluorometholone - - - - - 9 25 17 16 16 0.0 0.0 S01BA09 clobetasone - - - - - 12 12 14 13 13 0.0 0.0 S01BA13 rimexolone - - - - - 4 322 2 440 83 0.8 S01BC Antiinflammatory agents, non -steroids - - - - - 26 341 27 895 28 399 29 077 30 564 5.1 5.7 S01BC03 diclofenac - - - - - 7 512 7 688 7 732 7 782 9 009 1.5 1.7 S01BC10 nepafenac - - - - - 12 825 15 204 17 423 17 752 18 092 2.5 3.4 S01BC11 bromfenac - - - - - 6 465 5 400 3 545 4 061 3 938 1.3 0.7 S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION - - - - - 55 148 49 893 43 762 43 173 40 541 10.7 7.6 S01CA Corticosteroids and antiinfectives in combination - - - - - 55 148 49 893 43 762 43 173 40 541 10.7 7.6 S01CA01 dexamethasone and antiinfectives - - - - - 55 148 49 893 43 762 43 173 40 541 10.7 7.6 682 74 978 099 76 868 78 507 14.3 14.7 S01EA Sympathomimetics in glaucoma therapy 0.77 0.71 0.70 0.65 0.67 5 386 4 901 4 787 4 647 4 752 1.0 0.9 S01EA03 apraclonidine 0.01 0.01 0.01 0.01 0.01 238 169 205 178 224 0.1 0.0 S01EA05 brimonidine 0.76 633 4 492 4 571 1.0 0.9 120 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 S01EB Parasympathomimetics 0.05 0.04 0.04 0.04 0.04 907 917 910 841 858 0.2 0.2 S01EB01 pilocarpine (0.4 ml) 0.05 0.04 0.04 0.04 0.04 907 917 910 841 858 0.2 0.2 S01EC Carbonic anhydrase 1.68 1.84 1.90 2.02 2.13 11 520 12 539 13 374 13 984 14 820 2.2 2.8 S01EC01 acetazolamide (0.75 g) 0.10 0.09 0.11 0.11 0.13 1 623 1 687 2 065 2 107 2 253 0.3 0.4 S01EC02 diclofenamide (0.1 g) 0.00 0.00 7 ml) 0.34 0.38 0.43 0.46 0.52 2 567 2 840 3 152 3 443 3 777 0.5 0.7 S01EC04 brinzolamide (0.2 ml) 1.17 1.17 1.08 1.14 1.06 7 478 7 486 7 290 7 108 7 205 1.5 1.4 S01EC54 brinzolamide, combinations 0.07 0.20 0.28 0.31 0.43 614 1 554 2 062 2 594 2 936 0.1 0.6 S01ED Beta blocking agents 10.67 10.48 10.21 10.40 10.19 50 544 51 182 51 703 52 160 53 151 9.8 10.0 S01ED01 timolol 5.33 5.09 4.94 4.79 4.40 21 519 21 391 21 098 20 510 20 267 4.2 3.8 S01ED02 betaxolol 0.17 0.14 0.12 0.11 0.10 960 834 5.15 5.50 5.68 30 224 31 281 32 044 33 251 34 694 5.9 6.5 S01EE Prostaglandin analogues 6.41 6.34 6.17 6.27 6.26 38 603 38 866 38 665 38 696 39 101 7.5 7.3 S01EE01 latanoprost 3.98 3.95 3.88 3.86 3.90 24 167 24 533 24 257 24 309 24 369 4.7 4.6 S01EE03 bimatoprost 0.43 0.43 0.41 0.41 0.43 2 584 2 380 2 444 2 425 2 604 0.5 0.5 S01EE04 travoprost 0.90 0.81 0.65 0.69 0.56 5 844 5 206 4 520 4 026 3 633 1.1 0.7 S01EE05 tafluprost 1.10 1.16 1.24 1.31 1.36 7 156 7 675 8 197 8 698 9 384 1.4 1.8 S01F MYDRIATICS AND CYCLOPLEGICS - - - - - 5 208 5 556 4 995 4 918 5 061 1.0 1.0 S01FA Anticholinergics - - - - - 5 201 5 540 4 976 4 910 5 048 1.0 1.0 S01FA01 atropine - - - - - 1 851 1 553 1 336 1 120 1 075 0.4 0.2 S01FA04 cyclopentolate - - - - - 3 373 4 059 3 749 3 907 4 006 0.7 0.8 S01FA06 tropicamide - - - - - 162 128 86 93 156 0.0 0.0 S01FA54 cyclopentolate, combinations - - - - - <5 - - S01FB Sympathomimetics excl. antiglaucoma preparations - - - - - 39 46 51 30 37 0.0 0.0 S01FB01 phenylephrine - - - - - 39 46 51 30 37 0.0 0.0 S01G DECONGESTANTS AND ANTIALLERGICS - - - - - 184 820 185 939 201 407 202 110 236 257 35.8 44.3 S01GA Sympathomimetics used as decongestants - - - - - 20 455 19 535 20 161 19 732 23 417 4.0 4.4 S01GA01 naphazoline - - - - - 5 12 11 21 0.0 S01GA52 tetryzoline, combinations - - - - - 20 455 19 530 20 152 19 723 23 400 4.0 4.4 S01GX Other antiallergics - - - - - 167 905 169 762 185 118 186 023 218 054 32.5 40.9 S01GX01 cromoglicic acid - - - - - 23 575 23 034 23 718 22 328 25 368 4.6 4.8 S01GX02 levocabastine - - - - - 86 161 87 921 97 537 98 785 114 471 16.7 21.5 S01GX06 emedastine - - - - - 380 398 413 430 497 0.1 0.1 S01GX07 azelastine - - - - - 118 0 0 0 0 0.0 0.0 S01GX08 ketotifen - - - - - 20 747 21 391 23 557 24 107 30 054 4.0 5.6 S01GX09 olopatadine - - - - - 41 899 41 694 45 550 45 755 55 332 8,1 10,4 121 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 S01H LOCAL ANESTHETICS - - - - - 133 122 111 123 135 0.0 0.0 S01HA Local anesthetics - - - - - 133 122 111 123 135 0.0 0.0 S01HA02 oxybuprocaine - - - - - 93 97 85 100 99 0.0 0.0 S01HA03 tetracaine - - - - - 19 12 13 16 20 0.0 0.0 S01HA04 proxymetacaine - - - - - 23 14 13 10 17 0.0 0.0 S01J DIAGNOSTIC AGENTS - - - - - 27 27 32 31 36 0.0 0.0 S01JA Colouring agents - - - - - 27 27 32 31 36 0.0 0.0 S01JA01 fluorescein - - - - - 25 26 31 30 33 0.0 0.0 S01X OTHER OPHTHALMOLOGICALS - - - - - 61 072 69 033 79 807 88 992 98 296 11.8 18.5 S01XA Other ophthalmologicals - - - - - 61 072 69 033 79 807 88 992 98 296 11.8 18.5 S01XA03 sodium chloride, hypertonic - - - - - 24 34 39 63 105 0.0 0.0 S01XA18 ciclosporin - - - - - 784 1 823 2 697 3 881 4 252 0.2 0.8 S01XA20 artificial tears and other indifferent preparations - - - - - 60 852 68 604 79 216 87 932 97 241 11.8 18.3 S01XA21 mercaptamine - - - - - <5 6 10 10 - 0.0 S01XA25 lifitegrast - - - - - 6 26 0.0 S02 OTOLOGICALS - - - - - 24 528 22 510 20 226 22 924 28 871 4.8 5.4 S02A ANTIINFECTIVES - - - - - 6 437 5 536 5 224 4 986 4 676 1.3 0.9 S02AA Antiinfectives - - - - - 6 437 5 536 5 224 4 986 4 676 1.3 0.9 S02AA01 chloramphenicol - - - - - 13 11 0.0 S02AA03 boric acid - - - - - <5 8 20 5 <5 - - S02AA15 ciprofloxacin - - - - - 6 423 5 520 5 204 4 982 4 672 1.2 0.9 S02B CORTICOSTEROIDS - - - - - 12 168 7 855 1 355 1 429 6 083 2.4 1.1 S02BA Corticosteroids - - - - - 12 168 7 855 1 355 1 429 6 083 2.4 1.1 S02BA07 betamethasone - - - - - 12 168 7 855 1 355 1 429 4 440 2.4 0.8 S02BA08 fluocinolone acetonide - - - - - 1 703 0.3 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION - - - - - 7 030 10 163 14 369 17 171 19 308 1.4 3.6 S02CA Corticosteroids and antiinfectives in combination - - - - - 7 030 10 163 14 369 17 171 19 308 1.4 3.6 S02CA02 flumetasone and antiinfectives - - - - - 74 62 59 <5 42 0.0 0.0 S02CA05 fluocinolone acetonide and antiinfectives - - - - - 6 964 10 104 14 314 17 169 19 270 1.4 3.6 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS - - - - - 72 113 74 436 74 488 73 692 73 385 14.0 13.8 S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION - - - - - 72 113 74 436 74 488 73 692 73 385 14.0 13.8 S03CA Corticosteroids and antiinfectives in combination - - - - - 72 113 74 436 74 488 73 692 73 385 14.0 13.8 S03CA01 dexamethasone and antiinfectives - - - - - 10 738 10 956 10 854 9 588 8 414 2.1 1.6 S03CA04 hydrocortisone and antiinfectives - - - - - 63 009 65 134 65 319 65 568 66 243 12.2 12.4 122 4.15 V Varia V01 som under andre DDD bare data Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2019 Numbers of packages/year ATC 2015 2016 2017 2018 2019 V VARIOUS V01 ALLERGENS 11 619 12 876 14 582 16 203 18 981 2.3 3.6 V01A ALLERGENS 31 318 33 987 38 110 44 034 52 573 11 619 12 876 14 582 16 203 18 981 2.3 3.6 V01AA Allergen extracts 31 318 33 987 38 110 44 034 52 573 11 619 12 876 14 582 16 203 18 981 2.3 3.6 V01AA02 grass pollen 18 664 21 435 24 275 27 020 30 772 8 644 9 845 11 002 12 021 13 800 1.7 2.6 V01AA03 house dust mites 1 109 935 2 052 3 776 5 914 556 514 933 1 544 2 180 0.1 0.4 V01AA05 tree pollen (bj\u00f8rk) 9 499 9 665 10 232 11 260 13 039 5 535 5 791 6 259 6 585 7 227 1.1 1.4 V01AA07 insects 557 511 510 552 623 165 149 144 136 144 0.0 0.0 V01AA10 flowers 157 82 36 151 96 43 <5 10 32 0.0 0.0 V01AA11 animals 1 332 1 359 1 041 1 390 2 074 570 555 513 581 712 0.1 0.1 DDD/1000 inhabitants/day ATC 2015 2016 2017 2018 2019 V03 ALL THERAPEUTIC PRODUCTS 0.28 0.29 0.30 0.33 0.40 3 293 3 528 3 866 4 205 4 719 0.6 0.9 V03A ALL OTHER THERAPEUTIC PRODUCTS 0.28 0.29 0.30 0.33 0.40 3 293 3 528 3 866 4 205 4 719 0.6 0.9 V03AB Antidotes - - - - - 100 120 82 122 87 0.0 0.0 V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia 0.22 0.24 0.25 0.27 0.33 2 699 2 813 2 965 3 072 3 466 0.5 0.7 V03AE01 polystyrene sulfonate (45 g) 0.02 0.03 0.03 0.03 0.02 846 881 951 876 683 0.2 0.1 V03AE02 sevelamer (6.4 g 0.14 0.14 0.14 0.15 0.16 1 790 1 862 1 987 2 014 2 126 0.4 0.4 V03AE03 lanthanum carbonate (2.25 g) 0.06 0.07 0.07 0.07 0.07 603 644 562 590 592 0.1 0.1 V03AE04 calcium acetate and magnesium carbonate (6 tab) 0.01 0.00 0.00 0.00 0.00 12 V03AE05 sucroferric oxyhydroxide (1.5 g) 0.00 0.01 0.01 0.01 63 122 115 119 0.0 V03AE09 patiromer calcium (8.4 g) 0.02 0.07 <5 257 747 V03AE10 sodium zirconium <5 for antineoplastic treatment 0.05 0.06 0.06 0.06 0.07 57 61 61 38 35 0.0 0.0 V03AF01 mesna <5 9 10 12 8 - 0.0 V03AF03 calcium folinate (60 mg) 0.05 0.06 0.06 0.06 0.07 55 52 51 26 27 (14 mg) 0.00 for treatment of - - - - 280 371 579 736 865 0.1 0.2 V03AH Drugs for treatment of hypoglycemia - - - - - 28 24 28 28 32 0.0 0.0 V03AH01 diazoxide - - - - - 28 24 28 28 32 0.0 0.0 V03AX Other therapeutic products - - - - - 15 6 16 63 68 0.0 0.0 124 5 Historikk og nisjegrossister, med 2003 dagligvaregrossister. Fra er innsamling m\u00e5ned. Reseptregisteret i 2004 og er et pseudonymisert helseregister, det vil si fungerer som en s\u00e5ka lt tiltrodd tredjepart av tilgjengelig og siden \u00a7 legemidler (hjemlet Refusjonskodene utgangspunkt International Classification of Diseases 10 (ICD -10) eller International Classification of Primary Care 2 ATC/DDD -systemet anbefalt av WHO 1982 opprettet WHO et koordineringssenter ved Norsk medisinaldepot ( WHO Collaborating Centre for Drug Methodology ) med tilknytning til WHOs Europakontor med medlemmer fra 12 ulike land. Bakgrunnen for opprettelse av DDD er at statistikk i (kroner) for ATC classification and DDD assignment (https://www.whocc.no/filearchive/publications/2020_guidelines_web.pdf ) for mer informasjon. 127 Folk emengde i Norge 2015 -2019 (per 1. januar) Year 2015 2016 2018 2018 2019 Population 5 189 984 5 236 624 5 276 847 5 311 797 5328212 Men Women 2019 2 685 073 2 643 139 Kilde: Statistisk sentralbyr\u00e5 Martinsen JI, Ursin G, Weiderpass E, Thoresen GH, et al. Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry - based study. BMJ Open 2019;9(4):e028504. Amato E, Dansie HH, Soleng A. Increase of scabies infestations, Euro Surveill. 2019 Jun;24(23). Reichborn -Kjennerud T, Skurtveit S. Incidence of diagnosed pediatric anxiety disorders and use of prescription drugs: a nation -wide registry study. Eur Child Adolesc Psychiatry 2019;22:22. Baftiu A, Lima MH, Svendsen K, Larsson PG, Johannessen SI, Landmark CJ. Safety aspects of antiepileptic drugs -a population -based study of adverse effects relative to changes in utilisation. Eur J Clin Pharmacol 2019;75(8):1153 -60. Benko MC, C, Fungie G, Bordas R, Blix HS. Cross -national comparison of paediatric antibiotic use in Norway, Portugal Juzeniene A, et al. Cardio vascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case - control study. BMJ Open 2019;9(2):e025246. Bergene EH, Nordeng H, Ro TB, Steinsbekk A. Register - based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016. Acta Paediatr 2019;108(4):699 S. Tramadol use in Norway: A register d population study. Pharmacoepidemiol Drug Saf 2019;28(1):54 -61. Bramness JG, von Soest T. A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults. BMC Pulmonary Medicine 2019;19(1):52. Cesta CE, Cohen JM, K, Yu Y, Zoega H, Odsbu I. Antidiabetic medication use during pregnancy: an international utilization study. BMJ Open Diabetes Research and Care. 2019 Nov 1;7(1). https://drc.bmj.com/content/7/1/e000759 Diaz E, Omland G, Hannestad Y, Ruths S. Use of hormonal contraceptives among immigrant women and their daughters in Norway: Data from the K, Blix HS. Drug Use before and after Initiating Treatment with Acetylcholinesterase Inhibitors. Dementia and Geriatric Cognitive Disor ders Extra 2019;9(1):196 -206. Ekman J, Skjeldestad FE. Do Norwegian providers comply with national recommendations when prescribing combined oral contraceptives to starters? A cohort study. BMJ Open 2019;9(11):e027888. Evandt J, Skurtveit S, Oftedal B, K rog NH, Nafstad P, Skovlund E, et al. Agreement between self -reported and registry -based use of sleep medications and tranquilizers. Pharmacoepidemiol Drug Saf 2019;28(10):1336 -43. Evensen JU, Bull H, Martinsen EW, Ueland T, et al. Exploring the potential cost -effectiveness of a vocational rehabilitation program for individuals with schizophrenia in a high -income welfare society. BMC Psychiatry 2019;19:140 Fog AF, Straand J, Engedal K, Blix HS. Drug use differs by care level. A cross -sectional comparison between older people living at home or in a nursing home in Oslo, Norway. BMC Geriatrics 2019;19(1):49. Frank AS, Lupattelli A, Brandlistuen RE, Nordeng H. Maternal Thyroid Hormone Replacement Therapy Exposure and Language and Communication Skills of Offspring at 8 Years of Age. JAMA netw 2019;2(10):e1912424. Frank AS, Lupattelli A, Matteson DS, Meltzer HM, Nordeng H. Thyroid hormone replacement therapy pat terns in pregnant women and perinatal outcomes in the offspring. Pharmacoepidemiol Drug Saf 2020;29(1):111 -21. Fredheim OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer su rvivors in Norway 10 years after diagnosis. Pain 2019;160(4):852 -9. Hagen KB, Aas T, Kval\u00f8y JT, S\u00f8iland R. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5 -year prospective study. Breast 2019;44:52 -8. Handal , L, R, Engeland A, et al. Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and 129 Norway. Pharmacology Research & Perspectives 2019;7( 5). Heggelund L, Singh R, Aballi S, Rosseland CM, Mikkelsen Y, Damas JK. Retrospective analysis of co -medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012 -2018 using the Norwegian po pulation -based prescription database. HIV Med 2019;20:45. Helland Haugst\u00f8yl ME, Kval\u00f8y JT, K, et al. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Pr escription Database. Breast Cancer Res Treat J, Vries F Furu K. Adjusting using validation -stage cali bration survival and dichotomous outcomes. Statistics in Medicine. 2019 https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.81 31 Hovland R, Bremer S, Frigaard C, Henjum S, Faksv\u00e5g PK, Saether EM, et al. Effect of a pharmacist -led intervention on adhere nce among patients with a first -time prescription for a cardiovascular medicine: a randomized controlled trial in Norwegian pharmacies. Int J Pharm Pract 2019;29:29. Hylin H, Thrane H, Pedersen K, Kristiansen IS, Burger EA. The healthcare costs of treatin g human papillomavirus - related cancers in Norway. BMC Cancer. 2019 May 7;19(1):426. H\u00f8jlund M, -J\u00f8rgensen Correll CU. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. Br J Clin Pharmacol. BO. Validity of the FINDRISC as a prediction tool for diabetes in a contemporary Norwegian population: a 10 -year follow -up of the HUNT study. BMJ Open Diabetes Res Care. 2019 I, Thurston M, Hagquist C. Leisure -time physical activity among adolescents and subsequent use of antidepressant and hypnotic drugs: a prospective register linkage study. Eur Child Adolesc Psychiatry 2019;28(2):177 -88. Kravdal \u00d8, Grundy E. Children's age at parental divorce and depression in early and mid -adulthood. Population Studies 2019;73(1):37 al. Nonaspirin Nonsteroidal Antiinflammatory Drug Use in the Nordic Countries from a Cardiovascular Risk Perspective, 2000 -2016: A Drug Utilization Study. Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy 2019;39(2):150 -60. Langaas HC, Hurley E, Dyrkorn R, Spigset O. Effectiveness of an academic detailing intervention in primary care on the prescribing of non -steroidal anti -inflammatory drugs. Eur J Clin Opdal M, Johannessen SI, Johannessen Landmark C. Therapeutic drug gabapentin in various indications. Acta Neurologica Scandinavica 2019;139(5):446 -54. Lund IO, Skurtveit S, Handal M, e t al. Association of Constellations of Parental Risk With Children's Subsequent Anxiety and Depression: Findings From a HUNT Survey and Health Nafstad P, Magnus P, et al. Maternal history of miscarriages and measures of fertility in relation to childhood asthma. Thorax W, et al. Airway symptoms and atopy i n young children prescribed asthma medications: A large -scale cohort study. Pediatric Pulmonology 2019;54(10):1557 - Muller AE, I, Skurtveit S. Prescribed opioid analgesic use developments in three Nordic countries, 2006 -2017. Scand J Pain 2019;19(2):345 -53. Pedersen AB, Andersen IT, Overgaard S, Fenstad AM, Lie SA, Gjertsen JE, et al. Optima l duration of anticoagulant thromboprophylaxis in total hip arthroplasty: new evidence in 55,540 patients with osteoarthritis from the Nordic Arthroplasty Register Group. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union /European Economic Area, 2001 to 2018. Euro Surveill. 2019 Nov;24(46). doi: 10.2807/1560 -7917.ES.2019.24.46.1900656. Raknes G, in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: A nation -wide register -based controlled before -after study. Sci 2019;9(1):15085. Raknes G, Sm\u00e5brekke L. Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register -based controlled quasi -experimental before -after stu dy. SL, Hauge LJ, Kalseth J. Use of prescription medication prior to suicide in Norway. BMC Health Serv Res 2019;19(1):215. Rognli EB, Bramness Cannabis use in early adulthood is prospectiv ely associated with prescriptions of 130 Oct 2019 Sander Andersen A -M, Murray JA, Karlstad \u00d8 , Husby S, St\u00f8rdal K. Association Between Antibiotics in the First Year of Life and Celiac Disease. Gastroenterology. 2019 Schou MB, al. Systematic assessment of prescribed medications and short -term risk of myocardial infarction - a pharmacopeia -wide association study from Norway and Sweden. Sci Rep 2019;9(1): 8257 Solberg BS, Zenyats J, Klungs\u00f8yr K. Psychiatric comorbidity and genetic correlations provide new insights into differences between attention -deficit/hyperactivity disorder and autism spectrum disorder. Biol ogical Psychiatry 2019; 587 Brants\u00e6ter AB, Vestrheim DF. Indirect Effects of Pneumococcal Childhood Vaccination in Individuals Treated With Immunosuppressive Drugs in Ambulatory Care: A Case - cohort Study. Infect Kjennerud T, Stoltenberg C, et al. Tourette syndrome in children in Norway. Tidsskrift for Den Norske Legeforening Krokstad S, Helvik AS. Factors associated with alcohol consumption and prescribed drugs with addiction potential among older women and men - the Nord -Tr\u00f8ndelag health study (HUNT2 and HUNT3), Norway, a population longitudinal study. BMC riatrics Tevik A, Krokstad S, Helvik AS. Mortality in older adults with frequent alcohol consumption and use of drugs with addiction potential - The Nord Trondelag Health Study 2006 -2008 (HUNT3), LL, Dyb K. eHeal th initiatives; the relationship between project work and institutional practice. BMC Health Serv Res in antidep ressant use among children and adolescents: A Scandinavian drug utilization study. Acta Psychiatrica Scandinavica. 141. 10.1111/acps.13116. Wie B\u00f8rsheim NE. Epilepsy and autoimmune diseases: Comorbidity in a national patient cohort. Seizure 2019;75:89 -95. W\u00e6rholm AC, Meland E, Kjome RLS. Can subjective well - being and body concern in adolescence predict prescribed medication in adulthood? Findings from the Nord - Trondelag Health Study and the Norwegian Prescription Database. Scand J Public Health 2019: Aug 13 [Epub ahead of print] 2018 Andersson J, Hofsli M, Gade UL, Heegaard S, Pottegard A. Use of topical ocular antibiotics in young children: a Scandinavian drug Ophthalmol (Oxf) 2018;96(8):789 -94. Antonazzo IC, Be rge LI, Engeland A, Fasmer OB, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia 2018;38(11):1759 -64. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisation and polypharmacy aspect s of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS -active drugs in Norway, 2004 -2015. Epilepsy Res 2018;139:35 - 42. Bateman BT, Heide -J\u00f8rgensen U, Einarsdottir K, A, Reutfors J, Selmer R, Zoega H. Beta -blocker use in pregnancy and the risk of congenital malformations: An international cohort study. Ann Intern Med 2018; 169: 665 -73. Ben ko R, Matuz M, Silva Ferreira J, Machado MC, Furtado C, Fungie G, Bordas R, Blix HS. Cross -national comparison of paediatric antibiotic use in Norway, Portugal and Clin Pharmacol 2018 H, Ro TB, Steinsbekk A. Register - based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016. Acta Paediatr 2018;22:22. Req uests for new oral antibiotic prescriptions in children within 2 days: a Norwegian population -based study. Fam Pract 2018;35(6):690 -7. Charlton RA, Bettoli V, Bos HJ, Engeland A, Garne E, Gini R, Hansen AV, de Jong -van den Berg LTW, Jordan S, Klungs\u00f8yr K, Neville AJ, Pierini A, Puccini A, Sinclair M, Thayer D, Dolk H.The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures. Eur J Pharmacol 2018; 74:513 -20 Cohen J M, Wood ME, Hernandez -Diaz S, Nordeng H. Agreement between paternal self -reported medication use and records from a national prescription database. Pharmacoepidemiol Drug Saf 2018;27(4):413 -21. Cortese M, Riise T, Engeland A, Ascherio A, Bjornevik K. Urat e and the risk of Parkinson's disease men women. Parkinsonism Relat Disord 2018;52:76 -82. Dalen DM, Locatelli M, Strom An Equilibrium Model Estimated on Pharmaceutical Data. Atl Econ J 2018;46(3):281 -96. Danielsson KC, Borthen I, Morken NH, Gil hus NE. 131 Hypertensive pregnancy complications in women with epilepsy and antiepileptic drugs: a population -based cohort study of first pregnancies in Norway. BMJ Open 2018;8(4):e020998. Diaz E, Omland G, Hannestad Y, Ruths S. Use of hormonal contraceptives among immigrant women and their daughters in Norway: Data from the Norwegian Prescription Database. Acta Obstetricia et Gynecologica Scandinavica 2018. Egeland AC, Eide GE, Daltveit AK, Klungsoyr K, et al. Pregnancy -Related Risk Fa ctors Are Associated With a Significant Burden of Treated Hypertension Within 10 Years of Delivery: Findings From a Population -Based Norwegian Cohort. J Am Heart Assoc 2018;7(10):13. Engeland A, Bjorge S, Furu K. Tren ds in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Drug Lindbaek M. Prescribing antibiotics when the stakes are higher - do GPs prescribe less when patients are pregnant? A retrospective observational study. BJGP open 2018;2(2):bjgpopen18X101505. Fossum GH, Lindbaek M, Gjelstad S, Kvaerner KJ. Relationship between Maternal and First Year of Life Dispensations of Antibiotics and Antiasthmatics. Antibiotics (Basel) 2018;7(3):17. Frank AS, Lupattelli A, Matteson DS, Nordeng H. Maternal use of thyroid hormone replacement therapy before, during, and after pregnancy: agreement between self - report and prescription records and group -based trajectory mo deling of prescription patterns. Clin OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagnosis. Pa in 2018;07:07. Gulati al. intracranial hemorrhage (RICH) in users of oral antithrombotic Engeland A. Associations between attention -deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population -based cross -sectional study. Eur Child Adolesc Vederhus JK, Bramness JG. Use of drugs for alcohol use disorder in Norway 2004 -16. Tidsskrift for Den Norske Laegeforening 2018;138(18):13. Hoff M, Skurtveit S, Meyer HE, Langhammer AJ, Syversen U, et al. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT between Methylphenidate and Amphetamine use in Pregnancy and Risk of Congenital Malformations: A cohort study from the International Pregnancy Safety Lindberg M, et al. Association of Bariatric Surgery vs Medical Obesity Treatment With Long -term Medical Complications and Obesity prescription rates of anxiolytics and hypnotics to survivors of cancer in childhood, adolescence, and young adulthood -A population -based study. Pediatr Blood Cancer 2018;65(2). Kasciuskeviciute S, Gumbrevicius G, Vendzelyte A, Sciupokas A, P etrikonis K, Kadusevicius E. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti -Inflammatory Drug Use in Lithuania: I, Furu K, Skovlund E. Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation. Eur C. Leisure -time physical activity among adolescents and subsequent use of antidepressant and hypnotic drugs: a prospective register linkage study. Eur Child Adolesc al . Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II -IV. J Neurooncol Prospective Cohort Study of Breastfeeding and the Risk of Childhood SJ, Wilcox AJ, Nystad W, H\u00e5berg SE. Maternal history of miscarriages and measures of fertility in relation to childhood asthma. Thorax. 2019;74(2):106 - Nystad W. Association of Mate rnal Psychosocial Stress With Increased Risk of Asthma Development in Offspring. Am J Epidemiol.2018;187(6):1199 -209. Mauseth SA, Skurtveit S, Langhammer A, Spigset O. Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence. Int J Skovlund E, Medication use and association with urinary incontinence in women: Data from the Norwegian Prescription Data base and the HUNT study. Neurourol Urodyn 2018;37(4):1448 E, Bolin K, Stavem K, Ersb\u00f8ll AK. Finasteride treatment and male breast cancer: a register - based cohort study in four Nord ic countries. Cancer children 2004 -2015 [Forskrivning av legemidler mot astma Lagerlov P. Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway. JAMA netw 2018;1(7):e184145. Nakken O, Ass essing 132 amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotroph Lateral Scler IO, Gabrhelik R, Engelan d A, Handal M. Neonatal Outcomes after Fetal Exposure to Methadone and Buprenorphine: National Registry Studies from the Czech Republic and Norway. Addiction 2018. Nesvag R, Bramness JG, Handal M, Hartz I, Hjellvik S. The incidence, psychiatri c co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents. Eur Psychiatry 2018;49:16 -22. Parr CL, -Blix NA, Haugen M, et al. Vitamin A and D intake in pregnancy, infant supplem entation, and asthma development: the Norwegian Mother and Child Am J Clin 2018;107(5):789 M, Stephansson O. Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death. JAM A 2018. Raknes G, Simonsen P, Smabrekke L. The Effect of Low - Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before -and-After Prescription Database Study. J Crohns Colitis 2018;12(6):677 -86. Raman T,Bushnell Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Potteg\u00e5rd A, Pratt NL, Roughead EE, Saint -Gerons DM, St\u00fcrm er T, Su CC, Zoega H, Sturkenbroom M, Chan EW, Coghill D, Ip P, Wong I. Regional and national trends in attention -deficit/hyperactivity disorder (ADHD) medication use: a multinational study in North America, Europe, Asia and Australia. Lancet Psychiatry 20 18; 5(10):824 -835. Reset A, Skurtveit S, Furu K, Skovlund E. Effect of the market withdrawal of dextropropoxyphene on use of other prescribed analgesics. Scand J Pain 2018;18(4):667 -74. Roksvaag I, Skjeldestad FE. Decreasing trends in number of depot med roxyprogesterone acetate starters in Norway - Gulseth HL, et al. Pandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort study. Halvorsen S. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. Open Heart 2018;5(2):e000931. Skurtveit I, Nesvag R, Hauge LJ, et al. Increase in diagnosis of depressive disorders contributes to the increase in antidepressant use in adolescents. Acta Psychiatr Scand 2018;137(5):413 M. Psoriasis and cardiovascular disease risk factors: the HUNT Norway. Eur J, Klungs\u00f8yr K. Gender differences in Psychiatric Comorbidity in Adults with Attention Deficit/Hyperactivity av Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? E for Den Norske Laegeforening -5. E, Breidablik HJ. Is self -rated health in adolescence a predictor of prescribed medication in adulthood? Findings from the Nord Trondelag Health Study and the Norwegian Prescription Database. SSM Popul Health 2018;4:144 -52. Walle -Hansen MM, Hoye S. Geographic Variation in Antibiotic Consumption -Is It Due to Doctors' Prescribing or Schmidt M, Karlstad \u00d8, Potteg\u00e5rd A. Trends in Use of Paracetamol i Nordic Countries. Basic Clin Pharmacol AT, et al. Stratification by interferon -gamma release assay predicts TB. Engeland A, Bernt Fasmer O, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia 2017:333102417748573. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisa - tion and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS - active drugs in Norway, 2004 -2015. Epilepsy Res 2017;139:35 - 42. Bakken IJ, Furu K, Gr\u00f6neng GM, Stoltenberg C, \u00d6verland S, et al. General practice consultations and use of prescription drugs after changes to school absence policy. Tidsskr Nor Laegeforen 2017;137(16):1178 -84. Beisland C, Johannesen TB, Klepp O, et al. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population - based study. OncoTargets Does progestin -only contraceptive use after pregnancy affect recovery from pelvic girdle pain? A prospective population study. PLoS One 2017;12(9):14. 133 Blandhol M, Tysland T, Blix HS, Hoye S. Antibiotic s witch during treatment with antibiotics against respiratory tract infections in ambulatory care in Norway. Infect Dis (Lond) 2017;49(11 -12):854 -8. Brakedal Dolle C, Assmus J, et al. Glitazone Use Associated With Reduce d Risk of Parkinson's Disease. Mov Disord 2017;32(11):1594 -9. But A, De Bruin Bazelier V, Andersen M, Auvinen A, Starup - Linde J, MK, Vries F, Karlstad \u00d8, Ekstr\u00f8m, N, Haukka J. Cancer Risk among insulin users: comparing analogues with human insulin in the CARING five Users Acetylcholinesterase rs. Geriatr S, Daltveit AK, Vikse BE, Haugen M. Low Calcium Intake in Midpregnancy Is Associated with Hypertension Develop - ment within 10 Years after Pregnancy: The Norwegian Mother and Child Cohort Study. Journal of Nutrition 2017;147(9):1757 -63. Engeland A, Bjorge T, Klungsoyr K, Skurtveit S, Furu K. Preterm births and use of medication in early adulthood: a population -based registry study. Pharma - coepidemiology and Drug Safety 201 7;26(7):742 P, Schwarze PE, et al. Road traffic noise and registry based use of sleep medication. Environ Health 2017;16:12. Ezat B, Pihlstrom L, Aasly J, Tysnes OB, Egge A, Dietrichs E. Use of advance d therapies for Parkinson's disease in Norway. Tidsskr Nor Laegeforen 2017;137(9):619 -23. Fadnes LT, Diaz E. Primary healthcare usage and use of medications among immigrant children according to age of arrival to Norway: a population -based study. BMJ of analgesics during complete disease trajectories in patients who are diagnosed with and die from cancer within the five -year period 2005 -2009. European Journal of Pain 2017;21(3):530 -40. Fredheim OMS, Skurtveit S, Borchgrevink PC. Provision of analgesics to children before and after the new recommendations of Stimulants and Atomoxetine for Attention -Deficit/Hyperac - tivity Disorder among 5.4 million Children Using Population -based Longitu - dinal Data agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004 -2015. Eur J Clin Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy, and the risk of adverse neonatal outcomes and congenital malformations -A population base d European study. BMJ 2017. Mar 1;356:j629. http://www.bmj.com/content/356/bmj.j629.long Grinde B, Engdahl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Intern Med 2017;177(12):1774 -80. Halvorsen S, Ghanima W, Tvete IF, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J -Cardiovasc Pharmacother 2017;3(1):28 -36. Hoff M, Meyer HE, Skurtveit Sogaard AJ, Syversen U, et al. Validation of FRAX and the impact of self - reported falls among elderly in a general population: the HUNT study, Norway. Osteoporos Int easy access to contraception and Kjennerud T, Ystrom E, et al. Hypnotics use in children 0 - 18 months: moderate agreement between mother - reported survey data and prescription r egistry data. J 2017;10:28. Johannsdottir Skurtveit S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adoles - cence, and Young Adulthood: A Population -Based Study. TM, Jenum PA. Fecal carriage of extended spectrum beta - lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection - A three year c ohort study. PLoS One and Treatment in Relation to Children's Birth Month: Nationwide Study from Norway. Scand J 2017 Jun;45:343 -9. JH. Employees' drug purchases before and after organizational downsizing: a natural experiment on the Norwegian working population (2004 -2012). Scand J Work Environ Health 2017;43(4):307 -15. 134 Kjerpeseth Ellekj\u00e6r H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, use of antidepres - sant me dication in late mid -life: a register - based analysis of Norwegian women and men. Aging Ment Health. 2017 May;21(5):477 -486. doi: 10.1080/13607863.2015.1118010. Epub -Danielsson K, Heikinheimo O, Hognert H, Milsom I, et al. Contraceptive use O. Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2017;04:04. Milenkovic M, Haavik S. Recording of pharmaceutical interventions of potential clinical i mportance in Norwegian pharmacies. Norsk Farmaceutisk Hoff M, Forsmo S, et al. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway. Br J Dermatol Naldi L, Saunes M. The association between the clinical diversity of psoriasis and depres - sive symptoms: the HUNT Study, Dermatol 2017;31(12):2062 - 8. M\u00e5rild K, Bl ix HS, St\u00f6rdal K. Use of antibiotics in children during the period 2005 - 16. Tidsskr Nor Laegeforen 2017;137(18):1414 -9. Holmoy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compu lsory nationwide health registers. Amyotrophic Lateral sclerosis & Frontotemporal Degeneration 2017:1 -8. Odsbu I, Selmer R, Lundborg CS, Blix HS. Increased prescribing of systemic tetracyclines and PM, et al. Maternal Folate Intake during Pregnancy and Childhood Asthma in a Population -based Cohort. Am J Respir Crit Care Med Antibiotic - prescribing habits among Norwegian dentists: a survey over 25 years (1990 - 2015). Eur J Oral Sci 2017;125(4):280 -7. Raknes G, Smabrekke L. Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi -experimental study. PLoS One 2017;12(11):13. naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database. Pharmacoepidemiology and Drug Safety 2017;26(6):68 5- 93. Raknes G, Smabrekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteris - tics, and dispense patterns. A drug utilization cohort study. Pharmacoepide - miology and Drug Safety 2017;26(2):136 - 42. Rebnord, Strand, E., Midttun, \u00d8. et al. The kynurenine: tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease. Diabetologia 2017; Omland AK, Robsahm TE, et al. Cancer Risk in Women Treated with Fertility Drugs According to Parity Status -A Registry -based Cohort Study. Cancer Epidemiology Biomarkers & Prevention 2017;26(6):953 - 62. Sakshaug S, Handal M, Hjellvi k V, Berg C, Ripel A, Gustavsen I, et al. Long - term Use of Z -Hypnotics and Co - medication with Benzodiazepines and Opioids. Basic JA, Bramness JG. Assessing prescription drug abus e using functional principal component analysis (FPCA) of waste - water data. Pharmacoepidemiology and Drug Safety 2017;26(3):320 - 6. Samuelsen PJ, Nielsen CS, Wilsgaard T, Stubhaug A, Svendsen K, Eggen AE. Pain sensitivity and analgesic Tromso E, Jason LA, Kirkevold M. From good health to illness with post - infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory. BMC family practice 2 017;18(1):49. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non -refu - gees from War -Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. Journal of Immigrant and Minority Health 2017;19(3):582 -9. Svendsen K, Halvorsen KH, Vorren S, Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Eur J Clin Pharmacol 2017;18:18. Svendsen T, Brodtkorb A, Burns ML, Johann essen SI, Landmark CJ. Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate -A national approach to the evalu - ation of therapeutic drug 135 monitoring data and clinical outcome. Epilepsy Research 2017;129:125 -31. Svendsen T, Brodtkorb E, Reimers al. Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate -A national approach to the evaluation of therapeutic drug moni - toring data and clinical outcome. in Users of Acetylcholinesterase Inhibitors. Dement Geriatr Cogn Dis K, Seim A, Krokstad S, Helvik AS. Use of alcohol and drugs with addiction potential among older women and men in a population -based study. The Nord -Trondelag Health Study 2006 benzodiazepine and Z-hypnotic users and disability pension: an eight -year nationwide observational follow -up study. Scand J Prim Health Care 2017;35(3):240 -6. Urbaniak AM, Strom BO, Krontveit R, Svanqvist KH. Prescription Patterns of Non -Vitamin K Oral Anticoagulants Across Indications and Fact ors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012 -2015: A Study from the Norwegian Prescription Database. Drugs Aging 2017;34(8):635 -45. Vie TL, Hufthammer KO, Holmen TL, Meland HJ. Is self -rated health in ad olescence a predictor of prescribed medication in adulthood? Findings from the Nord Tr\u00f8ndelag Health Study and the Norwegian Prescrip HS, Tong A, Trifir\u00f2 G, Ziv -Baran T, Kim SK. Anti - biotic Use in Children - A Cross -National Analysis of 6 Countries. J Pediatr L. Psychosocial factors are strongly associated with insomnia in users and nonusers of prescribed sleep medication: Evidence from the HUN T3 study. J Multidisci - SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non -epilepsy disorders - a pharmacoepidemiological study and clinical Dorum LM, et al. Aspirin as secondary prevention in patients with colorectal cancer: An unselected population - based study. Ruths S. Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway. J Am Geriatr Soc AH, al. Prescription trajectories and effect of total hip arthroplasty on the use of analgesics, hypnotics, antidepressants, and anxiolytics: Results from a popu - total hip arthroplasty patients. N, et al. Opioids for outpatients with cancer in their last year of life: A nation - wide pharmacoepidemiological study. Journal of Opioid Management 2016;12(1):25 -36. Charlton RA, Klungs\u00f8yr K, Neville AJ, Jordan S, Pierini A, de Jong -van den Berg LTW, et al. Prescribing of Antidiabetic Medicines before, during and after Pregnancy: A Study in Seven European Regions. PLoS One Pierini Klungs\u00f8yr K, Neville AJ, Jordan S, de Jong -van den Berg LT, et al. Asthma medication prescribing before, during and after pregnancy: a study in seven European regions. BMJ Open 2016 Jan 19;6(1):e009237. leiner HF, Bjoro T, Midthjell K, Grill V, Asvold BO. Prevalence of thyroid dysfunction in autoimmune and type 2 diabetes : The population -based hunt study in Norway. J Clin Endocrinol S, Lund IO, Handal M. A Unique Opportunity to Study Short and Long Term Consequences in Children Prenatally Exposed to I llicit Drugs and Opioid Maintenance Treat - ment Using Czech and Scandinavian Registers. Cent Eur J Public Health 2016;24(3):248 -51. Garne E, Vinkel Hansen A, Morris J, Jordan S, Klungs\u00f8yr K, Engeland A, et al. Risk of congenital anomalies after exposure to asthma medica - tion in the first trimester of pregnancy - a cohort linkage study. BJOG Revilla -Lopez C, Diaz E. Patterns of pharmaceutical use for immigrants to Spain and Norway : a comparative study of prescription databases in two European countries. International Journal for Equity in Health 2016;15. Halvorsen S, Jortveit J, Hasvold P, Thuresson M, \u00d8ie E. Initiation of and long -term adherence to secondary preventive drugs after acute myocardial Nesv\u00e5g R, Handal M. Antidepressant drug use among adolescents during 2004 - 2013: a population -based M. Psychotropic drug use among 0 -17 year olds during 2004 - 2014: a nationwide prescription database study. BMC of Antidepressants to Survivors of Cancer in Childhood, Adoles - cence, and Young Adulthood: A Population -Based Study. J Adolesc Young Adult Oncol 2016;14:14. Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS, Luteijn JM, Linked Databases in Wales, Kieler H, et al. Use of drugs for ADHD among adults -a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol 2016;72(12):1507 - 14. Kaspersen SL, Pape Bjorngaard JH. and initiat ion of psychotropic medication: a case -crossover study of Occup Environ 2016;73(11):719 AK, Green A, Emneus M, Pukkala E, Bolin K, et al. Patterns of finasteride use in the male populations of fo ur Nordic countries: A cross -national drug utilization AM, Owe JF. Does the choice of antiepileptic drug effects of parental deaths among adults in Norway: Purchases of prescription medicine before and after bereavement. SSM Population d \u00d8, et al. Pre -eclampsia and Nystad W. Prenatal and infant paracetamol exposure and development of asthma: The Norwegian Mother and Child Cohort Study. Int J Epidemiol 2016;45(2):512 - al. Maternal plasma total neopterin and kynurenine/tryptophan levels during pregnancy in relation to asthma development in the offspring. J Aller AK, Handal M, Haugen M, H\u00f8iseth G, Knudsen GP, Paltiel L, Schreuder P, Tambs K, Vold L, Stoltenberg C. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol. 2016;45(2):382 -8. Mellbye A, Borchgrevink Fredheim OMS. The duration and course of opioid therapy in patients with chronic non -malig - JW, Dalgard O . Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population -Based Study. PLoS One I, Bramness JG, Hjellvik V, Handal M, Skurtveit S. Mental disorder diagnoses among child ren and adolescents who use antipsychotic drugs. Eur Neuropsychopharmacol 2016;26:1412 -8. Olah KS, Kim TH, Lee HH, Kim JM. Re: Use of hormonal contraceptives among immigrant and native women in Norway: data from the Norwe - gian Prescription Database The co ntraceptive situation in Korea. BJOG 2016;123(5):840. Roman M, Weiderpass Sakshaug S, Hofvind S, et al. Postmenopausal hormone therapy and breast cancer prognostic char - acteristics: A linkage between nationwide registries. Ca Epidemiology Weiderpass E, Ursin G, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway. Int J Cancer 2016;138(3):584 -93. Samuelse n PJ, Svendsen K, Wilsgaard T, Stubhaug A, Nielsen CS, Eggen AE. Persistent analgesic use and the association with chronic pain and other risk factors in the population -a longitudinal study from the Tromso Study and the Norwegian Prescription Database. Eur J Clin Pharmacol 2016;72:977 -85. Selmer R, Haglund B, Furu K, Andersen M, Norgaard M, Zoega H, et al. Individual -based versus aggregate meta - analysis in multi -database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. Pharmacoepidemiol Drug Saf 2016;25(10):1160 -9. Skipenes VP, Skjeldestad FE. Prevalence of combined Line TM, Berg TJ. Cost of diabetes in Norway 2011. Diabetes Res Clin Pract 2016;122:124 -32. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non -refugees from War -Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. J Immigr Minor Health 2016;21:21. Tjagvad C, Skurtveit S, Bramness JG, Gjersing L, Gossop M, Clausen T. Misuse of prescription drugs and overdose deaths. Journal of Substance Use 2016;21(5):515 -20. Tvete IF, Bj\u00f8rner T, Skomedal T. A 5 -year follow -up study of users of benzodiazepine: Starting with diazepam versus oxazepam. Br J Gen Pract 2016;66(645):e241 -e7. \u00d8vre -Eide V, Skjeldestad FE. Norway. Acta Obstet Gynecol Scand 2016;95(11):1244 Hjellvik V, Handal M. Reduced Prescribing rescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveil - lance? Epidemiology and Infection. 2015;143(9):1884 P, Skurtveit S, Clausen T, Kun\u00f8e N. The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study. Subst Abuse. 2015;9(Suppl 2):59 Garne E, Wang H, Klungs\u00f8yr K, Jordan S, Neville A, Pierini A, Hansen A, Engeland A et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf. 2015 Nov;24 (11):1144 M, Romundstad P, Skurtveit S. Prevalence of use of non - prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription Jordan SE, Klungsoyr K, Loane M, et al. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: S, Furu K. Preeclampsia in pregnancy and later use of antihypertensive drugs. European Journal of Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5 -year survey in Norway. Scand J Prim Health Care. 2015;33(4):252 M. Serotonin -Reuptake Inhibitors and Venlafaxine in early pregnancy and risk of birth defects - a population based cohort study and sibling design. BMJ 2015. Apr 17;350:h1798. Hage Moger TA. Socio -economic inequality in the use of procedures and mortality among AMI patients: Quantifying the effects along different paths. Health in empirical evidence from Chron Obstruct Pulmon 2015;10:1695 -702. doi: PC, Dale O, Romundstad PR, Mahic M, et al. Consumption of and satisfaction with health care among opioid users with chronic Off - Label Use of Mela - tonin - A Register Linkage S tudy between the Norwegian Prescription Data - base and Patient Register. Basic Clinl Pharmacol Monitoring of Selec - tive Serotonin Reuptake Inhibitors in doi: 10.1097/FTD.0000000000000169. Hoff A, S\u00f8gaard AJ, Syversen U, et al. Use of anti -osteoporotic drugs in central Norway after a forearm fracture. Archive s of Osteoporosis. 2015;10:30. doi: 10.1007/s11657 -015-0235 -2. H\u00f8iseth G, Middelkoop H. Has Previous Abuse of Fluni - trazepam Been Replaced by Clonazepam? European Addiction Research. B, Midthjell K, Graue M, et al. Anxiety, depression and timing of insulin treatment among people with type 2 diabetes: Nine -year follow -up of the Nord -Tr\u00f8ndelag Health Study, Norway. Journal of Psychosomatic Research. 2015;79(4) :309 -15. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Vejrup K, et al. Hormonal contraceptive use before and after conception in relation to preterm birth and small for gestational age: An A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2015;28:88 -91. doi:10.1016/j.seizure.2015.02.017 Kann IC, Lundqvist C, Lur\u00e5s H. Polypharmacy Among the Elderly in a List -Patient System. Drugs - Real World Outcomes. 2015;2(3):193 -8. doi: 10.1007/s40801 -015 - 0036 -3 Kelly E, Lu CY, Albertini S, Vitry A. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. Journal of Pharmacy Gissler M, et al. Use of antide pressants and association with elective termination of pregnancy: population based case -control study. BJOG -an International Journal V. Fertili ty history and use of anti - depressant medication in late mid -life: a register - based analysis of Norwegian women and men. Aging & 138 mental health. 2015:1 -10. doi: 10.1080/13607863.2015.1118010 Lund IO, Skurtveit S, Handal M. Commentary on Raitasalo et al: th e great potential in nation -wide registers to study prescription drug use and abuse. Addiction (Abingdon, England). 2015;110(4):644 -5. DOI: 10.1111/add.12856 Lund Handal M, Nordfjaern T, Brunborg GS, Rossow I. A Cohort Study on Long -Term Adverse Effects of Parental Drinking: Background and Study Design. Subst Abuse. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. Sep;19(8):1095 Nystad W. Grandmother's smoking when pregnant with the mother and asthma in the grandchild: the Norwegian Mother and Child Cohort Study. Thorax. The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study. LB, Engeland A. Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study. BMC IF, Tanum L, Steen VM, Bramness JG. Incident Users of Antipsychotic Agents and Future Use of Cholesterol -Lowering Drugs: An Observational, Pharmacoepidemiologic Study. Journal -E6. doi: 10.4088/JCP.14m08996. Suhrke P, Zahl PH. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: A register -based cohort study. Cancer Medicine. 2015;4(8):1303 -8. doi: 10.1002/cam4.474 Tvete IF, Bj\u00f8rner T, Skomedal T. Risk factors for excessive benzodiaz - epine use in a working age population: a nationwide 5 -year survey in Norway. Scand J Primary Health Prescription patterns of inhaled corticosteroids for preschool children - A Norwegian register study. Pediatric Allergy and Immunology. U, Brandt L, et al. Use of SSRI an d SNRI Antidepressants during Pregnancy: A Population -Based Study from Denmark, Iceland, Norway and Sweden. Plos One. 2015;10(12). epide Total drug treatment and comorbidity in myasthenia gravis: a population -based cohort study. Eur J Neurol 2014;21:94 8- 955 Bakken AH, Hunskaar S, Ruths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur J Clin Pharmacol 2014;70:873 -880 Berg -Hansen P, Moen S, Harb o H, Celius E. High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler 2014;20:1780 -1782 Ferrer P, Rafaniello C, Sabate M, Ballarin E, Coma A, Zara C, et al. Cross - national comparison of antiepileptic drug use: Catalonia, Denm ark and Norway, Health. 2014;11:e9405 -1. Fredheim M, Skurtveit S, Dale O, Romundstad P, Borchgrevink PC. Chronic pain and use of opioids: a population based pharmacoepidemio - logical study from the Norwegian prescription database and the Nord -Tr\u00f8n - delag health study (HUNT). B, Heyerdahl F, Lunn D, Hawton K. Change in access to prescribed medication following an episode of deliberate self -poisoning: a of b -Blockers and Prostate Cancer -Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High -Risk or Metastatic Disease. European Urology 2 014;65:635 -641. Halvorsen T, Martinussen PE. The geography of chronic obstructive pulmonary disease: A population -based study of Norway. Soc Sci Med 2014;21:25 -34. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Moster D, et al. Maternal hormonal contraceptive use and offspring overweight or obesity. Int J Obes. 2014;38:1275 -81. Halsteinli V. Cross -country comparisons of health -care costs: The case of cancer treatment in the Nordic countries. Health Policy 2014:115 ;172 -179. 139 Kann IC, Lundqvist C, Luras H. Prescription of addictive and non -addictive drugs to home -dwelling elderly. Drugs Aging. 2014 Jun;31(6):453 Karlstad \u00d8, Furu K, Skurtveit S, Selmer R. Prescribing of Drugs for Attention - Deficit Hyperactivity Dis order in Opioid Maintenance Treatment Patients in Norway. Eur Addict Res 2014;20:59 -65. Kieler H, Malm H, Artama M, Engeland K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case -control study. BJOG. 2014 Nov Amundsen EJ, Dalgard O. HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970 - 1984. Sc and J Gastroenterol. 2014 Dec;49(12):1465 -72. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short - and Long -Term Mortality Risk Associated with the Use of Antipsy - chotics Among 26,940 Dementia Outpatients: A Population -Based Am Geriatr 2014;22:321 -331. Mahic M, Fredheim OM, Borchgrevink PC, S. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. 2014 Nov 20;[Epub ahead of print]: doi 10.1002/ Co-morbidity in persistent opioid users with chronic non -malignant pain in Norway. Eur J Pain. 2014;18:1083 -1093 Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41 -80 year old Norwegians, 2005 -2010. Eur J Pain. 2014 Mar;18(3):438 - 46. Nordfj\u00e6rn T, Bjerkeset O, Bratberg G, Moylan S, Berk M, Grawe R. Socio - demographic, lifestyle and psychological predictors of benzodiazepine and z -hypnotic use patterns. Nord J 2014;68:107 Norum J, Olsen AI, Nohr FI, Heyd A, Totth A. Medical treatment of children and youths with attention - deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study. Glob J Health Sci. 2014 Jul;6(4):155 -62. Omland G, Ruths S, Diaz E. Use of hormonal contraceptives among immi - grants and native women in Norway: data from the Norwegian Prescription Database. BJOG 2014;121:1221 benzodi azepines benzodiazepine related drugs to pregnant women: a popula - tion -based cohort study. Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0 -14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Child - hood Diabetes Registry. Diabetologia 2014;57:57 -62. Skurtveit S, Selmer R, Odsbu I, Handal M. Self -reported data on medicine use in th e Norwegian mother and child cohort study compared to data from the Norwegian prescription database. Norsk Epidemiologi. 2014;24(1 -2). Str\u00f8m H, Selmer R, Birkeland KI, Schirmer H, Berg TJ, Jenum AK, et al. No increase in new users of blood glucose - lowering drugs in Norway 2006 -2011: a nationwide prescription database study. BMC Public Health. 2014;14:520. Svendsen K, Fredheim OM, Romundstad opioid use and socio -economic PA. High rate of per oral mecillinam treatment failure in community -acquired urinary tract S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013;42:514 -20. Berge LI, Riise T, Iversen KJ, Midthjell K, et al. Does diabetes have a protective eff ect on migraine? Epidemiology 2013;24:129 -34. Bjorner T. [Dispensing of benzodiazepines and Z drugs S, et al. Antidepressants to cancer patients during the last year of life --a population - based study. Psychooncology 2013;22:506 -14. Devold HM, Sogaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti -osteoporosis drug use in Norway. Osteoporos S, Vollset SE, et al. Effects of preconceptional paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population -based databases. British Journal of Clinical Pharmacology 2013;75:1134 KJ. Are children carrying the burden of broad -spectrum antibiotics in general practice? Prescription patter n for paediatric outpatients with respiratory tract infec - tions in Norway. Open 2013;3:e002285. M, Skurtveit S. A pharmacoepi - demiological cohort study of subjects 140 starting strong opioids for nonma - lignant pain: a study from the Norwegian Prescription Database. Pain 201;154:2487 -93. Hold\u00f8 I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. Arch Dis Child 2013;98:732 -6. Hoye S, Gjelstad S, Lindbaek M. Effects on antibiotic dispensing rates of interventions to promote delayed prescribing for respiratory tract infections in primary care. Br J GenPract. 2013;63:e777 -86. Jonasson C, Tvete IF, Hatlebakk proton pump inhibitor utilization in ga stroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scand J Klovstad H, screening with infor - mation and home sa mpling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial. BMC Infectious Diseases 2013;13:30. Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities ? Social Science and Medicine 2013;81:42 - 52. Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004 - 2008. J Vet Pharmacol Ther Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221 -32. Lillefjell M, Haugan T, Martinussen P, Halvorsen T. Treatment outcomes among individuals in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the dispensing of prescribed medications. Journal of Musculoskeletal Pain 2013;21:311 - 319. Log T, Skurtveit S, Selmer R, Tverd al A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record -linkage study. Eur J Clin Pharmacol 2013;69:111 Lund S, Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant w omen in opioid Maintenance Treatment. SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. ta Obstet Gynecol Scand 2013;92:1208 -1215. Multiple prescribers in older frequent opioid safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759 Nordeng H, Lupattelli A, Rom\u00f8ren Neonatal outcomes after gestational exposure to nitrofurantoin. Obstetrics and Gynecology 2013;121:306 -13. Nordfjaern T, Bjerkeset O, Moylan S, Berk M, Grawe RW. Clusters of person - ality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. Addict Behav 2013;38:2575 -80. Nordfjaern T. Prospective associations between benzodiazepine use and later life satisfaction, somatic pain and psychological health among the elderly. Hum Psychopharmacol 2013;28:248 -57. for Fetveit A, Dalen I, Straand J. Prescription peer academic detailing to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. Br J GenPract. 62. Nilsson M, Tornhage CJ, Lokk J. National surveys: a way to manage treatment strategies in Parkinson' s disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease. J Multidiscip Healthc 2013;6:239 PC. - tive prescriptions to can cer outpatients receiving opioids: A study from the Norwegian prescription database. Supportive Care in Cancer 2013;21:67 -73. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug expo - sure: inclusion of dispensed drugs before pregnancy may l ead to underesti - mation of risk associations. J Clin Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population -based cohort study. Journal of Women's Health 2013;22 :250 -8. Stephansson O, Kieler H, Haglund B, A, Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309:48 -54. Thelle Jugessur A, Graff -Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart 2013;99:1755 -60. Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3 -year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open 2013;3:e003296. 141 Westin AA, Bramness JG, Chalabianloo F, Rygnestad T, Slordal L. [Pregabalin should be moved Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti -diabetic agents. Diabet Med 2012;29:509 19 -\u00e5ringer i mai. [Increased use of antibiotics among nineteen -year - olds in May]. Tidsskr Nor Laegeforen 2012;132:1084 -8. Blix av antihypertensive legemidle r 1975 -2010. [Patterns in the prescription of antihypertensive drugs in Norway, 1975 - 2010] Tidsskr Nor -8. Bramness JG, Furu S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with ab use potential. Clin Pharmacol Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. Addiction 2012;107:967 -72. Devold H, Furu K, Skurtveit S, Tverdal A, Falck J A, S\u00f8g\u00e5rd AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in inci - dent users in Norway. Pharmacoepidemiol Drug Saf 2012;21:297 Devold HM, S\u00f8gaard AJ, Tverdal A, Falch JA, K, Meyer HE. Hip fracture and other predi ctors of anti -osteoporosis drug use in Norway. Osteoporosis International 2012;24:1225 -33. Fasmer S. Opioid switching to methadone: A pharmacoepidemiological study from a national prescrip - tion Palliative 2012;26:804 switching to methadone: a pharmacoe pidemiological study Gedde -Dahl A, Devold Statin in patients treated with antiepileptic drugs in Norway. Pharmacoepidemiol Drug Saf 2012;21:881 -5. Gjelsvik B, Heye rdahl F, Hawton K. Prescribed medication availability and deliberate self -poisoning: a longitudinal study. J Clin Psychiatry. Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004 -2011: A nationwide prescription database study. Scandinavian Journal of Public Health 2012;40:7 04-11. Hjellvik V, Mahic M, Tverdal A. Comorbidities in an asthma population 8 -29 years old : A study from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2012;21:1045 -52. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, N\u00f8rgaard M, Nielsen RB, Stephansson B. Selec - tive seroton in-reuptake inhibitors during pregnancy and risks of persistent pulmonary hypertension of the newborn: population based cohort study from the five Nordic countries BMJ 2012;344:d8012. Kjome RL, Roraas T, Granas AG, Sandberg S. in sale s of strips Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012;68:311 Holmen J. The HUNT study: Participation is associated with survival and depends on socioeco - nomic status, diseases and symptoms. BMC Medical Skurtveit S, Fredheim OMS. Concomitant medication among persistent opioid users with chronic non - malignant pain. Ac ta Anaesthesiologica Scandinavica 2012;56:1267 -76. Neutel CI, Skurtveit S, Berg is the point of guidelines? Benzo - diazepine and z -hypnotic use by an elderly population. Sleep Medicine 2012;13:893 -7. Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medica - tion in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199 -206 Neutel CI, Skurtveit S, Berg C. Benzodiazepine and z - hypnotic use in Norwe - gian elderly, aged 65 OM. Low -dose transdermal buprenorphine - long -term use and co -medication potentially addictive drugs. Acta Anaesthesiol Scand. 2012;56:88 -94. Nordfj\u00e6rn T. A population -based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z -hypnotic users. Addic - Straand J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? European Journ al of Clinical Pharmacology 2012;68:1085 -94. Pedersen Hansen Svendsen Fredheim Pregnan cy outcome after gestational exposure to erythromycin - a population - based register study from Norway. British Journal of Clinical Pharmacology 2012;74:1053 -62. R\u00f8nning PA, Helseth E, Meling TR, Johannesen population -based study on the effect of temo zolomide in the treatment Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use --a 4- year follow -up of 78,453 incident users. Clin Nordstr\u00f6m G, Hartz I. Mental distress and subsequent use of psychotropic drug s among adolescents - a prospective register linkage study. J Adolescent Health 2012;50:578 -87 Steffenak AKM, Wilde -Larsson B, Nordstrom G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationw ide prescription database study. Clinical Epidemiology 2012;4:225 Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. B MJ Open. 2012 Apr 5;2(2):e000614. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co - prescription of medi - cation for bipolar disorder and diabetes mellitus: A nationwide population - based study with focus on gender differences. BMC Medicine 2012;10:148. Svendsen K, Skurtveit S, Romundstad Differential patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain 2012;16:359 -69. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012;41:196 -201. Von Soest T, Bramness W, Wichstr\u00f8m L. The relationship between socio -economic status and antidepressant prescription: A longitudinal survey and register study of young adults. Epidemiology and Psychiatric Sciences 2012;21:87 -95. within the refer - ence range as a predictor of future hypothyroid ism and hyperthyroidism: 11 -year follow -up of the HUNT Study in Norway. J Clin Endocrinol Metab. Tverdal A. Cigarette smoking and risk of s ubsequent use of antibacterials: a follow -up of 365 117 men and women. J Antimicrob Chemother 2011;66:2159 -67. Bramness JG, -42 Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observa tion study. BMC 2011;11:144. Locatelli M, Str\u00f8m S. Generic substitution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49 -59. Engeland Vangen S, Vollset SE, Fu ru K. Risk of diabetes after gestational diabetes and preeclampsia. A registry - based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157 - 63. Espnes MG, Bj\u00f8rge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011;20:243 -8. Fasmer OB, Riise in opioid maintenance therapy: A - SJ, W. High validity of mother -reported use of antiasthmatics among children: a comparison with a population -based prescription database. J Clin Epidemiol 2011;64:878 -84. Furu og ungdom i 0 -17 ing. [Chlamydia infections in South - and -up]. Tidsskr Nor Laegeforen 2011;131:461 Godman B, Sakshaug C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce rei m- bursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121 -9. 143 Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba J, Dalen H, Lindb\u00e6k M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? J Antimicrob Chemother Nafstad P, Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. Pediatr Allergy Immunol 2011;22:528 -36. Handal M, Engeland A, opioid analge sics and co -medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Pharmacol 2011;67:953 -60 Harman C, Reid M, Thomas KV.In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year -long assessment of community drug usage. Environ Sci Technol. 2011;45:5676 Hartz I, Bramness Prescription of antidepressants to patients on opioid maintenance - A, Str\u00f8m H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. Epidemiology 2011;22:418 -21. Hofvind S, Sakshaug S, Ursin G, Graff -Iversen S. Breast cancer incidence trends in Norway -explained by hormone therapy or mammographic scr Skurtveit S, Nafstad P, Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. Pharmacoepide - miol Drug Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of anti - psychotics and antidepressants in general practice and specialist midler til Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation -wide population. Epilep sy Selbaek G, Nordeng H. Concomitant use of anti - dementia drugs with psychotropic drugs in Norway --a population -based study. Pharmacoepidemiol Drug Saf. 2011;20:1319 -26 Log Hartz I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults - a population -based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90 -8. Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign - or Norwegian -born parents. Scand J Pain 2011;2:36 -44. Mahic M, Skurtveit S, Selmer R, R\u00f8nning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimimab in N orway Drug 2011;20:457 -63. Neubert A, Hsia Y, de Jong -van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, N\u00f8rgaard M, Clavenna A, Wong IC. Comparison of anti -diabetic drug prescribing in children and adolescents in seven European countries. Br J Clin Pharmacol. 2011;72:969 P, Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? JE.Use of ADHD drugs in the Nordic OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the migraine and antidepressant medica - tions: Complete one year data from the Norwegian population. J Affective Disorders 2011;129:198 -204. 2010: Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co -medication among users of antiobesity drugs: a population -based study. Pharm World Sci. 2010;32:752 -8. Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs --a population base d study. Pharmacoepidemiol Drug Saf -9. 144 Andersen JB, JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010;17:1445 -50. Berg A, Furu K, analgetika [Use of glucosamine does reduce the need for pain -relieving drugs]. Tidsskr Nor Laegeforen 2010;130:1463 -6. Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. Drugs: Education, Prevention, and Pol icy 2010;17:168 -80 Bramness Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gaba - pentin using the HE, Falch JA, S\u00f8gaard AJ. Prescription of anti -osteoporosis drugs during 2004 -2007 - a nationwide register study in Norway. Eur J Clin Pharmacol P. Increasing use of opoids from 2004 to 2007 - Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010;14:289 - 294. Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen \u00d8, Borchgrevink P. Prescrip - tion of o pioids to children and adolescents; a study from a national prescrip - tion database in Norway. Pediatric Anesthesia 2010;20:537 - Furu Skurtveit S, JE, Almarsdottir AB, S\u00f8rensen HT. The Nordic Countries as persistence and safety of antipsychotic medication: a national registry - based 3 -year follow -up. Eur J Clin Pharmacol 2010;66:911 - 7. Hartz I, Tverdal A, Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. Soc Sci Med 2010;70:921 -5. Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population -based cohort study of 16 000 individuals. Scand J Public Health 2010;38:465 -73. Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235 -42. Hunskaar S, Bi\u00f8rn E, Lur\u00e5s H. Competition in general practice: prescriptions to the elderly in a list patient system. J Health Econ. 2010;29:751 -64 Karlstad \u00d8, Nafstad P, Tverdal A, Skurtve it S, Furu K. Prevalence, incidence and persistence of anti -asthma medication use in 2 - to 29 -year -olds: a nationwide prescription study. Eur J Clin atric comorbidity in patients with a Clin Kjome RL, Granas AG, Nerhus TH, Sandberg S. The prevalence of self -monitoring of blood glucose and costs of glucometer strips in a nation - wide cohort. Diabetes Technol Ther 2010;12:701 -5. Korn\u00f8r H, R, Tverdal A. Benzodiazepines predict use of opioids - a follow -up study of 17 074 men and women. Pain Med 2010;11:805 -14. Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeate d use of prescribed opioids. Prospective population -based cohort study. Ann Epidemiol 2010;20:890 -7. K, anti -inflammatory drugs: use and co -treatment with potentially interacting medications in the elde S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine i Sogn og Fjordane [Use of lithium in the Norwegian counties Fjordane]. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004 -2007 - a prescription database study. J Affect Disord 2009; 117:208 -11. Bramness JG, J, Engeland A. An increa sed risk of road traffic accidents after prescriptions of lithium or valproate? Pharma - coepidemiol Drug Saf 2009;18:492 -6. 145 Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord 2009;118:2 24-8. Devold H, -medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Brit J Clin Pharmacol 2009;67:234 Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Borchgrevink P. Prescription pattern of codeine for non - malignant pain in Norway - a pharmacoepidemio - logical study from The Norwegian Prescription Database. Scand 2009;53:627 -33. Gjerden P, Bramness and potential abuse of anticholin - ergic antiparkinson drugs in the use of anticho - linergic antiparkinson drugs and safety and receptor drug -binding profiles antipsychotic agents. Eur antipsychotic and anticholin - ergic antiparkinson drugs in Norway after Clin Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320 -6. Hartz I, Tverdal A, Skurtveit S. A comparison of self - reported data on disability pension status with data from a nationwide adm inistrative register. Nor J Epidemiol 2009;19:169 -172. Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addic - tive drugs in Norway - use among disability pensioners. Nor J Epidemiol 2009;19:209 -218. Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007 -08. Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z -hypnotics. A prescription database study of predictors. J Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database Pharmacoepidemiol Drug Saf 2009;18:572 -8. Landmark CJ, Larsson P, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population -based study of prescriptions. Epilepsy Res 2009; 87: 31 -9. Selmer R, Sakshaug S, Skurtveit S, Fu ru K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Pharmacol 2009;67:355 -62. Skurtveit S, Furu K, of low dose tr ans- dermal buprenorphine - did it influence use of potentially addictive drugs in chronic non -malignant pain patients? Eur J Pain 2009;13:949 T, M\u00f8rland J, Bramness J, Engeland A. Road traffic accident risk in patient s with diabetes mellitus, receiving blood glucose -lowering drugs. Prospective follow -up study. Med 2009; 26:404 Viktil K, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy - a population -based coho rt study Pharmacoepidemiol Drug Saf Norge S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185 -90. JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril\u00ae) in Europe. Nor J Epidemiol 2008;18:167 -72. Bram ness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074 -5. Bramness JG , Skurtveit S, Neutel CI, M\u00f8rland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. J T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx -PAD) study. Scand J Prim Health S, Furu K. Prescription druguse among fathers and mothers before and during preg - nancy. A population - based cohort study of 106,000 pregnancies i n Norway 2004 -06. Br J Clin Pharmacol 2008;65:653 -60. registerbasert kohortstudie. [Traffic risks associated with the prescription of med icinal drugs: a registry -based cohort study] Nor J Epidemiol 2008;18: 159 -66. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; 18:129 A, Neutel CI, M\u00f8rland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and use of antipsychotic medication: linking population -based prescription data - base to the HUNT study. Pharmacoepidemiol Drug Saf 2008;17:372 -7. Litleskare I, Blix H, norske kreftpasi - enter [Variable prescription of opioids Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later - a follow -up study of 13 390 men and women aged 40 -42 years. Pharmacoepidemiol Drug Saf 2008;17:926 -933. Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:714 -17. Str\u00f8m H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose -lowering drugs. Nor J Epidemiol 2008;18:191 -94. 2007 : Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. J Antimicrob Chemother 2007;59:1161 -6. Blix HS, Engeland Age - and gender -specific anti - bacterial prescribing in Norway. er? [The use of antidepressants amongst children and adolescents - did the warnings lead to fewer prescriptions?] Tidsskr Nor Carisoprodol use and abuse in Norway. A pharmacoepidemio logical study. Br J Clin Pharmacol 2007;64: 210 -8. Bramness JG, Korn\u00f8r H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007;90:203 -9. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. The risk of ro ad traffic acci - J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry -based cohort study. Ann Epidemiol 2007;17:597 -602. Furu K, Skurtveit S, Langhammer A, Use of anti - asthmatic medica - tions as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol 2007;63:693 -8. S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual -level prescription database Langeland N, Hausken T, P. A large community outbreak of waterborne giardiasis -delayed detection in a non-endemic urban M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007;64:476 -81. Sakshaug S, R\u00f8nning M. [Changes in the sale and use of flunitrazepam in Norway, 1999 - 2004]. antibi otic prescriptions in respirato ry tract infections be improved? A cluster - randomized educational intervention in general practice --the Prescription Peer Academic Detailing (Rx -PAD) L. [Are ics M, Dalen I. A cluster - randomized educational intervention to reduce inappropriate prescription patter ns for elderly patients in general practice --The Prescription Peer Academic Detailing (Rx -PAD) Sakshaug S, R\u00f8nning M. [How many and who are receiving for Prescription An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53 -56. 2001: tion in a public health perspective: Establishing a national prescription register in Norway. Nor J Epidemiol 2001;11:55 -60. Utgitt av Folkehelseinstituttet Published by Norwegian Institute of Public Health Juli 2020 Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned fra as PDF from "}